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Abstract 
Metal and metal oxide nanoparticles including calcium oxide, gold, and superparamagnetic iron 
oxide nanoparticles (SPIOs) were synthesised using a range of techniques including reduction, co-
precipitation and spinning disc technology.  SPIOs were primarily synthesised via a co-precipitation 
method using iron (II) chloride, iron (III) chloride and ammonia; a spinning disc reactor and gaseous 
ammonia were trialled successfully for scale up, producing spherical particles of 10-40 nm in 
diameter as analysed by TEM.   
Nanoparticles were coated via a novel solvent-free grinding process which was successful for drug 
molecules, immunogenic peptides and amino acids; the mode of binding theorised to be taking place 
via an electrostatic interaction between the SPIO and the carboxyl, amine or hydroxyl groups on the 
coating materials.  Recrystallisation of the coating materials to form HCl salts, was found to increase 
the binding efficiency with no detrimental effects to the particles.  These coated SPIOs were found 
to be stable in a range of buffered solutions as well as blood and cell culture media.   
Separation of particles by size exclusion chromatography (SEC), dialysis and magnetic separation was 
only effective for a small range of coatings, with high speed centrifugation at a speed of 60 000 rpm 
being confirmed as the only universally successful method.   
Imaging of citrate capped gold nanoparticles using a CT phantom revealed that gold concentrations 
of 3700 mg.l-1 were required for in vivo use and so this was not continued.  Coated SPIOs however 
produced relaxation times comparable with Endorem®, as well as being non-toxic.  SPIOs coated in 
this way were more stable than Endorem® and stayed in solution retaining their superparamagnetic 
properties for periods in excess of 72 days with only a negligible degree of degradation.   
Various peptides were synthesised using an optimised microwave assisted solid-phase peptide 
synthesis (SPPS) method using double the suggested coupling times, all of which were analysed for 
purity and structure using MALDI-TOF MS and HPLC.  A cell-penetrating peptide (CPP) synthesised 
via this method was coated onto SPIOs and mixed into a gel for transdermal delivery using porcine 
skin.  An NMR profile of the skin using a 0.25T NMR MOUSE® before and after application of the gel 
showed that after an incubation period of 2 hrs the CPP-SPIOs had penetrated the skin leading to a 
reduction in signal.  This has potential applications for subcutaneous drug delivery and 
hyperthermia.   
Cell studies using U937 and BMDCs indicated by both ICP and fluorescence microscopy that SPIOs 
coated with fluorescently labelled peptides were successfully taken up into cells.  SPIOs were further 
5 | P a g e  
 
investigated as vectors for delivery of immunogenic peptides, namely p53(105) using female 
C57BL/6 mice.  Results indicated that mice immunised with SPIO as a vector showed similar levels of 
immune response to the p53(105) following immunisation as when incomplete Freund’s adjuvant 
(IFA) was used.  However, SPIO immunisations produced a significantly increased specific response 
compared to the condition using IFA.  Results indicate that SPIO could be successful as a vector for 
cancer vaccines.          
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Chapter 1.1:   Synthesis and functionalization of metal and 
metal oxide nanoparticles 
 
Section 1:   Synthesis of Nanoparticles 
 
Nanotechnology is defined as science, engineering and technology conducted at the nanoscale, with 
nanoparticles being those with at least one dimension being between 1 and 100 nanometres. 
 
In his talk “Plenty of room at the bottom” Richard P. Feynman talks about manipulating and 
controlling things on a small scale; the underpinning motivation for the field of nanoscience. 1  He 
talked about rearranging atoms so that we can create substances that are an exact number of atoms 
high or wide, what we would consider to be nanoscience, although the term was not coined until 
over a decade after his talk, by Professor Norio Taniguchi. 2  Although we are not there yet, it points 
in the direction in which nanotechnology is ultimately travelling.  We can now through carefully 
controlled reactions produce particles of specific sizes and shapes. 3 
 
As illustrated in Eric Drexler’s “Engines of creation” he also believes that technology will lead the way 
to being able to arrange atoms individually, and here he coins the term “molecular technology” 
which is another way of saying nanotechnology, being slightly more descriptive. 4  He talks about 
perfecting the art of building at the molecular level, paying attention to both omission of nucleotides 
in construction of DNA, and amino acids in construction of proteins, which is of particular relevance 
to this research.   
 
Above all, both Feynman and Drexler highlighted the abundance of progress that still remains to be 
made in nanoscience, as well as opening our eyes to all of the potential benefits and applications (as 
well as dangers) of being able to precisely manipulate things at a molecular level. 
 
Nanoparticles are found in many natural environments, for example they are present in volcanic ash, 
ocean spray, and even homing pigeons. 5  Although we are adept at exploiting natural resources, for 
scientific purposes it is often necessary to artificially synthesise nanoparticles.  The main methods 
that will be discussed herein are: Thermal decomposition, 6-12 Microemulsion (and reverse 
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microemulsion), 13-27 Sonochemical, 28-38 Spinning Disc39-41 and Calcination, 26, 42-47 although brief 
mention will be given to other methods. 
 
When discussing each synthesis the merits of the synthetic route, and also the drawbacks with 
regards to general effectiveness, and in terms of green chemistry will be discussed.  As the focus on 
nanotechnology and producing nanomaterials becomes wider spread, it is important that we not 
only find effective ways of producing these materials with high purity and even size distribution, but 
also that we do it in a way that is sustainable. 
 
 
Figure 1.  Image showing the basic processes for synthesis of particles for biomedical applications 
 
  
1.1 Thermal Decomposition, Calcination and Annealing 
 
  
These three methods all require some degree of heating but are used in different parts of the 
process.  Thermal decomposition is used in the primary synthesis of the particles, whereas 
calcination and annealing are used to change the particle structure post-formation.  During thermal 
decomposition a precursor material, typically a complex of a metal salt such as copper chloride,48 
iron carbonyl, 49 and iron acetyl acetonate 10 is heated until is decomposes to form the nanoparticle.  
Different decomposition temperatures give rise to nanoparticles of different sizes and so through 
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controlling the reaction temperature by manipulation of solvents, it is possible to carefully control 
the size of the materials produced. This occurs because the nucleation rate is affected by 
temperature, with smaller crystals being formed at higher temperatures due to slower nucleation.  
One issue with thermal decomposition is that the particles formed are not stable in air and become 
easily oxidised e.g. Iron nanoparticles becoming oxidised to iron oxide and magnetite (Fe3O4 
containing iron (II) and iron (III) ions) being oxidised to maghemite (Fe2O3 containing only iron (III) 
ions).  For this purpose a stabilising agent is added, with oleic acid and various oleate salts being 
popular (Figure 2). 10, 48, 50 The oleate ion has a hydrophobic tail and hydrophilic head, allowing it to 
form a micelle-like structure around the particles.  Stabilising agents like this prevent aggregation 
and Ostwald ripening, as well as protecting the particle from oxidation. 50  
 
 
 
Figure 2. Images of oleic acid, one of the most popular stabilising agents in the formation of 
nanoparticles. 
  
Although more benign, low energy, methods of synthesis are being explored thermal decomposition 
remains a popular option for many types of nanoparticle as it can be carried out in organic solvents, 
which further protect the particle from risk of oxidation. 50  As has been previously mentioned, use 
of metal acetyl acetonate precursors containing metals such as copper and iron are commonly used 
for thermal decomposition (typically in the presence of stabilising materials such as oleyl amine 
and/or oleic acid)10, 48, 50 but other precursors containing ligands such as tetraethoxysilane and 
tetramethoxysilicate to create silica and silica coated nanoparticles, are also well documented. 18, 51  
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Although organic solvents are the usual choice, decomposition can be achieved in aqueous solvents, 
using an aqueous soluble precursor.  An example of this is the thermal decomposition of a Cu-oleate 
precursor, formed from CuCl2 and sodium oleate, to form copper nanoparticles.
48  In this instance 
the concentration of the capping agent leads to different sizes of particle.  Aqueous soluble 
magnetite particles have also been produced, by using iron acetyl acetonate in tri ethylene glycol 
(TEG), with the resultant particles being coated with the TEG. 52  Aqueous syntheses are preferential 
as they eliminate the use of organic solvents, and so reduce pollution from the reaction.  It also gives 
rise to aqueous soluble particles, which can lend themselves to biomedical applications. 53, 54  
  
In order to overcome the problems associated with using solvents in syntheses, a method has been 
reported for the solvent free synthesis of magnetite.10 The experimenters dissolve the iron acetyl 
acetonate precursor in a mixture of oleic acid and oleylamine, dehyrate the mixture and then heat it 
to 300 °C (for various times), leading to nanoparticles of different sizes, with size being dependent 
on the heating time.  As could be predicted, longer reaction times lead to larger particles, however 
the experimenter notes that in the absence of solvent there is also an absence of Ostwald ripening 
where smaller particles are added to larger particles thus increasing the number of large particles 
and decreasing the number of small particles.  This results indicate that the solvent free methods are 
a possible solution to this problem. 10   Also of note is that this method overcomes the issue of 
temperature limitations.  Whilst the boiling point of the solvent in traditional thermal decomposition 
methods limits the reaction temperature, in this solvent free method the temperature can be higher 
or lower as desired.  
  
Another issue with thermal decomposition is the use of high temperatures to decompose the 
materials.  For example, during the formation of ZnO nanoparticles zinc acetate is used, both 
because of its high solubility and its "low decomposition temperature".7, 55  The reported low 
temperature is above 200 °C, which is a relatively high temperature, considering other particles can 
be formed at room temperature.    
  
Annealing is used in conjunction with many synthetic methods, but is a method of changing the 
particles from one form into another rather than a method of formation itself.  Annealing involves 
heat treating the particles post formation in air or an inert atmosphere, in order to change the 
microstructure of the particles.  For example, during the formation of tungsten nanoparticles from 
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tungsten hexacarbonyl  via thermal decompositon, amorphous particles are formed. 11  By annealing 
at temperatures of 600 °C, these amorphous particles all became body centred cubic crystalline. 
  
Calcination, another heating technique, can be used either to decompose the precursor materials, or 
to affect the particles post formation. 42  During calcination any salts present which decompose at 
the temperatures applied, are converted into oxide.  Calcining also drives off any water associated to 
the particles, leading to anhydrous materials.  Nickel oxide (NiO) nanoparticles can be formed via a 
calcining procedure during which the precursor material, basic nickel carbonate, is trapped within a 
gel and dehyrdated prior to calcining, leading to uniform particles that do not agglomerate. 45  This is 
unusual as typically calcination leads to agglomeration of particles, and in fact this property has been 
exploited during the formation of TiO2 particles, to form larger structures with smaller pore size for 
potential use in photocatalysis and other applications. 26  However, the method of forming a gel/sol 
gel  followed by hydration and then calcination has been applied successfully in other cases. 44   
 
So, whilst these synthetic routes lead to materials with carefully controlled particle sizes, there are 
disadvantages such as the high reaction temperatures (and energy requirements), and the resultant 
coating of the particles, which need to be overcome.     
  
1.2 Microemulsion/Reverse Microemulsion 
  
Microemulsions are colloidal 'nano-dispersions' of two immiscible liquids (typically referred to as oil 
and water) stabilized by a surfactant film.  They are thermodynamically stable and can interact to 
allow chemicals trapped within them to react with each other, as illustrated by the channel between 
the micelles illustrated in Figure 3. 25  In a microemulsion droplet size is typically 6-80 nm and these 
droplets are often referred to as "nanoreactors".15  Also documented are "miniemulsions" with a 
droplet size of a few hundred nanometres. 56  The term "microemulsion" refers to emulsions in 
which the droplets are oil in water and the surfactant has the hydrophilic heads exposed on the 
outside of the micelle.  The term "reverse microemulsion" refers to an emulsion in which water 
droplets are suspended in oil and the hydrophobic tails of the surfactant are on the outside of the 
(reverse) micelle. 
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Figure 3.  Showing how two micelles can fuse together to form a fused dimer.  Note that in the centre 
the two membrane of the two micelles have formed one large membrane with a channel in the 
middle through which contents can mix.  
 
The miroemulsion can be tailored to both organic and aqueous soluble materials as the colloids can 
be inverted to have either the hydrophobic or hydrophilic groups on the outside (direct or reverse 
micelles) as illustrated in Figure 4. 25  A typical surfactant is sodium dodecyl sulphate (Figure 5), 
which has a long chain hydrocarbon tail which can interact with non-polar media, and a hydrophilic 
head, suitable for interaction with polar (aqueous) media.  Microemulsions can be tailored to 
produce nanoparticles of specific sizes, as the inside of the micelles will limit the nanoparticle 
growth, particularly if the film is sparingly flexible.  This area can also affect other factors such as 
concentration and ratio of reactants.  It is also worth noting that as the particles are formed within a 
refined space, the possibility of agglomeration (reversible clumping together of particles) and 
aggregation (irreversible clumping together of particles) is greatly reduced. 25 
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Figure 4. Showing how the hydrophobic ends of the surfactant can point inwards to form a Direct 
micelle, and outwards to form a Reverse micelle. 
  
Microemulsion techniques are popular for the formation of iron oxide, 14, 15, 21, 24, 27 silica, 18 silver, 22 
titanium dioxide, 19, 26 and zinc oxide nanoparticles, 17amongst other applications which include the 
formation of hydroxyapatite, a calcium containing compound widely used to coat prostheses due to 
its high biocompatibility. 57  
  
A typical example of the microemulsion technique is the in situ formation of chitosan coated iron 
oxide nanoparticles, which are currently desirable for biological applications such as controlled drug 
release and enzyme immobilization. 58  For this reaction the well documented surfactant Triton X-
100 (Figure 5) is used to form a water in oil emulsion. 15, 17, 19, 56  In this example the resultant 
particles are square, with a spherical coating of chitosan.  This method is in contrast to the 
traditional method of chitosan magnetite particles, suspension cross-linking, during which a 
suspension of the polymer is created in an immiscible liquid and then hardened to form solid 
capsules via covalent cross-linking. 
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Figure 5. Sodium dodecyl sulphate and Triton X-100; two popular surfactants 
 
1.3 Co-precipitation / Massart's Method 
  
Many syntheses exploit the co-precipitation method whereby the reagents containing the ions to be 
incorporated into the nanoparticle are mixed together, and a reducing agent, such as sodium 
hydroxide or lithium borohydride, is added thus producing a precipitate of the desired nanoparticles. 
59-63  Coating agents can also be added to protect/stabilise the particles as they form.  In a novel 
application, ibuprofen loaded dextran nanoparticles were fabricated through a co-precipitation 
method during which ibuprofen in a supersaturated solution was precipitated using a change in pH, 
following which a positively charged dextran analogue was then deposited on the surface of the 
ibuprofen particles to form a kind of nanocapsule.  It is claimed that this method could be used for 
other drug molecule, thus lending it to potential biomedical applications.  Such formulations could 
improve dissolution of less soluble drugs such as diclofenac, or the cancer drug taxol, and thus solve 
some of the issues faced in modern medicine.  64, 65 
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1.4 Sonochemical Methods 
 
Sonochemistry / Ultrasound have been applied to the fabrication of many types of nanoparticle, 
including zinc oxide nanocups, nanorods and nanoflowers. 3  It has also been used to improve the 
“greenness” of reactions, including the formation of silver nanoparticles using gelatin as a stabiliser 
and glucose to replace NaBH4 as the reducing agent. 
30  Other examples of synthesis using ultrasound 
include magnetite nanoparticles, 31, 32, 37 gold-ruthenium nanoparticles, 34 and gold nanoparticles 
synthesised on the surface of chitosan. 36 
 
At frequencies of 20 kHz to 1 MHz sonochemistry can be performed, which involves acoustic 
cavitation, illustrated in Figure 6.  The sound waves create bubbles in the solvent in which reactants 
can be trapped.  The bubble, through a series of compressions and rarefactions, expand and 
contract, until it reaches an unstable size at which it collapses, creating temperatures reported as 
high as 5000 °C and pressures of up to 2000 atm. 66  The cooling rates in these systems are also 
extraordinary, at 1010 K.s-1.  For the formation of HfO2 nanoparticles, enhanced reaction rates and 
smaller particles were formed using sonochemistry as opposed to other reaction routes. 38  The 
precursor materials used in ultrasound reactions are the same as those used for other methods, 
such as a metal chloride, a base to reduce it, and a stabilising agent.  For example, CuO nanoparticles 
have been fabricated from CuNO3 in the presence of NaOH, using PVA (poly vinyl alcohol) as a 
stabiliser. 33   
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Figure 6. Showing how cavitation bubbles can form using ultrasound 
 
 
Ultrasound is reported as being a green alternative to other reaction routes, in that it can be carried 
out at ambient temperatures, has short reaction times, and overall lower energy requirements. 30  
However, as with other methods, it may be necessary to perform a calcining/annealing step 
following the initial ultrasound reaction.  This reduces how green the reaction is, as the high 
temperatures used require a large amount of energy.  This is a common requirement for 
nanoparticles formed from ultrasound as the rapid cooling rates prevent the formation of highly 
crystalline particles (the resultant particles are more like a powder).   
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1.5 Spinning Disc Reactor  
 
To synthesise nanoparticles on a spinning disc reactor, the reagents are fed into the reactor at 
specific rates, as controlled by a mechanical pump (Figure 7).  It is possible to use both liquids and 
gases in the reactor, as in the case of synthesis of superparamagnetic iron oxide particles. 39  In this 
case ferrous and ferric chloride solutions of varying concentrations are fed onto the reactor at a 
controlled rate ( 1 ml s-1 ) and NH3 gas is introduced.  This can also be carried out using NH4OH 
solution via a separate feed.  The disc of the reactor, on which the reaction occurs, contains many 
grooves of a specific size, and as the reactants are introduced to the spinning disc micro-mixing 
occurs, which can affect particle size. 67  A combination of the movement of the fluid caused by the 
spinning effect pushing the fluid towards the edge of the disc, and the friction created by the surface 
of the disc, lead to turbulent areas in the fluid.  These “turbulent waves” travel in two directions: 
circumferentially and helically.  The circumferential waves travel from the centre of the disc to the 
discs edge, and the helical waves are observed in zones.  Both of these waves can be tailored by 
varying feed rates and spin speeds to control mixing and transport rates and thus control particle 
size.  It is also possible to heat the disc, which can affect particle size as crystallisation will be 
affected by temperature (more crystalline materials will be formed at higher temperatures). 67 
 
 
Figure 7. Showing the components of a spinning disc reactor67 
   
Other particles have been synthesised using this technology including MgO, 68 Ag, 41 and 
hydroxyapatite. 39  During manipulation of disc speed it was found that as the rotational speed of the 
disc increased, the size of the particles generally decreased, although in the case of iron oxide 
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nanoparticles the reaction occurs spontaneously i.e. before micromixing, so altering disc speed is 
thought to be unlikely to affect nanoparticle size, although it may reduce agglomeration and limit 
Ostwald ripening. 
  
It is possible to coat the particles in situ by adding the coating material to one of the feeds, usually 
the one containing the metal precursor.  In this way Fe3O4 nanoparticles have been coated with 
alginic acid and Ag nanoparticles with starch. 41  The latter example can be used to illustrate how 
benign reaction materials can be used to replace hazardous chemicals.  In this example the starch 
replaces many alternative coating materials and glucose is used as the reducing agent.  As explained 
previously, benign chemistry is becoming more popular and so technologies that allow green 
principles to be applied are preferable.  The spinning disc system also allows recycling of unused 
materials and can be used as a continuous reactor, creating less waste and reducing the start-up 
costs associated with batch processes. Of particular significance is the fact that spinning disc 
technologies allow scale up of this process, which means that large quantities of the desired material 
can be made, and thus commercialised. 69    
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Section 2: Coating of Nanoparticles 
 
Nanoparticles can be formed pre-coated70-72 or can be coated after formation in various ways that 
will be discussed, with the coating material carefully chosen so as to suit a specific function.  Whilst 
some nanoparticles may remain stable without a coating agent, it is more often the case that the 
coating is essential for stabilisation of the particle, as well as biocompatability and biodistribution in 
biological applications. 73-76  In some cases the coating agent is added in situ to ensure that the 
particle only grows to a particular size.  Restriction of size based on formation inside micelles or in 
the presence of surfactants is discussed in detail in Section 1.  In these cases, were the coating agent 
removed, the particles would undergo Ostwald ripening to become much larger particles (Figure 8), 
thus affecting their physical and chemical properties and possibly rendering them useless for certain 
applications, particularly those that require a specific size.  For example, the magnetic properties of 
iron oxide (magnetite) nanoparticles can differ greatly depending on their size, and so larger 
particles would be useless for certain magnetism based applications. 37, 77-79  For delivering 
substances into cells, particles of 40-60 nm are optimal, and particles larger than 500 nm are not 
able to enter cells. 80  Ostwald ripening works on the principle that although smaller crystals are 
kinetically favoured and will form quicker than larger crystals, larger crystals are thermodynamically 
favoured and if left in solution for too long, or in the absence of an agent to control growth 
(microemulsions, capping agents etc.) the particles will grow.  If the particle is capped post-
formation, then typically the coating agent is required to stop the particles from sticking together to 
form larger particles through aggregation or agglomeration.   
 
Different functional groups are required for interaction of a molecule with particular nanoparticles.  
For example, thiols are typically used for gold nanoparticles, 81, 82 and silane groups for modification 
of silica surfaces. 83, 84  Other nanoparticles are more versatile, having a selection of moieties that will 
form an interaction with their surfaces.  These will be discussed in further detail throughout this 
section. 
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Figure 8. A schematic of Ostwald ripening showing how the smaller particles “feed” the larger 
particle, leading to one very large particle and a few very small particles. 
 
Coating of particles is also essential if the particle is required to be soluble in either polar or non-
polar solvents, as the metallic and metal oxide nanoparticles are essentially insoluble.  This is 
particularly important for biological applications, as particles are required to be aqueous soluble for 
the majority of these applications.  Finally, the coating may functionalise the particles for a more 
specific application, such as targeting cancer cells with antibodies. 85   
  
The principle behind coating nanoparticles is that there will be an interaction between part of the 
coating molecule and the surface of the particle, although polymers such as chitosan and dextran 
rely on crosslinking around the surface. 58, 74, 86, 87  Typically linkage groups include carboxylic acids, 
alkane thiols, alcohols, amines, organosilicon derivatives, and dialkylsulphides. 88  Each of these is 
able to adopt a charge either through acidic or basic dissociation or through conjugation, which 
allows an electrostatic interaction between the molecule and the charged surface of the particle.  
The "tail" end of the molecule is of equal importance, as this will allow the particle to be soluble in 
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the reaction medium, or alternatively leave it free to interact with a target.  A typical example of this 
is the frequently applied oleic acid, which has a long hydrocarbon tail, meaning that when the acid 
head group attaches to the particle, the hydrophobic tail group renders the particle soluble in non-
polar (organic) solvents. 10, 50   
  
2.1 In situ coating 
  
As mentioned previously, some particles are coated during their formation, so that they are soluble 
in particular media.  Iron oxide particles capped with PEG, PVP and PEI are typical of this type of 
reaction, and in this case a combination of the coating agent and reaction temperature are used to 
limit the size of crystal growth to 4-14.9 nm. 89  During this thermal decomposition reaction the long 
organic chains of the oleic acid molecules form a micelle type structure around the particle as it 
forms, with the thermal decomposition reaction occurring in the centre of the micelle.  At the end 
the nanoparticles are coated with the oleic acid, thus rendering the particles hydrophobic.  It is 
possible to perform a ligand exchange on these particles, which will be discussed later on. 
  
In contrast to the production of these hydrophobic particles, it is possible to cap the particles with a 
hydrophilic coating.  A popular example of this is coating with the sugars dextran or chitosan. 74, 86, 87, 
90  In these cases the coating materials are added at various concentrations with the aqueous ferrous 
and ferric chlorides prior to reduction under basic conditions.  Thus, as the particles are formed the 
coating agents form electrostatic associations with the particles and so coat them.  The size of the 
particles in this case is controlled by the reducing agent rather than the coating material, and the 
reaction is carried out at ambient temperatures.  The majority of commercially available SPIOs are 
coated with dextran type materials. 91  Research has shown that dextran coatings on iron oxide 
nanoparticles are not strongly bound and so there is a problem with precipitation at some 
concentrations. 87  As such, a facile method for coating SPIOs, and indeed other metal oxides, 
rendering them stable for longer periods of time would be advantageous.   
  
 
 
 
26 | P a g e  
 
2.2 Ligand Exchange 
  
Many metal oxide particles that are coated in situ are often hydrophobic due to synthesis in organic 
solvents, although aqueous synthesis to form water soluble NPs is becoming more common.  
Hydrophobicity severely limits their biological applications, and so further reaction is required in 
order to make them suitable. In addition to this, if the particle is to be functionalised for a particular 
purpose, a different functional material may be required and often this cannot be used to cap the 
particle during formation due to incompatability with reaction conditions or the reactants 
themselves.  For example, peptides would be susceptible to cleavage of amide bonds by ammonia or 
sodium hydroxide during SPIO formation, and would degrade at the high temperatures required for 
thermal decomposition (245 °C for thermal decomposition of acetyl acetonate).  Whilst a ligand can 
be altered very simply by, for example, an oxidation reaction, this is sometimes not sufficient for the 
desired purpose.  A popular option for changing the coating material is ligand exchange which works 
on the principle of swapping the coating ligand with another ligand, having a higher affinity for the 
nanoparticle (Figure 9). 92   
 
There are various methods of ligand exchange including heating, stirring and manipulating ligands 
through changes in pH. 50, 70, 72, 77, 93-96  Initial attempts at ligand exchange involved heating the 
particles to a high temperature in a suitable solvent.  More recently the ligand exchange has been 
effected at ambient temperatures by stirring with the replacing ligand.  Investigations into coating 
iron oxide nanoparticles with dopamine have led to much faster methods of ligand exchange, during 
which oleic acid coated particles were prepared and isolated, and dopamine hydrochloride solution 
at pH4 added and stirred (for only two minutes) to yield dopamine functionalised particles. 93  This is 
a much improved method to the previous ones involving long reaction times and emulsification, 
leading to complicated and time consuming isolation steps, not to mention large amounts of waste. 
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Figure 9. Showing how the ligands on an iron oxide nanoparticle can be changed via ligand exchange.  
 
  
2.3 Further Reaction 
  
As mentioned, one way in which to alter the functionality of the coating agent is to further react it 
by, for example, oxidation or reduction. 92  Another method, is to add another molecule to the 
coating agent via a covalent bond. 97  An example of how this can be done is illustrated by the 
commercially available "Molday ION Carboxyl Terminated" (BioPal), a SPIO with a coating agent 
containing terminal carboxyl groups ( also available with terminal amines that can be further 
reacted).  The principle behind these particles is that they can be covalently linked to another 
molecule, providing it has a terminal amine (or alternate functional group for alternate terminating 
groups) via a simple coupling reaction usually involving a carbodiimide.  A linking of these particles 
with spermidine has been reported, but its applications potentially extend to many different 
molecules. 98  
 
Another example of further reaction, is the addition of folic acid to the glutathione coating of gold 
nanoparticles.  In this instance the sulfur-containing cysteine in the centre of the glutathione (Glu-
Cys-Gly) forms an electrostatic interaction with the gold nanoparticle which is strong enough to 
withstand the coupling conditions required to covalently link the carboxylic acid or amine groups 
located at the ends of the polypeptide, to the folic acid molecule (Figure 10).97  This particular 
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example has clinical applications as the folic acid is used to target and detect cancer cells via linkage 
with the folate receptor which is overexpressed in cancerous cells.  
  
 
 
 
 
Figure 10. Reaction scheme showing the sequence of reactions for forming the folic acid conjugated 
gold nanoparticles. 
 
 
2.4 Self-Assembled Monolayers 
  
Self-assembled monolayers are a single layer of a coating molecule which arranges itself 
spontaneously on the surface of the particle.  The mechanism behind this spontaneous process is 
that the head group of the coating molecule is attracted to the nanoparticle (typically a metal or 
metal oxide) leading to an electrostatic interaction, and the other end of the molecule will be either 
polar or non-polar depending on the solvent in which the nanoparticle is to be dissolved or 
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suspended (Figure 11).  Of equal importance is the interaction between the coating molecules 
themselves, as van der Waals interactions between the molecules help to stabilise the particle.  
However, interactions between coating molecules on separate particles can cause problems, if they 
interact with each other this may cause agglomeration or aggregation of particles. 99   
 
 
 
 
 
Figure 11. Showing how the head group of the coating molecule, referred to as the surface active 
head group, adsorbs to the surface, leaving the alky chain to interact with the solution.  The coating 
molecules are attracted to each other via intermolecular interactions 99   
  
 
Organothiols such as n-dodecanethiol (Figure 12), have been reported to form SAM's on the surfaces 
of many metal nanoparticles including Au, Ag, Fe and Ni. 99-101  The thiol group is able to form an 
interaction with the particle, with the hydrocarbon chain forming a spacer, and the tail group 
interacting with the surrounding solvent.  There have also been extensive studies into the 
application of carboxylate anions, particularly on the surface of Al2O3 and AgO surfaces. 
99    
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Figure 12. n-dodecanethiol 
  
Self-assembled monolayer formation is a desirable option for coating particles as it requires no 
auxiliaries, heating or other complicated steps.  However, it is not suitable for all coating materials 
on all substances, and in the event that a complete monolayer does not form, other components of 
the reaction mixture such as the solvent, can form an interaction with the particles, leading to an 
impure product.  In terms of scale-up this is undesirable as extraction/separation steps, usually 
requiring solvents, are necessary to obtain a pure product.  For biomedical applications purity and 
quality control are essential due to FDA regulations and the monitoring of both effectiveness and 
side effects.  It is also possible that a bilayer, or several layers, will form on the particle, which will 
increase the size of the particles possibly to a size that renders them unsuitable for certain 
applications.  
 
2.4 Determining Effectiveness of Coating 
 
There are several ways in which the effectiveness of a coating method can be measured.  Powder 
diffraction methods may show the coating if the capping agent remains crystalline.  If the coating 
material contains a particular functional group then IR spectroscopy could be used, and EDX can be 
used to determine if particular elements only present in the coating material can be identified 
around the particle.  TEM images may show an area around each individual particle which 
corresponds to the coating material and DLS will show an increase in particle size that may be 
dependent upon the coating.  Although the particles will not go into solution unless they are coated, 
UV-vis is another technique that allows for confirmation of the presence of coating materials. 102   
 
TGA can be used to determine the mass of coating material present on the surface of a known mass 
of nanoparticles.  This involves heating a known mass of nanoparticles in an inert atmosphere by 
increasing the temperature in increments over a period of time and weighing the sample throughout 
to create a graph.  This shows a decrease in mass corresponding to the coating material alone being 
removed, followed by a second dip corresponding to the breakdown of the particle itself.  Typically 
the temperature is increased to 600 °C over a period of four hours. 103   
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Where the coating material is chiral a technique known as circular dichroism can be also be used, 
and would be particularly useful where larger polypeptides are used as the functionalising material. 
104    Realistically these analysis tools must be used in conjunction with each other for a definite 
characterisation.   
 
An important factor to consider when looking at either charge or size of the particles is the 
interaction of the particles with each other, as illustrated in Figure 13. 105  The coating materials will 
lead to repulsion between particles and so a reduced likelihood of aggregation.  However, if the 
particles get closer together then due to their high surface energy, a consequence of their small size 
and large surface area, the van der Waals interactions between the particles increase leading to 
increased aggregation.  For this reason many particles are synthesised in very dilute concentrations, 
and a stabilizing/coating agent may be selected which sterically hinders particle interaction.  For 
example, citrate capped gold nanoparticles are synthesised using a gold solution of 0.01% (w/v) in 
water. 72 
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Figure 13. Showing how van der waals energy changes with separation distance for different 
nanoparticles. 
 
Zeta potential is another useful tool in determining the nature of coatings.  It measures the charge of 
the area surrounding the nanoparticle rather than the nanoparticle itself.  This is illustrated in Figure 
14. 
 
 
Figure 14. The diagram shows that the particle itself is negative, the particles bound directly to it are 
positive and the particles attracted to these negative again.  This leads to an overall negative charge 
over the particle and thus a negative zeta potential. 
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The zeta potential of the particle plays an important role when it is to be used for biomedical 
applications in which it is required to deliver substances into cells. 76  As shown in Figure 15, when 
the particle is taken into the cell via pinocytosis it is encapsulated in a lysosome/endosome with an 
internal environment that is capable of degrading certain particles, for example SPIOs which will 
degrade at ca. pH 4.5 - 5.0.  However, if the particle is cationic, then it will interfere with the proton 
pump, causing an influx of protons into the endosome.  This is known as the proton sponge effect. 
106  As a result of this, a large quantity of chloride ions will enter and remain in the cell, thus causing 
water to enter leading to swelling and bursting of the lysosome and release the particle along with 
the coating, possibly an active agent, into the cytosol (Figure 16).      
 
 
Figure 15. Image shows a nanoparticle approaching the cell and interacting will the cell wall.  The cell 
forms a vesicle known as a lysosome around the nanoparticle as it enters the cell.76 
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Figure 16. Schematic showing how cationic nanocarriers are able to induce osmosis into the cell, 
resulting in endosome rupture and release of the particle into the cell.106 
 
The example of endosome rupture is useful in showing the importance of charge on the particles.  
However, it has been discovered that if a particle is too charged then it may not interact with the cell 
in the desired way. 76  The charged particle is able to interact with the cell wall (positively charged 
particles are taken up better than neutral or negative as the cell wall has a slight negative charge), 
but if the charge on the particle is high then it will be accelerated towards to the cell by electrostatic 
interactions.  This does not leave time for the particle to recognise specific domains on the cell, and 
it can end up binding to an irrelevant part and so not have the desired effect, such as binding to 
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receptors.  In contrast, if the charge on the particle is too low then the electrostatic interaction 
between the particle and the cell may not be sufficient to pull the particle in the desired direction 
and so it will move away from the target by means of thermal diffusion and Brownian motion, and 
also not have the desired effect.  So, the zeta potential of the particle must be tailored for 
biomedical applications because as discussed, it is essential for interaction between the nanoparticle 
and its target. 76  
36 | P a g e  
 
Section 3: Purification of Nanoparticles 
 
There are several different ways of isolating these particles and separating them from any unreacted 
material or free coating.  This is essential when the particles are being used for applications as any 
free material may cause anomalies or incorrect conclusions to be drawn.  The methods most 
frequently highlighted in the literature include; use of antisolvents and washing, magnetic 
separation, size exclusion chromatography, dialysis, and centrifugation. 16, 107-114    
 
3.1 Antisolvent Precipitation and Selective Precipitation 
  
As with organic synthesis, it is possible to purify and isolate the product (in this case the coated 
nanoparticles) by selecting a suitable anti-solvent, in which the coating material is insoluble. 92  On 
addition of this solvent the coated particles should precipitate out first, as energetically, it is more 
unfavourable to keep these particles suspended in the anti-solvent than the free coating material.  
An example of this method can be found in the formation of CdSe nanoparticles coated with TOPO 
(trioctylphosphine oxide), where hexane is used to precipitate the TOPO-CdSe particles out of 
solution. 115  In all cases in which this method is employed, it is essential that the primary solvent 
(that in which the particles are dissolved) and the anti-solvent are miscible.    
  
3.2 Size Exclusion 
 
Size exclusion chromatography is a viable method of separation if the size of the coated particles and 
the size of the free coating material are very different.  For example, the size of the largest amino 
acid (tryptophan) is in the region of 1.5 nm, whereas the size of an iron oxide nanoparticle prepared 
via the microemulsion method is around 10-15 nm.   
 
The technique, also known as gel filtration uses specialised beads with pores of different sizes, 
controlled by the cross-linking of the substance from which they are made.  SEPHADEX (SEparation 
PHarmacia DEXtran) for example, is made of cross-linked dextran and comes in many different bead 
sizes ranging from "10" which separates peptides and small biomolecules with a molecular weight > 
700, to "75" which is used for large biomolecules with a molecular weight > 80 000. 
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In brief, the beads are swelled in an appropriate buffer or solution and packed into a separating 
column.  The components to be separated are dissolved in the buffer and added to the top of the 
column, and washed through the column using a continuous flow of buffer.  The fractions are 
collected, each containing different molecules depending on the retention time of each component.  
The larger molecules will move around the beads, and so will move through the column quicker and 
elute in the earlier fractions, whereas the smaller molecules will fall through the pores in the beads 
and so their path through the column will entail moving through each individual bead that they 
come into contact with, meaning that they will be retained on the column for longer, and so will 
elute in the later fractions (Figure 17).  The length of the column, the size/type of beads, and flow 
rate can be tailored for optimal separation.   
  
 
 
Figure 17. Showing the movement of small and large molecules through a size exclusion column 
packed with porous beads.  
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3.3 Magnetic Separation 
  
Magnetic separation is carried out by using a rare earth magnet with a very strong magnetic field, 
and is only suitable for magnetic nanoparticles such as iron and nickel metals and oxides.  Whilst 
gravity cannot act on the particles strongly enough to pull them out of the solution, the magnet is 
sufficiently strong so as to be able to pull the solvated particles out of solution.   
  
The magnetic force which acts on a particle is given by: 
 
FM=μ0χVpH∇H, 
 
where H is an external magnetic field, χ is the magnetic susceptibility, and Vp is particle's volume. 92 
  
  
Theoretically, this method will only work for particles of 50 nm or more in solution/ as for smaller 
particles the combined energy of thermal diffusion and Brownian motion overcome the force 
imposed by the magnetic field, and so the particles remain stable in solution. 92  
  
During synthesis of hydrophobic coated iron oxide nanoparticles, a rare earth metal magnet such as 
neodymium, is typically used to settle the particles when they are suspended in solvent.  This is 
repeated several times with the solvent being decanted off and the resulting product washed with 
fresh solvent until a pure product is obtained.  This settling technique is frequently used during the 
formation of coated nanoparticles. 108  However, in these cases the particles tend to be aggregated, 
due to insolubility in the reaction media, and so do not fit the theoretical values.  In fact it has been 
found that even in solutions the calculated properties can be inaccurate as they are extrapolated 
from data on the bulk material, ignoring the changes in properties observed at the nanoscale such as 
dipole-dipole interactions and magnetic properties, which will be discussed further in Section 2. 
  
Magnetic separation is considered to be superior to size exclusion techniques as it is quicker and 
does not suffer from some of the limitations of SEC, such as incompatible materials and limitations 
with bead and pore size. 108  From a green chemistry perspective, it is superior as it does not require 
excessive solvents and reduces the need for an extraction step at the end of the separation. 
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3.4 Dialysis 
  
Dialysis, like size exclusion, works on the principle that the coating agent is much smaller than the 
coated nanoparticles.  In this case rather than using porous beads, semi-permeable tubing with a 
pore size to match the application, is used. 110, 113  The solution containing the coated nanoparticles 
and the free material is sealed into the tubing and the tubing placed into a beaker of buffer which is 
gently agitated (usually through stirring) and can be heated if required.  The free coating material 
will diffuse out of the tubing into the surrounding buffer until equilibrium is achieved.  By replacing 
the buffer with fresh buffer at intervals, the equilibrium can be shifted so that virtually all of the free 
coating material diffuses out of the tubing and the resultant nanoparticle solution contains only the 
coated particles.  This process is illustrated in Figure 18, 116 which shows the dialysis technique being 
used to separate antibodies from other components in a mixture of proteins.  In this instance pores 
of ~ 24 Å are used although other tubing with different pore sizes are available. 116 
 
  
Figure 18. A membrane with pores of 24 Å is being used to separate antibodies of 150 Å which are 
desired, from undesired components such as 2-mercaptoethanol which is 5 Å.  Tubing with smaller 
pore sizes is available commercially. 
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3.5 Centrifugation  
  
It has been previously mentioned that the gravitational force that acts on the nanoparticles in 
solution is not sufficient to force them to sediment.  The force of Brownian motion and thermal 
diffusion on these small particles is larger than the force of gravity on them and so they are able to 
remain suspended.  However, it is possible to increase the gravitational force on these particles and 
so force them to sediment out.  During centrifugation the gravitational force increases dramatically, 
for example at a speed of 60 000 rpm, the gravitational force is 200, 000 times greater.  By tailoring 
the centrifugal force and the time it acts on the particles, and working on the principle that the 
larger particles will sediment out first, it may be possible to draw the coated particles, but not the 
free material, out of solution.  It is also possible to create a density gradient within the centrifuge 
tube which can help to separate out particles of different sizes (Figure 19). 110, 113   
  
 
 
 
Figure 19. Image showing how solvents of different densities can be exploited to create a gradient 
within the centrifuge tube.  This example shows separation of organelles. 
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3.6 Alternatives 
 
In addition to these techniques it is worth noting that electrophoresis can also be exploited for the 
separation of particles, discriminating not only size but shape. 112  Eletrophoresis can be used to 
separate gold and silver nanoparticles of varying shapes and sizes by coating them with PEG 
terminated in COOH groups and passing them through an electrophoresis gel by tailoring the pH and 
gel type (Figure 20). 111  This has proved useful as for certain applications, particularly catalysis, 
where the shape of the particle is essential to its function.  Other methods of separation tend to 
discriminate solely by size.  During this project, the aim was to separate the free coating material 
rather than from other particles, and so this type of method will not be discussed in further detail.       
 
 
 Figure 20. Gel electrophoresis for separation of nanoparticles108 
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Chapter 1.2:  Nanoparticles and Medical Imaging 
 
Medical imaging is essential for the detection, diagnosis and treatment of disease.  There are several 
imaging techniques commonly used in hospitals for these three functions including Ultrasound, X-
Ray computed tomography (CT), magnetic resonance imaging (MRI) and positron emission 
tomography (PET).  Imaging can be defined using Equation 1, where in order to make an image mass 
and energy are measured as a function of their three-dimensional location and time, although 
generally images are based on energy rather than mass as is the case with many types of medical 
imaging. 117 
 
U = (m,E)(x,y,z)(t) 
 
Equation 1. Definition of an image (U), where m = mass, E = energy, (x,y,z) are the three dimensions 
in space, and t = time. 
 
Ultrasound exploits high frequency sound waves that are detected as they are reflected from various 
structures within the body.  It is commonly used for diagnosis of heart diseases, 117-119 various 
ailments of the gastrointestinal (GI) tract, 120 and for dating and monitoring pregnancy. 121, 122  CT 
(computed tomography) makes use of X-rays generated at the time of imaging and is most 
commonly used as a modality for detecting broken bones and infections such as pneumonia as well 
as for angiography which is essential for treatment of aneurysms. 123  MRI (magnetic resonance 
imaging) exploits the magnetic susceptibility of tissues within the body.  Whilst commonly used for 
detecting cancer and soft tissue damage, with the addition of an imaging agent such as a barium 
meal, it can aid in the diagnosis of obstructions to or within various organs. 124  PET (positron 
emission tomography) is the only one of these techniques that relies on the introduction of an 
imaging molecule in order to build an image, as it requires a signal that body tissues alone cannot 
produce.  A radioactive tracer is introduced to the body, usually bound to a molecule that will bind 
to a specific target. 124-127  The tracer will bind to the target tissue and when the body is scanned the 
radioactive label is detected and an image built based on the prevalence of the radioactivity across 
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the body.  This has proved particularly useful in the detection of diseases such as Alzheimer, where 
Pittsburgh Compound B binds specifically to beta amyloid plaques. 127, 128  
 
Whilst contrast agents are necessary for PET imaging they are not essential for either CT or MRI, but 
under certain circumstances they are useful: The natural contrast of bodily tissues is exploited as 
much as possible but when two tissues show very similar contrast it may be necessary to introduce a 
contrast agent to create a difference in contrast (by affecting the relaxation of protons within one of 
the tissues) and obtain a better image of the tissue or organ in question.  A typical example of this 
would be the similarities between blood vessels and kidney tissue. 129  In addition to this, contrast 
agents can be doctored so that they bind specifically to certain types of tissue or molecules, for 
instance by adding an antibody for a tissue-specific antigen, leading to further advances in diagnosis 
and molecular imaging. 130-132  By making imaging agents tissue specific it is possible to track the 
delivery of drugs and movement of immune cells such as T cells in vivo.  T cells can be tracked using 
high field MRI (around 10 T). 132  Thus the fields of nanomedicine, molecular imaging and 
immunotherapy can be joined together to form a system analogous with Ehrlich’s magic bullet. 133    
 
The science of designing and making imaging agents comes under the term “Nanotechnology”.  A 
more in depth definition of this is as the synthesis, application and study of materials of 1-100 nm in 
at least one dimension, that also exhibit some form of novel or enhanced characteristic that is not 
observed at either the quantum or macromolecular level.  The only properties that have 
demonstrated a clear difference between the nanoscale and these other scales are either magnetic 
or optical, 134 although nano-gold exhibits physiological inertness compared with bulk gold, a useful 
property when developing contrast agents or delivery systems. 81  
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Section 1:  X-Ray Imaging 
 
1.1 Background 
 
X-rays were first discovered by Wilhelm Conrad Roentgen during experiments on vacuum tubes. 135 
Figure 21 shows the first X-ray image that Roentgen took of his wife’s hand. 
 
 
 
Figure 21. An image of Roetgen’s wife’s hand, taken days after the discovery of X-rays. 136 
 
In medical imaging, X-rays are generally produced with an X-ray tube powered by an X-ray generator 
which produces a high voltage to accelerate electrons from the cathode to the anode in the tube.  
The resulting high-energy electrons produce X-rays when they strike the anode. 
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X-rays interact with matter in accordance with Beer’s law (Equation 2). 117 
 
I=I0e
-μt 
 
Equation 2. Beer’s law where I0 is the number of X-rays entering an object, I is the number of X-rays 
exiting an object, t is the thickness of an object and μ is an intrinsic property of the material called 
the linear X-ray attenuation coefficient. 
 
Attenuation (μ) is proportional to the atomic number cubed (z3) and so for materials with high 
atomic number the X-rays will interact more strongly, leading to a greater loss of energy for X-rays 
passing through the material.  X-ray interactions are primarily involved with exciting the inner 
electrons of a material to a higher energy level and in some cases this can lead to production of 
further X-rays, known as Auger electrons, which will interact with tissue and interfere with the 
images produced unless they are captured.  For this reason the energy of electrons and 
concentration of imaging agent must be carefully selected to avoid this effect as much as possible.   
 
As an X-ray beam passes through a body it undergoes changes with some of the X-rays being 
scattered and others being absorbed by the body tissues. The absorption is attenuation as described 
in Beer’s Law.  So, the beam exiting the body differs from the beam that enters the body in that it 
has varying intensities at various points depending on the tissue that it has passed through, and so 
contains information that can be recorded and then transformed into a visual display. 
 
Historically X-ray detection has been by means of photographic film where the high or low energy of 
the X-ray beam develops the film or leaves it untouched, leading to a negative print. 117  However 
nowadays detectors typically consist of an X-ray attenuator that turns the X-ray signal into either an 
optical or electronic signal which can then be processed, and a device for recording the light or 
electrons.  Digital detectors are now used and imaging conducted using digital detectors is referred 
to as computed tomography (CT) or digital radiography. 
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1.2 Contrast Agents 
 
Bone and soft tissues are easily distinguishable by X-ray imaging due to their difference in 
composition. Soft tissue contains low atomic number atoms such as carbon and bone contains 
higher number atoms such as calcium.  However, many tissues in the body have very similar 
composition making it difficult to tell them apart on an X-ray image, and for this reason, imaging 
media need to be introduced in order to clarify the image.  These can work in two possible modes; 
as a positive contrast agent, whereby the agent reduces interaction of the X-rays in the tissue by 
means of lowering attenuation leading to more energy from X-rays reaching the detector, or as a 
negative contrast agent which increases the interaction of the tissue or area with the X-rays by 
increasing attenuation, thus leading to less energy from the X-rays reaching the detector. 117 
 
1.2.1 Positive Contrast 
 
Carbon dioxide, containing atoms with low atomic numbers, is often used as a positive contrast 
agent for imaging of the gastrointestinal (GI) tract, with some patients being given carbonated drinks 
prior to X-ray. 137-140  Areas where the positive contrast agent is present appear lighter on images as 
the gases used do not interact strongly with the X-rays and so it is easier for the X-rays to pass 
straight through that area to the detector without any significant loss of energy.  One widely used 
positive contrast agent is barium sulphate, otherwise known as barium meal, which is also used for 
imaging of the upper GI tract. 
 
1.2.2 Negative Contrast 
 
Typically these contain high atomic number atoms, with iodinated agents being commonly used, as 
iodine has an atomic number of 53, making it significantly different from the atoms found in tissues 
(Carbon z=6, Oxygen z=8, Nitrogen z=7).  Iodipamide© and Iohexol© are two popular contrast agents 
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(Figure 22) that can be administered intravenously to aid diagnosis and treatment, particularly for 
problems with blood vessels such as obstructions and haemorrhages. 141, 142  
 
  Iohexol© 
 
 
 Iodipamide© 
 
Figure 22. Commonly used X-Ray imaging agents  
 
In recent years gold has been investigated for use in X-ray contrast, having an atomic number of 79.  
Gold nanoparticles (GNPs) have been suggested as an alternative to iodinated media due to their 
increased contrast, residence time, and inertness.  Figure 23 shows that gold is superior to iodine in 
terms of contrast. 143 
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a) Imaging of iodinated contrast agent vs. gold nanoparticle contrast agent performed using X-ray 
phantom 
 
b) Image of rat kidneys using intravenous iodinated imaging media 
 
 
c) Image of rat kidneys using intravenous gold imaging media 
Figure 23. Images showing the contrast between iodine and gold as X-Ray imaging agents. 144 
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Whilst GNPs may seem like an ideal replacement for iodinated media, particularly due to the side 
effects and risks involved in using them, they also have their problems.  In preliminary studies it has 
been shown that far from being cleared by the renal system as is the case with media such as 
Iodipamide©, GNPs are too small to be cleared by the reticuloendothelial system (RES) and so 
accumulate in the liver causing liver damage. 71, 145 This is a problem that needs to be overcome if 
GNPs are to be successful in making it to the market as an in vivo imaging agent. 
 
1.3 Applications 
 
Iodine occurs naturally in the body in many forms including that of the hormone thyroxine, so it is 
important that when the contrast media is administered to the body it has levels of iodine that far 
exceed those naturally present.  A single dose of X-ray contrast medium commonly contains around 
2000 times more iodine than the body and so overcomes this problem. In addition to this, it is 
efficiently cleared from the body with low incidence of side effects, although side effects such as skin 
irritation, kidney damage and anaphylactic shock can occur. 146  
 
Iodinated contrast media are commonly used for angiography. 138, 147   The media is injected 
intravenously and blood flow can be monitored as it pumps the media around the body.  This can 
highlight any blockages in blood vessels and is also useful for diagnosis and treatment of aneurysms 
where contrast agent is used to help to guide the surgeon during the procedure to fill the aneurysm 
(Figure 24). 123   
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Figure 24. Image showing how blood vessels can be imaged via CT angiography.  The first and second 
images show the blood vessels in the brain as they are flushed with Iodipamide© and imaged by CT.  
The final image shows a large dark area, which is the aneurysm picked out, again using Iodipamide© 
contrast agent. 
 
Another important application of X-Ray contrast media is for imaging of the gastrointestinal (GI) 
tract.  A barium meal (barium having a high atomic number of 56) which is essentially barium 
sulphate, is taken orally and its passage through the GI tract monitored by X-Ray.  It is also possible 
to use carbon dioxide gas in addition to the barium meal for a double-contrast analysis. 148  Other 
applications include urography, 149, 150 myelography151, 152 and arthography. 153 
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Section 2: Magnetic Resonance Imaging 
 
2.1 How MRI works 
 
Hydrogen nuclei (protons) possess a natural magnetization and so, when placed in a magnetic field, 
will align themselves with that field.  MRI works on the basis that protons in different environments 
will behave in different ways when the magnetic field is manipulated.   
 
Medical MRI works in the following way:  an initial magnetic field is applied and so the protons in 
body tissues in the form of water or fat, will align themselves with this field.  When a radio 
frequency pulse is applied the nuclei rotate by 90° so that they are at a right angle to the original 
magnetic field (B0).  When aligned in this way the nuclei precess in phase with each other.  Following 
the Rf pulse two things happen, both of which can be measured.  The nuclei flip back from the 90° 
rotation to realign with the original magnetic field, known as longitudinal relaxation, or spin-lattice 
relaxation (T1), characterised as an increase in signal as they return to their original position.  The 
longer it takes for the protons to return to alignment with the magnetic field the smaller the signal 
received.  The nuclei also begin to precess out of phase with each other, with some precessing faster 
and some falling behind, known as spin-spin relaxation (T2) due to the fact that in this case the nuclei 
transfer energy to each other as they spin.  In this case the signal is lost as the net precession adds 
up to a total loss of phase (Figure 25). 129, 154  These values are often reported as R values, where R1 = 
1/T1 and R2 = 1/T2.  This calculation makes the small numbers for T1 and T2 more manageable and 
shows a quicker relaxation time as a more positive number. 129 
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Figure 25. a) b) Spin-lattice relaxation (T1); c) d) Spin-spin relaxation (T2)154  
 
T2* is similar to T2 in that it involves the nuclei precessing out of phase, but whilst T2 comes about 
purely through spin-spin relaxation, T2* occurs faster because it also involves inhomogeneities in the 
magnetic field and can be affected by the magnetization of the material itself.  T2 and T2*are related 
by the equation in Equation 3 where γ is the gyromagnetic ratio and ΔB is the variation in magnetic 
field. 129 
 
1/T2* = 1/T2 + ½ γ ΔB 
Equation 3.  Equation showing the relationship between T2 and T2* 
 
Once these relaxation times have been measured the signal, which will be large for long relaxation 
times and small for short relaxation times, is converted into an image, with the larger signal 
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translating as a white area, ranging through shades of grey, to the smallest signal for the shortest 
relaxation times translating as a dark or black area.  Differences in proton density and relaxation 
times between tissues lead to natural contrast in MRI images, but in some instances the proton 
environments are so similar that further contrast needs to be created. 129  
 
2.2  Contrast Agents 
 
Different bodily tissues have different relaxation times and thus appear differently on images, 
depending on the hydrogen density of the tissue (Table 1.) 
 
Tissue T1-weighted image T2-weighted image 
Fat Bright Bright 
Aqueous liquid Dark Bright 
Tumour Dark Bright 
Inflammatory tissue Dark Bright 
Muscle Dark Dark 
Connective tissue Dark Dark 
Hematoma, acute Dark Dark 
Hematoma, subacute Bright Bright 
Flowing blood No signal No signal 
Fibrous cartilage Dark Dark 
Hyaline cartilage Bright Bright 
Compact bone Dark Dark 
Air No signal No signal 
 
Table 1. Indicating the MRI similarities and differences between tissues in the absence of contrast 
agent.129  
 
Some tissues have very similar relaxation times, such as tumour and inflammatory tissue.  129, 154  As a 
result it is necessary for contrast agents to be introduced.  To reduce the T1 relaxation times which 
54 | P a g e  
 
leads to an increased signal intensity on T1 weighted images (positive contrast agents) or decrease 
the T2 relaxation times leading to a decrease in signal (negative contrast agents).  Thus the contrast 
of tissues is altered so that they can be differentiated from each other with greater ease on the 
resultant image.  These agents will work either by altering T1 leading to T1 weighted images, by 
altering T2 leading to T2 weighted images, or in some instances the contrast agent is capable of 
altering both T1 and T2 significantly and so either can be exploited. 
129 
 
2.2.1  Positive Contrast Agents 
 
The first positive contrast agent to be produced was Gd-DTPA (Magnevist, Schering AG), in 1988. 155  
Gd itself has seven unpaired 4f electrons and the largest spin moment (S= 7/2) of all of the rare earth 
metals meaning that it has a strong magnetic effect making it suitable for MRI contrast.  However, 
Gd3+ is highly toxic and so has to be heavily chelated before it can be administered into the body. 155-
159  Chelating has the effect of reducing the proton relaxivity of Gd, meaning that although alone it 
has a very strong relaxation effect in low doses, it must be administered in large doses in the 
chelated form leading to some severe side effects such as nephrogenic systemic fibrosis, which 
increased in incidence as the use of Gd chelates for MRI increased.160  It is thought that the disorder 
occurs when other metal ions such as Zn, Cu or Fe replace the Gd, leading to dissociation of free Gd3+ 
into the body.  Due to this problem there is continuous research into the development of suitable 
chelating agents which do not allow this to occur, such as the ligands offering eight coordination 
sites (Figure 26). 156  In addition to this, compounds containing other elements have been explored 
such as manganese161, 162 and iron163  both producing T1 weighted images where the tissue 
surrounding the imaging agent appears lighter than other tissues (Figure 27).   
The type of image produced is affected not only by the nature of the tissue surrounding the contrast 
agent but also by the rate at which any water associated with the Gd chelate exchanges with water 
in the nearby tissues.  This can be affected by the number of water molecules present and the 
nature of the chelating agent, and so the chelating agent should be carefully chosen.  
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Figure 26. Structural formula of common Gd chelates.  Note that there are eight coordination sites 
making this a very stable chelating agent (A-D).  Lower image shows the structures of two 
representative commercial gadolinium MRI contrast agents; (a) gadobenic acid and (b) gadoxetic 
acid with optimum doses of these agents being 1 mmol kg-1 in adults. 156 
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Figure 27. The left hand image shows an image of a rat brain and eye sockets before addition of a 
contrast agent.  The right hand image shows white enhanced areas where the positive contrast 
agent, in this case Mn2+ has accumulated in the tissue.164 
 
Whilst Gd is typically used to image organs, blood vessels, intestines and occasionally the brain, 
through its formation of protein adducts the possibility of using Gd to image proteins (specifically 
human serum albumin (HSA)) has been explored.  The in vivo imaging of proteins would be beneficial 
for identifying the presence of disease related proteins and the presence of certain cell types. 
Whilst these Gd complexes themselves cannot cross the blood-brain barrier, they can slowly leak 
across and accumulate in lesions where the blood-brain barrier has been disrupted. 161, 165, 166 
 
2.2.2  Negative Contrast Agents 
 
Recently superparamagnetic iron oxide (SPIO) nanoparticles have been used as negative contrast 
agents. 167-171  The iron oxide structure contains both Fe2+ and Fe3+ ions which have unpaired 
electrons within the lattice that are able to align with the magnetic field leading to the paramagnetic 
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effect.  When the SPIOs, such as Endorem©, which was recently removed from the market due to 
safety issues, are used for imaging of the GI tract they are introduced to a particular part of the body 
and a magnetic field applied, the magnetic effect of the SPIOs greatly reduces the relaxation time of 
the protons in the surrounding tissues, thus making them appear dark on the image.  In particular, 
SPIOs are useful for imaging of the liver, as SPIOs are taken up by Kupffer cells, which are specialized 
macrophages found in the liver lining (Table 2). 172   
 
Class Agent Trade Name Status Mean 
Particle 
Size 
Oral SPIO AMI-121 (Ferumoxsil) Lumirem, Gastromark Approved > 300 nm 
 OMP Abdoscan Approved 3.5 um 
SSPIO 
(Small 
superparamagnetic 
iron oxide) 
AMI-25 (Ferumoxide) Endorem, Feridex Approved 80 - 150 
nm 
 SHU555A 
(Ferucarbotran or 
Ferrixan) 
Resovist Phase III 
complete 
62 nm 
USPIO 
(Ultrasmall 
superparamagnetic 
iron oxide) 
AMI-227 
(Ferumoxtran) 
Sinirem, Combidex Phase III  20 - 40 
nm 
 NC100150 Clariscan Phase III 20 nm 
 CODE 7228 Advanced Magnetics Phase II 18-20 nm 
 
Table 2. Examples and properties of Commercial SPIO Agents91 
 
Whilst it is beneficial to have an effective imaging agent, the doses cannot be too high as they 
shorten the T2 to such a degree that it is too short to provide a signal.  Optimal doses are typically 8-
16 μmol of Fe per kg. 91  The problem with this approach is that it does not take into account the 
effect that any coating agent or solvent-solvent interactions, which may alter relaxation times.  
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2.3  Detection, Diagnosis and Treatment 
 
MRI and the various contrast agents associated with it have been used in various areas of research 
into both diagnosis and treatment of disease. 134, 167, 173-178  The high resolution of MRI allows for very 
precise detection of diseases such as cancer, and so is an invaluable tool in its diagnosis.  In addition 
to this it is possible to functionalise the contrast agents that are used in order to treat the disease, 
monitoring it by MRI as treatment progresses. 176 
 
2.3.1 Hyperthermia 
 
The National Cancer Institute defines hyperthermia in terms of a cancer treatment in which body 
tissue is exposed to high temperatures (113° F ) to damage and kill cancer cells. 179  113 °F is roughly 
45 °C so the research shows that the SPIOs are able to induce sufficient temperatures for 
hyperthermia treatments.   
Hyperthermia is a rise in normal body temperature caused when the body absorbs more heat energy 
than it can dissipate; this can be local or systematic. The use of hyperthermia in the treatment of 
diseases, specifically cancers, dates back to the time of Hippocrates who used hot iron to cauterize 
surface tumours.  In more recent years this technology has been brought up to date with the use of 
pyrogens (such as bacterial toxins), high frequency radiation and magnetic fluid hyperthermia.73, 78, 
178, 180-184   
Hyperthermia is emerging as a promising application of SPIOs for treating cancer.  Due to their 
superparamagnetic nature SPIOs, when placed in a rapidly oscillating magnetic field, are able to flip 
rapidly leading to localised heating effects.  Work carried out on Ehrlich carcinoma’s in mice 
indicated that the SPIOs could induce a maximum temperature of 47 °C in the centre of a tumour 
measuring 78.2 ± 3.5 mm3. These elevated temperatures led to restriction of blood vessels around 
the tumour and thus hypoxic conditions, leading to apoptosis and a subsequent slowing in tumour 
growth. 178 
Hyperthermia works by damaging cancerous cells and proteins associated with those cells so that 
either the cells die or they are more susceptible to radiation (radiotherapy).  So, hyperthermia can 
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be used either on its own as a localised, regional or whole body therapy, or in conjunction with the 
more commonly used radiotherapy and chemotherapy. 179  
The possible side effects of traditional hyperthermia techniques, in which probes or directed 
microwave or radio-waves are used to create a rise in temperature, include burns, blisters and 
general discomfort as well as possible bleeding and blood clots. 179  This is because these methods 
are not specific enough and may damage healthy tissues.  By using nanoparticles to direct the 
heating effect to certain areas only, it is possible that the heating affect could be mainly contained to 
the tumour area only (although whole body hyperthermia for treating metastatic cancers would not 
benefit), thus reducing side effects. 179  
A specific method has been to use modified aminosilane magnetite nanoparticles which have a 10-
fold higher uptake by malignant prostate cells than by normal prostate cells, making it easier to 
facilitate a specific hyperthermia treatment. 185  If this contrast can be repeated in other types of 
cancerous cells, it would give a much more specific response to the effects of hyperthermia than 
other methods.186  Another example of the success of using magnetite nanoparticles for 
hyperthermia is the use of dextran magnetite for oral cancer hyperthermia186  In this study the 
particles were injected into the tumour directly and the hyperthermia group showed a significant 
reduction in tumour growth and a significant increase in survival rates when compared with the 
control group. 
Hyperthermia has also been used for inducing production of heat stress/heat shock proteins which 
have will be explored in Ch. 1.3, Section 7.4. 
Currently the main method for delivering SPIOs to the desired area for hyperthermia is through 
injection directly at the site, although it is possible that other methods could be used. 
 
2.3.2 Transdermal drug delivery 
 
In 1995 transdermal drug delivery was hailed as “a breakthrough in the field of controlled drug 
delivery systems”. 187  Oral drug delivery routes are problematic as the drug must pass through the 
digestive system where it is subject to enzymatic attack and degradation by pH, and then must also 
evade breakdown by the liver via the first pass effect.  For many therapeutics, such as insulin, the 
conditions in the GI tract render them useless.  Bearing this in mind it is obvious that the 
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transdermal route, bypassing all of these problems, would be more desirable.  However, the 
transdermal route is not without its own complications. 
The skin is designed to prevent the passage of many substances, and so is a barrier for the delivery 
of drugs.  Therefore, most drugs are unable to pass through the skin at a rate that is beneficial 
therapeutically, with rates being reported as being between 500 and 10, 000 times slower in the 
stratum corneum than in the dermis or sub-cutaneous tissue. 188  When determining the dosage of a 
drug required the actual amount of drug that must be applied in order for an effective amount to 
enter blood circulation must be considered.  As the rate of passage is so low a vast amount of the 
drug will be wasted, and only very potent drugs are usually effective.  In addition to this, the stratum 
corneum (Figure 28) only allows the passage of small, lipophilic molecules of < 400 Da (400 g.mol-1), 
which further reduced the number of different drugs for which this technique is useful. 188   
To increase the permeability of the stratum corneum a process known as electroporation can be 
carried out. 189 This involves applying short, high-voltage pulses to the skin which create pathways in 
the pores through which aqueous medium, or indeed hydrophilic drug molecules, can pass. 189   
Other methods for increasing permeability include pressure waves, 190 thermal ablation, 191 and 
ultrasound. 192  
 
 
 
Figure 28. Images of the skin in different formats.  The first image shows the structure of the skins 
with the second image being a schematic showing the building blocks of the skin.  The right hand 
image shows the molecules that make up the various areas of the skin. 
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Patches have previously been favoured, with the first patches being developed by Tojo in 1987 for 
the treatment of motion sickness.  Since then many other applications have been trialled which 
include the popular nicotine patches, hormone replacement therapy (HRT) and pain relief. 188 
For these reasons hypodermic injections have been favoured for delivery of therapeutics, and recent 
efforts have been focused on synthesis and trialling of microneedles.  These needles are able to 
bypass the stratum corneum and so allow delivery of large macromolecules that would not 
otherwise be able to pass the top layer of skin. 188  One study reports using materials such as 
polyglycolic acid (PGA) and polylactic acid (PLA) and their copolymers.  These needles were 
synthesised with a diameter of ~ 100 µm at the base and ~ 10 µm at their tips, and were plated at 
300 needles per cm3, and were found to be successful in piercing the stratum corneum. 193  
However, these techniques are limited in that they require a professional to administer the injection, 
in contrast to creams and patches that can be administered by the patients themselves. 
Microemulsions have also been explored as an alternative to traditional gel preparations and have 
been found to enhance the delivery of both lidocaine and acetaminophen. 23  A more recent study 
(2006) into the effectiveness of microemulsions in improving passage of diclofenac through the 
stratum corneum, showed an 8-fold increase in the concentration of diclofenac passing into blood 
circulation in rats.       
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Figure 29. Showing the possibilities for maximising drug delivery 194 
 
Whilst all of these are good options for improving passage of drugs across the stratum corneum, 
they are all limited by both the solubility and size of the drugs, and means that delivery of peptides 
and DNA/RNA is not possible via transdermal routes.  One research group reported using a cell-
penetrating peptide to modify iron oxide nanoparticles in order to carry siRNA to cancer cells.  The 
results of the study showed an enhanced permeability and retention effect which has the possibility 
to be useful for MRI and other drug delivery applications. 195 
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Figure 30. Showing an iron oxide nanoparticle coated with a cell penetrating peptide, with siRNA held 
between the amine moieties at the terminal end of the peptide.195 
 
2.3.3 Anaemia 
 
Iron oxide was used for years in the treatment of Anaemia with various preparations being used to 
overcome problems with toxicity and bioavailability. 196  Studies into bioavailability have used 59Fe 
for radioactive tracing of iron from IV preparations (59Fe AMI-25), through the liver and its 
subsequent incorporation into haemoglobin.  Studies on rats showed that 1 % of the 59Fe had been 
incorporated into erythrocytes after 2 days, rising to 20 % by day 49 with similar rates being 
observed for haemoglobin. 197  More recently studies into using iron oxide nanoparticles coated with 
ascorbic acid (vitamin C) have been carried out which indicate that the two substances combined 
lead to an overall increase in the bioavailability of iron to the body. 196  In their patent Salah El-Din et 
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al describe using ascorbic acid coated SPIOs to treat anaemia orally, and claim that this single dose 
preparation is able to increase iron levels back to normal within 10 days. 196     
As well as being used for detection or diagnosis of disease SPIOs can be used for the treatment of 
disease.  The particles can be conjugated to drug molecules and used as a delivery system, 198 or can 
be used to stimulate hyperthermia so that cancer cells can be specifically killed through heating. 182, 
199 In a very different application, SPIOs have previously been used in the treatment of anaemia as 
the body can process the SPIOs, using the iron for making haemoglobin. 200  
 
 
2.4  Structure of iron oxide  
 
The atoms in the iron oxide bulk material are arranged in what is referred to as an inverse spinel 
structure.  What this means is that there are two types of metal coordination site, one being 
octahedral (2/3) and the other being tetrahedral. 201  In a regular spinel structure the general 
formula is AB2X4 where A is usually M
2+, B is M3+ and X is generally oxygen.  However, in an inverse 
spinel half of the sites occupied by M2+ ions are generally swapped for M3+ ions as illustrated in 
Figure 31.   
 
Figure 31. Crystal structure of magnetite with blue atoms representing tetrahedrally coordinated 
Fe2+; red atoms representing octahedrally coordinated 50/50 Fe2+/Fe3+; white atoms are oxygen.   
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This structure explains why during synthesis of Fe3O4 the molar ratios of the Fe
2+ and Fe3+ are 2:3 
respectively. 
What is also clear from this structure is that at the surface of any material made from iron II, III oxide 
is that there will be Fe2+ and Fe3+ ions exposed at the surface.  This gives the material a positive 
charge which makes it able to interact with any solvents of coating materials nearby.  There will also 
be O2- ions present at the surface which under certain conditions allow the substances to interact 
electrostatically with positively charged materials. 
 
2.5 Magnetic properties of bulk iron oxide 
 
Iron oxide as mentioned consists of Fe2+ and Fe3+ ions which contain electrons with unpaired spins 
which make the material paramagnetic, meaning that these unpaired spins will align with a magnetic 
field when exposed to it but return to their original unaligned state when the magnetic stimulus is 
removed.  In the bulk material the electrons are arranged in magnetic domains, known as Weiss 
domains that are separated by an area called a Bloch wall.  The alignment of spins with the magnetic 
field can be parallel or anti-parallel depending on the direction of the electron’s spin. 92  
 
 
2.6 Magnetic properties of iron oxide at the nano scale 
 
The magnetic properties of magnetite in its nano form differs from magnetite in its bulk form 
primarily due to the fact that in the nano form the particles become so small that the formation of 
Bloch walls becomes energetically unfavourable, leading to the formation of crystals that have a 
single Weiss domain (single-domain crystals) as depicted in Figure 32. These single domain crystals 
have a much higher saturation magnetization as the whole crystal is able to align itself within the 
magnetic field. 92  Iron oxide nanoparticles therefore exhibit stronger paramagnetism than ordinary 
iron oxide and so are given the term superparamagnetic.  Despite this large magnetism SPIOs do not 
retain any magnetization when the magnetic field is removed, as thermal energy is strong enough to 
randomize the orientations of the SPIOs leading to disorder of the electron spins. 
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Figure 32. Image showing how at decreasing particle size fewer Bloch walls form leading to a 
reduction in the number of Weiss domains with the smallest particles having a single Weiss domain.92  
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Figure 33. Showing how protons or electrons align with the magnetic field depending on their spin 
(opposite spin leads to alignment in opposite directions to the magnetic field).  
 
2.7 Current status of clinical application 
 
Of the numerous iron oxide nanoparticles produced so far only two of these have been approved for 
clinical use, and more recently these have been removed due to bioaccumulation to toxic levels in 
some long lived cells leading to side effects.  These fall under the categories of ferumoxides 
(including Endorem®) and ferucarbotran. 
Ferumoxides are SPIOs coated with a low molecular weight dextran.  As has been mentioned 
previously, polymers such as dextran make the particles water soluble and increase biocompatibility.  
The particle size is 120-180 nm which is large enough that the particles will be picked up by the RES.  
Side effects from these preparations include low blood pressure and back pain, although side effects 
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are only severe enough to stop diagnosis in 2.5 % of patients.  The optimal dose it set at 0.56 mg 
(0.01 mmol) of iron per kg of body weight. 202-205 
Ferucarbotran®, also known as Resovist®, is a carboxydextrane coated SPIO with a particles size of 
45-60 nm.  It has a similar mode of action to the ferumoxides but has significantly lower incidences 
of side effects and can be delivered in much larger doses over a short period of time with no ill 
effect.  The application of a bolus injection technique to this drug is very different to the delivery of 
ferumoxides which need to be injected slowly over the period of up to half an hour, as oppose to the 
bolus which can be delivery is 20 – 30 seconds. 206  The optimal dose for Resovist® is set at 0.45 
mmol of iron per patient for patients < 60 kg, and 0.7 mmol of iron for patients > 60 kg.  Vasodilation 
(possibly due to the bolus technique) and paraesthesia are the most common side effects for this 
imaging agent 206   
Both of these are used for liver imaging as upon clearance by the RES the SPIOs are transported to 
the liver (if it is functioning normally), spleen, bone marrow and lymph nodes.  These iron 
compounds are degraded in lysosomes (~ pH 4.5) and the resultant iron ions are used to form iron 
compounds in the body such as haemoglobin, or else are cleared from the body. 
Other potential imaging agents such as Clariscan®, a PEG coated SPIO formulation and Ferumoxtran-
10 for diagnosis or prostate cancer have been unsuccessful in gaining FDA approval.  Clariscan® led 
to severe side effects and Ferumoxtran-10 led to false positives in too many cases.  Recently 
Resovist® has been taken off the market due to concerns over safety and it looks likely that 
ferumoxides will also be removed from clinical application for similar reasons. 207   
Although SPIO preparations have proved to be non-toxic in an in vitro setting, when administered in 
vivo they have a negative effect on cell homeostasis and are able to bioaccumulate in cells.  In high 
concentrations SPIOs can hinder cell proliferation by altering the cytoskeleton. 208  If targeted to the 
correct cell this could be exploited to hinder cancerous cell growth, but in a normal setting it is 
detrimental to the patient. 
Although SPIOs are so far unfavourable as IV agents, the oral agents for GI imaging such as 
Ferumoxsil® and Lumirem® are still available on the market although there is very little demand for 
these as other preparations such as barium sulfate and Gd chelates are already well established. 124, 
148, 156, 209   
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Chapter 1.3:  Cancer Immunotherapy 
 
Section 1: Cancer 
 
1.1 Background 
 
Cancer is a multifaceted disease that is characterised by unlimited replication of cells and other 
attributes which will be discussed in detail later on.  One definition of cancer cells is that they are 
altered self-cells that have escaped normal growth-regulating mechanisms. 210 
It has been reported that in 2008, 12.66 million people were diagnosed with cancer worldwide, and 
7.56 million people died from cancer. 211  The statistics reflect both developed and developing 
countries, although incidence and deaths from cancer are generally higher in developing countries.  
The same data indicates that men are at an increased risk of developing cancer, with 204 men per 
100, 000 in the UK being diagnosed, as opposed to 165 per 100, 000 women.  These statistics show 
that lung, breast, colorectal and prostate cancers are the most prevalent in the UK, accounting for 
54% of cancer diagnoses (Figure 34). 211 
 
 
 
Figure 34. Bar chart showing the number of deaths from different types of cancer worldwide in 2008 
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As mentioned, cancer is a disease defined by several characteristics, each of which must be acquired 
during the development of the disease in order for a successful tumour to develop.  The key 
characteristics are referred to as the Hallmarks of Cancer (Figure 35) 210 and include: limitless 
replicative potential, sustained angiogenesis, evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, and tissue invasion and metastasis. 210   
 
 
 
 
 
 
Figure 35.   Digram naming the six hallmarks of cancer 
 
More recently two other hallmarks have been discovered, although these have not yet been 
confirmed.  They are; Reprogramming of energy metabolism, and Evading immune destruction. 212, 
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213  By looking at the different hallmarks together and understanding that in order to become 
successfully established the cells must undergo multiple mutations to develop each of these 
hallmarks, it is clear to see that cancer is a very complex disease, and so must be better understood 
in order for simple treatments to be developed. 
 
1.2  The hallmarks of cancer 
 
Tumorigenesis is a multistep process that is thought to involve six key processes, revealing cancer to 
be a disease involving dynamic changes in the genome.  This process is analogous with Darwinian 
evolution where, through a series of mutations in the genome, normal cells are transformed into 
cancerous cells, adapted to survive and thrive in their environment.  These genetic mutations are 
involved primarily in disruption of the cell’s normal relationship and response to surrounding cells 
and the body’s defence mechanisms, including recruiting normal cells to assist their survival.  These 
acquired capabilities of cancer are referred to as the six hallmarks of cancer (Figure 35). 210  With the 
addition of two possible new hallmarks this number could increase to eight. 
 
1.2.1 Self-sufficiency in Growth Signals 
 
Our body cells are designed so that they are carefully controlled in terms of growth, proliferation 
and senescence.  This is essential for the growth of normal tissues, as without these controls tissues 
will not function properly and will not form the correct shapes and arrangements needed to make 
up working organs.  Whilst normal cells rely on neighbouring cells to signal for them to proliferate, 
known as heterotypic signalling, cancer cells are able to stimulate or regulate their own 
proliferation. 214  The three main ways in which they achieve this are herein described. 
Cells are able to produce their own growth signal ligands and the receptors needed in order to 
respond to them.  This is known as autocrine stimulation. 215  When this occurs the cell is no longer 
dependent on other cells within the tissue for proliferation, and so an element of the regulation is 
no longer controlled. 
Neighbouring cells release small levels of growth factors that cancer cells would not usually respond 
to, but overexpression of growth factor (GF) receptors can make the cell hyperreponsive to these 
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low levels.  One example of this type of cancer adaptation is in the overexpression of the HER2/neu 
receptor in stomach and mammary carcinomas. 216  
Alternatively, the same types of receptors may be mutated so that they are able to fire independent 
of the ligand they come into contact with.  As has been mentioned, in order to successfully become a 
tumour, normal functioning neighbouring cells are often co-opted into supporting the growth in 
some way.  It is possible for cancer cells to produce signals (proteins) that will induce the 
surrounding cells to produce growth signals. 217 
 
 
1.2.2 Insensitivity to Antigrowth Signals 
 
Normal cells are subject to control of proliferation by antigrowth signals that either force the cell to 
stay in the growth phase (G0 phase) as oppose to the active proliferation stage, or that induce the 
cell to enter a postmitotic state associated with terminal cell differentiation, after which the cell can 
no longer proliferate. 214  Nearly all antiproliferative signals are directed through the retinoblastoma 
protein (pRb) which, when hypophosphorylated, will block proliferation by altering the function of 
certain transcription factors (E2Fs) involved in progression from the growth phase to a stage of 
active cell division.  One of the most well documented antigrowth factors, TGFβ, works by 
preventing phosphorylation and thus inactivation of pRb in various ways including by synthesis of 
proteins that are able to block complexes responsible for phosphorylation. 218  One of the ways that 
cancer cells lose their responsiveness to antigrowth signals is by down-regulation of TGFβ receptors 
or by producing mutant receptors.  If receptors do not work then pRb can become 
hyperphosphorylated, inactivated, and so E2Fs are free to signal to the cell to enter a state of active 
proliferation.  It is also possible for the pRb gene itself to become mutated leading to a non-
functional protein, or as in the case of human papillomavirus, the pRb function is eliminated as viral 
oncoproteins hijack cell machinery. 210, 212, 213   
In addition to these mechanisms, cancer cells are also able to switch off expression of integrins and 
other molecules that send antigrowth signals to the ECM.  This means that progrowth signalling 
molecules are favoured, and the cell can avoid terminal differentiation by shifting the balance of 
molecules that lead to differentiation back to favour growth and proliferation. 210 
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1.2.3 Evading apoptosis 
 
If a tumour cell population is to prosper then it must increase levels of proliferation (as detailed 
previously) and decrease cell attrition (reduction in numbers/size), the main source of which is 
breakdown due to apoptosis or programmed cell death.  The idea that apoptosis was a barrier to 
cancer was first suggested in 1972 by Kerr et al. when it was noted that when hormones were 
removed from rapidly growing hormone-dependent tumours there was mass apoptosis. 219  Since 
this time anti-apoptotic oncogenes have been discovered which support the theory.  Studies indicate 
that apoptosis is triggered by overexpression of certain oncogenes, supporting the theory that 
apoptosis is a defence mechanism against cancer. 
 
Resistance to apoptosis can be acquired through many different routes, with the most commonly 
occurring mutation involving the p53 tumour suppressor gene.  Non-functional p53 proteins are 
prevalent in over 50% of human cancers. 220  Loss of this protein leads to less detection and thus 
removal of damaged DNA.  The p53 protein will be discussed in more detail in Ch. 2; Section 4. 
 
1.2.4 Limitless Replicative Potential 
 
Research over the past 40 years has indicated that even with the cancer cells being completely 
independent of their environment in terms of regulatory and growth signals, this is still not sufficient 
for the cell to prosper and form a tumour.  Normal cells in culture are found to have a finite 
replicative potential, termed senescence, being able to replicate only a certain number of times 
before further proliferation leads to them going into a crisis state as faults within the cell, including 
fusion of chromosomes to each other, stop it from further replicating and induce mass apoptosis. 221   
 
However, if a cell is able to multiply successfully without limit then it is said to have been 
immortalized, and this is what is observed with most cancer cells in culture. 214  Normal cells can 
double 60-70 times, but as cancer cells suffer very high rates of attrition, this replication barrier 
becomes a problem if they are to amass enough cells to successfully form a tumour.   
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The main defence mechanism against immortalization is the presence of telomeres on each 
chromosome.  These act as a barrier to chromosomes fusing together which leads to karyotypic 
disarray (a characteristic of the crisis state that leads to cell death).  However, there are a limited 
number of these and at each replication one of the telomeres is removed.  Once every telomere has 
been removed the cell will eventually die.  What is noticed in cancer cells is that the telomeres are 
maintained. 222  The most commonly reported reason for this is the upregulation of the telomerase 
enzyme which adds hexanucleotide repeats onto the ends of telomeric DNA, thus preventing the 
chromosomes from fusing together and increasing the cancer cells replicative potential. 223  This 
property of cancer cells is exploited for the synthesis of monoclonal antibodies.  A plasma cell 
producing a specific type of antibody can be fused with a cancer cell and thus become immortalised, 
leading to an immortal cell which can replicate and produce masses of a particular antibody. 214 
 
1.2.5 Sustained Angiogenesis   
 
Virtually all cells in a tissue need to be within 100 μm of a capillary in order to receive the oxygen 
and nutrients that they need, so in order for the tumour cells to survive they must develop an 
angiogenic ability so that new blood vessels can be grown in the proliferating tissues.  Proliferating 
tissues do not naturally have angiogenic ability, this is developed via a series of signals and 
interactions with over two dozen angiogenic inducer factors and endogenous inhibitor proteins 
currently known. 214  Vascular endothelial growth factor (VEGF) plays an important role in the control 
of angiogenesis and experiments have shown that in the presence of anti-VEGF antibodies 
neovascularisation is impaired. 224  In this study it was shown that subcutaneous tumours were 
unable to exhibit rapid growth when the antibodies were introduced, further proving that 
angiogenesis is important in the formation and expansion of tumours. 225 
 
It is thought that tumours activate the “angiogenic switch” by altering  levels of angiogenesis 
inducers through increasing gene transcription leading to increased expression of growth factors 
such as VEGF and decreased expression of inhibitors such as β-interferon. 226, 227  It is also possible 
that changes in expression are a result of loss of function of other proteins such as the p53 tumour 
suppressor which regulates the anti-angiogenic regulator thrombospondin-1.  When p53 becomes 
75 | P a g e  
 
non-functional the levels of thrombospondin-1 decrease and so angiogenesis can occur. 228  
However, the mechanisms by which the balance of various angiogenic factors is changed is little 
understood and much further research will need to be carried out before it will be possible to fully 
understand the ways in which cancer cells induce vascular formation. 
 
1.2.6 Tissue Invasion and Metastasis 
 
Metastases are the cause of 90 % of human cancer deaths, and so understanding the way in which 
cancers invade tissues and metastasise is of the utmost importance. 229  The reason that some cancer 
cells break off and form new “colonies” is thought to be because in the new area of the body there is 
more nutrients and space, but it is a very complex process that is at present not sufficiently 
understood.  One key factor that seems to lead to metastasis in particular is the malfunction of 
proteins known as cell-cell adhesion molecules (CAMs).  In one case it was found that in cancer the 
N-CAM molecule undergoes a switch in expression from a highly adhesive form to a weakly adhesive 
or repulsive form.  It seems that this lack of adhesion it what leads to cells breaking away from the 
mass and relocating in other parts of the body.   
 
In terms of tissue invasion proteases that can facilitate invasion of cancer cells across blood vessel 
walls and through normal epithelial cell layers play a large part although this is also poorly 
understood. 230, 231  
 
1.2.7 Two New Hallmarks? 
 
Although there is currently not enough evidence to justify calling the following two characteristics 
new hallmarks, there is an increasing body of evidence to suggest that the reprogramming of energy 
metabolism and evading immune destruction are likely to be characteristics that are essential to the 
formation of successful tumours. 213 
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1.2.7.1 Reprogramming of energy metabolism 
 
The uncontrolled and rapid cell proliferation associated with cancer requires a huge amount of 
energy, and so respiration in these cells is of utmost importance. 
 
Normal body cells respire aerobically, starting with glycolysis during which glucose is broken down to 
pyruvate in the cytosol.  Following this the pyruvate is, for the majority, taken up into the 
mitochondria where it undergoes a series of reactions forming adenosine 5’- triphosphate (ATP) 
energy and consuming oxygen.  Under anaerobic conditions this pathway is changed and the 
pyruvate is diverted through a different series of reactions. 213  Typically the cells in an environment 
with plentiful oxygen will respire aerobically, and those in a hypoxic environment will respire 
anaerobically.  However, it has been observed that many cancer cells are able to reprogram 
themselves to favour glycolysis even when the concentration of oxygen is high.  This seems 
counterproductive as there is an 18-fold lower efficiency when compared to anaerobic respiration. 
213  So, what is the reason for this adaptation if not for more energy? 
 
The answer is that we do not really know, hence why this hallmark of cancer has not been accepted 
officially.  A theory was first proposed by Potter in 1958, and further improved by Vander Heiden et 
al. in 2009. 232  They suggest that when the pyruvate from glycolysis is not passed on to the 
mitochondria, this allows diversion of the glycolytic intermediates to other processes.  These might 
include synthesis of macromolecules and organelles that are essential to the production of new cells.  
So, whilst the energy produced from respiration might be less, the materials available for 
synthesising new cells increases.  In addition to this, the cancerous cells up-regulate glucose 
receptors, and so increase the overall amount of glucose entering the cell, thus providing more 
materials and so more energy. 232 
 
This theory has not gained sufficient evidence, however it has been noted that embryonic tissues 
behave in a similar way.  Embryonic cells have to proliferate at a rapid rate, and so would also be 
relying on a supply of materials for making new organelles and such like. 213  Bringing these two 
types of tissues together, it is a logical assumption that the reasons for the two different cells to 
have this anaerobic glycolysis adaptation are the same, and the idea of having a large supply of 
materials for organelle synthesis is a sensible suggestion.  However, as with any theory there must 
be more evidence before this can be fully understood, and accepted as a true hallmark. 
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1.2.7.2 Evading immune destruction.   
 
Whilst there is little evidence to support reprogramming of energy metabolism as a true hallmark, 
there is even less evidence for evading immune destruction.  However, it does pose some interesting 
questions.  The immune system, as will be discussed later on, is designed to eradicate cells displaying 
foreign antigens, which includes cancerous cells with gene mutations.  In fact it has been shown that 
when cancerous tissue from an immune deprived individual is implanted into another individual with 
a fully functional immune system, the cancer is not able to establish a tumour. 233, 234  So, the 
question posed is how do cancers adapt to evade eradication by the immune system? 
 
There are several theories in development with one of the most prevalent being coercion of immune 
cells.  As cancers recruit cells of neighbouring tissues it is also possible that they recruit immune cells 
and in doing so are capable of evading immunosurveillance.  This in addition to immune tolerance 
will stop the immune system from recognising the cancer cells and their antigens as foreign and so 
reduce the chance of the immune system eliminating potential cancer cells. 213 
 
 
 
1.3  Treatment 
 
The original treatment for cancer was surgery. 214  Through history there have been reports of 
tumours being removed through surgical processes.  This is a very effective method of treatment, 
but only as long as the whole tumour is removed and no metastasis has occurred.  Whilst surgery 
can remove any affected localised tissue, if the disease has spread or has entered the blood or 
lymph, then surgery is useless in its general treatment and so other methods of treatment need to 
be adopted. 214 
 
Radiotherapy was the next method to be discovered.  It works on the principle that radiotherapy 
damages DNA, and cancer cells are more susceptible to death from DNA damage as their DNA is 
already mutated and so does not have the capability to repair itself, meaning that the cell will die.  
However, Radiotherapy can cause cancer in unaffected cells due to DNA damage, as it does not 
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specifically target cancerous cells, hence side effects such as sickness and hair loss.  These therapies 
typically target fast growing cells as cancer is fast growing, but both hair follicles and epithelial cells 
in the lumen of the small intestines are fast growing and so are targeted due to lack of specificity. 214   
 
Chemotherapy is the most recent treatment to be trialled, and there is a wide variety of anti-cancer 
drugs currently on the market including Docetaxel, Paclitaxel and Doxorubicin.  These work by 
disrupting the cell cycle (essential for tumour formation) in a variety of ways which include the 
prevention of microtubule disassembly which stops the spindle required for metaphase from 
forming (Paclitaxel).  Alternatively Doxorubicin prevents the DNA double helix from being resealed 
following DNA replication, and so stops the cell cycle at an even earlier phase. 235   
 
An example of another drug trialled for use in chemotherapy was Motexafin Gadolinium (MGd). 236  
This drug is an inhibitor of ribonucleotide reductase, and works by halting the synthesis of 
deoxyribose nucleotides which are essential for the synthesis (replication) of DNA.  However one 
year on from the original trials with this drug the FDA deemed it unsafe and so it is no longer in use. 
236  However, another motexafin derivative, Motexafin Lutetium, is currently used for the treatment 
of superficial cancers.  Although similar in name it has a completely different mode of action.  This 
derivative preferentially accumulates in tumour cells, thus making it specific, and causes local 
cytotoxic effects through production of singlet oxygen.  
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Figure 36. Motexafin Gadolinium complex with the Gd ion being coordinated to five nitrogen atoms 
and two acetate ions.236 
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Section 2:  The immune system and Immunisation 
 
The word immunity comes from the Latin immunitas, which was a word for the special protection or 
exemption from tax offered to roman soldiers by their emperors.  The development of successful 
vaccines to provide immunity has been historic, starting with Edward Jenner’s smallpox vaccination 
in 1776 the field of vaccination/immunisation has since been growing. 237  Whilst Jenner used a 
different strain to vaccinate against smallpox (he took puss from cowpox sores and injected these 
into patients, which created immunity against smallpox), Pasteur carried on this work but using 
weakened forms of a pathogen to create an immune response and thus immune memory. 238  His 
most notable work was using weakened cholera to immunise chickens against cholera.  A twist on 
this was the use of weakened toxins by Emil von Behring, which is widely used as the Diptheria 
vaccine and is also the method behind the creation of antivenom. 237   
 
Nowadays, vaccines are created using weakened forms of a virus or disease, or more simply by 
administering pathogen specific antigens.  Over the past two decades we have developed a 
comprehensive understanding of how the immune system works to create an immune response and 
subsequently immune memory.   
 
Niels Jerne was the first immunologist to correctly hypothesise that we are born with a set of 
antibodies that are able to complement any antigen that we can possibly encounter.  This 
contradicted previous beliefs that the body produced antibodies to fit the antigens it had 
encountered. 238 
 
The immune system works following the series of events described in the following paragraphs: 
 
The immune system is divided into the innate immune and adaptive systems.  The passive immune 
system is not antigen specific, and is more of a general barrier to infection, where the immune cells 
involved such as macrophages, engulf and destroy pathogens indiscriminantly.  As well as these 
indiscriminant immune cells, the innate immune system includes physical barriers to infection such 
as skin, hair, and mucous. 238 
 
The adaptive immune system consists of a variety of cells that work together to recognise, respond 
to, and remember foreign antigens. 239  This system begins with a number of proteins that circulate 
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in the blood referred to as complement which alert the immune system is a foreign 
microorganism/pathogen is encountered.  This is known as opsonisation. 238  Although complement 
is involved in other processes in the immune response such as disabling MO’s only its role in alerting 
the immune system will be mentioned here.  Due to signalling involving these proteins other 
components of the innate immune system such as macrophages are drawn to the site of infections.  
Macrophages such as dendritic cells are able to engulf pathogens, cut up their antigens 
(polypeptides) and then present parts of these antigens on their surfaces.  From this point onwards 
these cells are referred to as antigen presenting cells (APC).  The APC’s then take the antigens to the 
lymph nodes where they encounter T lymphocytes, also known as helper T cells.  There are many 
variants of these cells, each with a different antibody on their surface.  This variation is brought 
about by gene shuffling in a variable region of the DNA which can produce enough different 
combinations so as to lead to antibodies able to recognise a very large number of different antigens. 
240   
 
When the APC finds a T lymphocyte with a complimentary antibody it binds to it and thus activates it 
to replicate and produce proteins that are able to activate both B lymphocytes and killer T cells (KT). 
238, 239  The B lymphocytes produce large numbers of genetically identical cells, known as plasma 
cells, that can produce antibodies of one specific shape identical to that present on the surface of 
the activated T cell.  These are able to bind to the antigen that has been encountered.  Antibodies 
are able to bind to two antigens at a time as they have two identical variable regions (Figure 37).  
This means they are capable of “clumping” pathogens together, marking them out for phagocytosis 
and in some cases completely disabling them.  In addition to this, antibodies are able to neutralise 
toxins, in which case they are more commonly referred to as antitoxins. 238  
82 | P a g e  
 
 
Figure 37. Image showing the structure of an antibody.  The variable regions make up the antigen 
binding sites which are identical on a specific antibody.  The disulphide bonds hold the light chains 
and heavy chains together to maintain the antibody structure.   
 
As well as producing plasma cells that are capable of producing specific antibodies known as 
monoclonal antibodies for one type of plasma cell, B lymphocytes also divide to produce long-lived 
memory cells.  The benefit of this is that, should the same pathogen invade again, the B memory 
cells are able to mount a much faster immune response and hopefully lead to eradication of the 
disease before symptoms are observed.  When booster vaccines are given it is with the aim of 
producing sufficient long lived memory cells so that some form of remembered immunity is present.  
The mechanism behind forming long-lived memory cells is currently ill understood. 238  
 
Killer T (KT) cells are different to the antibody producing B lymphocytes in that they kill infected cells 
directly themselves.  KT cells have antibodies that are again identical to the originally activated T 
lymphocyte but in this instance they are able to recognise which cells are infected with the pathogen 
and kill them using enzymes and cell signals.  KT cells are able to tell if a pathogen has entered a cell 
as we have specific antigens/proteins on the surface of our cells that help our immune cells to 
recognise them as self-cells.  This is referred to as self-recognition and is essential to avoid 
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autoimmune diseases.  These proteins, referred to as major histocompatibility complex (MHC), 
become damaged when the pathogen enters the cell.  When the KT cell approaches it is able to 
recognise that the cell is a self-cell, that is has been damaged, and will also recognise antigens left on 
the surface of the cell by the invading pathogen. 238   
 
KT cells are also able to recognise if proteins expressed by a cell have been altered for example by 
mutations.  In this way KT cells are able to not only recognise and kill infected cells but also 
potentially cancerous cells that have produced incorrect proteins through gene mutation. 214, 238, 239  
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Section 3: Identifying immunogenic peptides 
 
Tumour specific antigens include those encoded by genes that are only expressed in cancer (tumour) 
cells, including those expressed as a result of gene alteration by mutation and those that are 
overexpressed by tumours, for example the folate receptor which is often used to target cancerous 
cells. 
In order to create cancer vaccines it is essential to search for antigens that distinguish cancer cells 
from normal cells.  The main method for this is SEREX (Serological Identification of Recombinantly 
Expressed Clones), 241 the procedure for which is outlined in Figure 38. 241 
 
It is essential to identify antigens that are expressed mainly or solely in cancers, and more 
specifically those that can elicit immune responses in the host, and as of 2007 over 2,500 tumour 
antigens had been identified using SEREX including those for prostate cancer. 242, 243  It is hoped that 
it will eventually be possible to produce a multivalent vaccine that is able to target several antigens 
displayed by a particular tumour.   
 
Figure 38. Flow chart describing the steps undertaken during SEREX screening. 
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Section 4:  P53 
 
The immunology section of this project focuses on the tumour suppressor protein p53 (encoded by 
the TP53 gene), or rather the mutated analogues of the protein that are strongly associated with 
certain types of cancer.  The rationale behind this choice was that the collaborating research group 
(working at the John van Geest cancer research centre under the leadership of Professor Robert 
Rees) were at the time of this research, focussing heavily on this peptide; they were currently 
trialling immunisation methods with this peptide and were in the process of synthesising a tumour 
model.  
 
The role of p53 is complex and is summarised in Figure 39.  220, 244-246 Mutated p53 is unable to block 
growth of damaged cells which may lead to cancer if other mutations initiate rapid cell growth.     
 
 
Figure 39. Diagram illustrating p53 role in the body.  Blue boxes indicate ways in which p53 can be 
activated, and purple boxes show the roles of p53 in protecting the body. 
 
Typically if a cell becomes damaged, by radiation for example, then p53 halts cell production until 
DNA damage can be repaired.  If repair is not possible it will initiate apoptosis.  p53 is found in low 
levels in cells all the time but when DNA is damaged it is expressed at high levels, the reasons for 
which are explained below. 
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Figure 40 shows that when the damage to a cell is significant the p53 acts to induce apoptosis in the 
cell.  During radiotherapy and chemotherapy cells can become badly damaged and in this case the 
p53 initiates apoptosis, which leads to the symptoms of radiation sickness as well as those 
associated with chemotherapy.  Whilst p53 essentially stops damaged cells from replicating, and can 
induce apoptosis of these damaged cells, it can also help to rehabilitate damaged cells, so that once 
their DNA is repaired they can re-enter the normal cell environment.  When damage is observed, 
p53 induces cell-cycle arrest and the cell is not able to replicate until the DNA is repaired and the 
p53 leaves the cell.  P53 is a transcription factor, and works by binding to the DNA in a claw-type 
action, thus hindering RNA polymerase and preventing transcription and thus translation.  The key 
amino acid involved in binding to the DNA is arginine.  In the p53(105) used in this research the 
mutated gene leads to the substitution of an arginine group, which will essentially reduce the ability 
of the peptide to bind to the DNA, thus leading to a peptide with impaired function. 220, 244-246   A 
typical mutation is illustrated in Figure 41. 246  
 
 
Figure 40. Diagram showing the way in which fully functional p53 regulates cell growth/repair/death 
following DNA damage. 
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Structure of p53 region we are interested in :  GFRLGFLHSGTAKSV 
 
Structure of mutated p53(105) : GFHLGFLQSGTAKSV 
 
Figure 41. Part of the sequence of functional p53, and the same sequence with a common mutation 
 
Although 95 % of p53 mutations occur in the DNA binding region, 246 other mutations occur in places 
involved in positioning other amino acids in a suitable position for DNA binding, and so even if all 
arginine residues are present, it may be impossible for them to get into a position in which they can 
bind to the DNA.  In addition to this, mutated p53 is capable of acting as a negative inhibitor.  Its 
shape has changed enough that it can no longer serve its intended function, but not so much that it 
is not capable of blocking an enzymes active site, thus preventing functioning p53 from binding and 
increasing the likelihood that a damaged cell will escape apoptosis and divide, leading to a possible 
tumour. 220, 228, 244 
 
One angle for treatment has been to exploit viral vectors and try to insert the gene for functional 
p53 into the host DNA.  This method is problematic as the side effects from using this type of vector 
are significant, and the body quickly becomes tolerant to the treatment and stops responding.  
Vectors are discussed in more detail in Ch. 1.3; Section 6. 
 
By a series of gene switching experiments it has been possible to show that when the p53 gene is 
switched off, equating to a non-functional protein, when exposed to radiation levels known to cause 
a significant amount of DNA damage mice that have the p53 gene switched on would die.  In 
contrast, those mice with the p53 gene switched off were able to survive.  In a second step the mice 
whose p53 gene remained “off” developed tumours whereas those who had the gene switched back 
on again did not.  This is an illustration of how p53 is useful for preventing tumours, but could in 
some ways hinder the recovery process. 244, 245  
 
P53 causes a response that will kill damaged cells - this is why radiation sickness occurs, and also 
why during chemotherapy cells die and the symptoms such as sickness and hair loss occur.  
However, it should be noted that with p53 turned off, although the mouse does not show any short-
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term toxicity in the long term the mouse is unable to react to mutated DNA and so cancer occurs. 244, 
245   
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Section 5:  Peptide Synthesis 
 
Whilst antigens can be extracted from cultures or the genes spliced into bacteria and produced in 
large quantities it is easier to control  the quality of peptide produced synthetically, and recent 
advances in solid phase, and microwave chemistry in this area now allow us to synthesise peptide 
whether antigenic or not in nature, quickly and easily. 
In nature polypeptides are made via a condensation reaction that links amino acids together to form 
an amide bond.  This task is carried out by ribosomes.  In order to mimic nature and synthesise 
peptides in laboratory conditions, initially solution phase synthesis was carried out using coupling 
agents such as Dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) which work by 
activating the carboxylic acid ready for addition.  In order to prevent side reactions to give unwanted 
peptide products, the carboxylic acid terminal of one amino acid must be protected, for example by 
reaction with ethanol and thionyl chloride to yield the ester.  The amine group of the other amino 
acid must also be protected, typically done using protecting groups such as tert-butoxycarbonyl 
(BOC), and fluorenylmethyloxycarbonyl chloride (Fmoc). 247 This means the reaction can be carried 
out to selectively yield only the desired peptide.  However, there are many drawbacks to the 
solution phase route such as the formation of DCC-urea, an insoluble by-product that is very difficult 
to remove from the products.  These methods also suffer from low yields (< 10 %) due to the 
protection and deprotection steps that accompany the addition of each amino acid onto the chain, 
as well as the conditions for these steps being so harsh that they can damage the peptide by 
cleavage of amide bonds, or oxazolone formation which can lead to racemization. 248 
 
So, in 1963 Bruce Merrifield pioneered work into solid phase peptide synthesis, which has 
dramatically improved both the process and the yield. 249  The principle behind this process is that 
the peptide is built onto a solid support, meaning that the product, on the insoluble support, can 
easily be separated from excess reagents and soluble by-products by simple filtration and washing.  
The most commonly used support is the cross-linked polystyrene (PS) based support although others 
are available. 247  Key features of the support include the ability of it to swell when put into a solvent 
as 99 % of the coupling sites are not at the surface of the bead but inside it, and so it must increase 
in size to allow reagents to diffuse to the coupling site.    
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The first amino acid is linked to the support by a linking group such as the linker designed by Wang. 
250, 251  Examples of linkers are shown in Figure 43, with the ball depicting the various matrices that 
can be used for the solid support. 
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Figure 42. Schematic to indicate how peptide formation takes place during solid phase peptide 
synthesis  
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Figure 43. Linkers commonly used for SPPS.  These resins are compatibile with Fmoc chemistry and 
TFA cleavage.247 
 
The amino acid linked to the support is generally linked via the carboxylic acid group and has a 
protecting group on the amine to allow a selective reaction.  Amino acids to be added onto this are 
also protected on the amino group and a deprotection step must be carried out before the coupling 
can take place.  Whilst both of the commonly used protecting groups (BOC and Fmoc) are effective 
in protecting the amine functionality harsh conditions are needed to remove the BOC group, namely 
strongly acidic conditions, which may either cleave the resin or lead to damage of fragile sequences 
in the peptide.  Fmoc on the other hand, is removed under very mildly basic conditions which do not 
put the peptide at risk of damage, and for this reason it is generally preferred for SPPS. 252  
 
Whilst protection of the amino group during coupling is important, of equal importance is protection 
of side groups.  Some amino acids contain amino, carboxylic acid, thiol or hydroxyl side groups that 
could react during coupling and each of these needs to be rendered inactive in order for the reaction 
to proceed with the desired selectivity. 248  The protecting groups need to be able to remain 
attached during the deprotection step but be cleaved in the final cleavage step under conditions that 
do not damage the peptide.  Typically TFA-labile protecting groups are used.  
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The coupling step itself can be carried out using a multitude of reagents that activate the carboxylic 
acid group by turning it into a carboxylate with diisopropylethylamine (DIEA) being the most 
commonly utilised reagent for this step.  As previously mentioned, in solution phase synthesis the 
coupling reagents most often employed were dicyclohexylcarbodiimide (DCC) or 
diisopropylcarbodiimide (DIC), but in SPPS the most commonly used reagents are O-(benzotriazol-1-
yl)-1,1,3,3,-tetramethyluronium tetrafluoroborate (TBTU) or N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-methylmethan-aminium hexafluorophosphate N-oxide (HBTU). 
 
During the final cleavage step trifluoroacetic acid (TFA) will remove the polymer support and the 
protecting groups, but it also leads to the formation of carbocations that will react with the electron 
rich side chains of amino acids (Cys, Met, Tyr, Thr, Ser, Trp) to form unwanted products.  This can be 
prevented by the addition of scavengers including silane containing molecules such as 
triisopropylsilane (TIS).  Thiol cocktails can also be used although these are toxic and have a bad 
odour, reducing suitability for synthesis of peptide for biomedical applications. 247 
 
Overall, procedures in SPPS are able to overcome many of the problems originally encountered in 
the synthesis of peptides, and so the technique can be easily utilised to make a wide array of 
different peptides. 
 
 
 
  
94 | P a g e  
 
Section 6:  Vectors 
 
In order to effectively target and deliver immunogenic peptides to cells it must be possible for the 
nanoparticle to avoid clearance by the reticuloendothelial system, and possibly to bind to the cell in 
order to aid endocytosis.  For instance, it is essential that peptides are taken up by dendritic cells if 
they are to illicit an immune response. 253-255 This can be achieved in a number of ways which include 
adding biomarkers such as antibodies recognising specific CD molecules, onto the surface of the 
nanoparticle and more simply, ensuring the nanoparticle is a suitable size for uptake.  Dendritic cells 
will not take peptides up on their own as it is energetically unfavourable to do so, and so delivery 
agents, known as vectors, are used to increase the size and make the energetic conditions more 
favourable. 80   
 
6.1 Viruses  
 
Viruses are designed to invade cells and this can be exploited in order to get other substances into 
the cell.  Viruses are also able to insert their own DNA into the host DNA and thereby hijack host 
machinery to enable virus replication.  As viruses have their own DNA is it possible to replace viral 
genes with desired genes, such as functional p53, and so deliver a working gene into the cell.  This 
type of gene therapy has been used in the treatment of cystic fibrosis and other genetic disorders. 
256 
Viruses can also be exploited to deliver drug molecules and immunogenic antigens into cells. 76, 257    
The shigella virus has recently been used to target dendritic cells as it has a surface receptor that 
binds specifically to antigens on the surface of dendritic cells. 258 Due to this interaction endocytosis 
can be facilitated and molecules can be delivered into the cells, leading to maturation into APC’s.  As 
dendritic cells are key to promoting an immune response these are very promising peptide delivery 
agents. 
Whilst viruses are very effective as vectors they can also produce severe side effects such as intense 
immune responses and insertional mutagenesis.  In addition to this, whilst the body might allow the 
virus to infect cells a first time, it can form a type of immune memory that makes it impossible to use 
this type of therapy repeatedly. 259 
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6.2 Recombinant proteins 
 
Recombinant proteins are receiving much attention as they offer the same benefits as viral vectors 
but are less likely to lead to the side effects associated with viruses.  Recombinant proteins contain 
peptide sections present on viral particles that are essential for delivery of genes into a cell. 260  
Protein sections involved in gene delivery are selected and engineered into a single molecule, 
including polylysine containing segments involved in increased uptake into the cell, cationic peptides 
that are able to bind DNA, and antibodies for targeted delivery.  Typically recombinant proteins are 
designed with gene delivery in mind, but could be engineered to deliver other molecules into the 
cell.  These proteins have the advantage of being more biocompatible that other methods of gene 
delivery such as cationic compounds, but are complicated to synthesise.  The use of recombinant 
proteins to illicit an immune response against is illustrated in Figure 44. 260 
 
 
 
Figure 44. Schematic showing how by combining recombinant proteins with tumour cells it is possible 
to mount an immune response against tumour cells. 
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6.3 Organic cationic compounds  
 
Cationic polymers, being positive, are able to bind to the negatively charged DNA and form a type of 
micelle around the DNA leading to a complex known as a polyplex.  The positive charge on the 
particles also allows them to interact with the cell membrane and thus facilitates endocytosis.  Block 
copolymers including PEO blocks have been formulated and made into polyplexes with DNA.  As has 
been mentioned the toxicity of any substance must be assessed before it can be approved for 
human use.  The advantage of using these copolymers is that by altering the length of each block the 
toxicity could be greatly reduced, thus tailoring the vectors to their use. 261 
 
 
Liposomes, when made from cationic lipids, are classified under the organic cationic compounds 
title. 261-266 Liposomes have been used extensively to deliver drugs to target molecules and have a 
membrane in which targeting molecule such as antibodies and peptides can be embedded (Figure 
45).  The inner space of the membrane can carry drug molecules or ferrofluids enabling a further 
drug payload or alternatively a method for tracking.  Antibodies used on the surface would ensure 
that the liposome will preferentially bind to a particular type of cell, hopefully inducing endocytosis.  
The size of the liposome is of key importance, as small molecules will not be taken up by the cell as 
they are energetically unfavourable, and large molecules will be too big for the cell to engulf.  
Typically liposomes of 50-100 nm are considered thermodynamically optimal although much of the 
literature suggests 200 nm liposomes have better uptake. 235, 267   
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Figure 45. Showing a liposome with an antibody embedded into the membrane for targeting, a PEG 
protective layer with hydrophobic tails embedded in the membrane, a lipid soluble drug on the 
hydrophobic inside of the bilayer and a drug in aqueous fluid on the inside 
 
6.4 Other Nanoparticles 
 
Other types of particles, including SPIOs and GNPs can be functionalised to bind to specific cells 
using the antibody method.  This targeting has been exploited for imaging of tumours, 85, 268-270 
hyperthermia to kill cancer cells, 175, 182, 183, 199, 271 and drug delivery to specific cells. 97, 272  Folic acid is 
frequently reported as being a good functionalising molecule for increasing cellular uptake and is in 
fact five times more effective than PEG alone, although PEG is more commonly utilised. 272   
Nanoparticles are particularly efficient for reducing the enzymatic attack of nucleic acids.  The 
nanoparticle will physically hinder the enzyme from interacting with the DNA, although it may still be 
able to attack the exposed end of the DNA.  In addition to this, the positively charged particle may 
repel the enzyme and thus reduce the likelihood of attack. 261, 264, 266  
Molecular imaging is of key importance in the tracking and treatment of disease and has been 
defined as a non-invasive, quantitative procedure during which imaging of biomolecules or biological 
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process is repeated.  This must be occurring within a living organism.  SPIOs can act as both a passive 
and an active targeting imaging agent which makes them ideal for molecular imaging.  By coating 
with dextran it is possible to attach magnetite nanoparticles to the surface of the cell, although this 
leads to a decreased likelihood of nanoparticle uptake. 273  However, in this instance the binding of 
the particles to the outside of the cell leads to cell death which can be exploited for use in cancer 
therapy. 178, 181, 199  SPIOs also lend themselves to theranostic applications as they can be attached to 
drug molecules and so be used both for treatment and diagnosis purposes.  Additionally, due to their 
superparamagnetic properties they can be directed to a specific target by using a magnetic field 
gradient, and manipulated to produce hyperthermia in a specific region, such as a melanoma. 178, 181, 
199 
 
Gold nanoparticles can also be functionalised with a wide variety of molecules, with binding typically 
being through electrostatic interaction with amine and carboxyl groups, and more importantly 
through interaction with thiols. 82, 97, 175  Gold nanoparticles are also traceable as they have unique 
optical properties.  It is possible to trace GNP’s using optical coherence tomography (OCT) and to 
activate them using infra-red (IR). 175  It is also simple to make GNP’s of various sizes and shapes with 
a high degree of control, and so they lend themselves well to biomedical applications where quality 
control is of huge importance. 82, 274 
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Section 7:  Adjuvants 
 
As cancer antigens are essentially “self” antigens and the immune system is carefully designed and 
trained to not react to these antigens, it is difficult to produce an immune response by means of 
vaccination. 214  As we develop in utero we develop immune tolerance to certain antigens, such as 
those associated with ourselves, and also those crossing the placenta due to infections in the 
mother.  In addition to this, cancer cells also undergo immunoediting, with each repeated evasion of 
destruction by the immune system the cancer becomes more and more ‘invisible’ to the immune 
system until it does not illicit any immune response.  Another possibility being explored is that the 
cancerous cells are able to influence regulatory T cells, in a similar way in which they influence 
neighbouring cells to support them, to ignore their antigens and thus induce immune tolerance.  
However, there is evidence to suggest that by continually prolonging toll like receptor (TLR) 
signalling, it is possible to reverse immune tolerance to tumours and TSA’s but first the technology 
for carrying out this signalling must be devised and refined. 214 
Adjuvants come in different forms but they all have the general purpose of increasing or enhancing 
the immune response to weak antigens, and are subdivided into vehicles (vectors which have been 
previously described in Ch.1.3; Section 6) and immunostimulants. 257, 275-278  Vehicles present the 
relevant antigen to the immune system in what is described as an ‘optimal manner’, which can 
include controlled release of the antigen including depot delivery systems.  It is possible that the 
continual release of the antigen over time serves to stimulate the TLR’s, which was one of the aims 
set out for reversal of immune tolerance.  Viruses which are able to infect APCs are classed as 
vehicle type adjuvants. 257, 279, 280 
 
In addition to the delivery of the antigens the vehicle can also deliver immunostimulants and so 
further increase the immune response.  Immunostimulants engage the innate immune system by 
direct stimulation.  Species such as those in the mycobacteria family are used as adjuvants. 281, 282   
Biomolecules in the bacterial cell wall can stimulate an immune response, and with the relevant 
antigen being present this immune response can be directed against that antigen.  
 
The first instance of a type of adjuvant was designed by William Coley in 1983. 283  He noticed 
regression of tumours that were injected with weakened strains of bacteria, and spontaneous 
regression in some patients who had bacterial infections.  We now know that this system, known as 
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“Coley’s toxin” worked because it stimulated the immune system to react in that area, thus leading 
it to the site of the damaged cells.  It is also possible that the fever associated with the bacterial 
infection led to the formation of heat shock proteins which themselves lead to an increased immune 
response, as heat shock proteins are immunodominant antigens (strong antigens). 284  In addition to 
this use of bacteria, it has been found that children exposed to a wide range of pathogens are less 
likely to develop certain childhood leukaemia’s, which supports the theory that by reacting to other 
strong antigens we stimulate the immune system to react to weaker antigens. 284 
Whilst Coley’s toxin was successful in treating cancer for a time, the creation of a vaccine that leads 
to immunity against cells expressing tumour specific antigens (TSA) is preferable as it is specific to 
the cancer cells only and provides memory cells in case of recurrence of the cancer.   
According to Debensky Jr and Reed the idea adjuvant will be stable, safe, and easily biodegradable as 
well as being eliminated from the body without problems. 277  It will also be able to promote an 
antigen-specific immune response.  This is one of the aims of the research carried out within the 
scope of thesis.  
 
7.1  Freund’s Adjuvant 
 
As previously mentioned mycobacteria are used in preparations including Complete Freund’s 
Adjuvant (CFA) which contains either components of the bacterial cell wall or heat treated bacteria.  
CFA has been used in clinical trials such as a study on squamous cell carcinoma tumours, with 
positive effect. 277, 285  However, the use of these bacterium and their components leads to problems 
due to the large inflammatory response produced.  The response to this problem has been to 
remove the mycobacteria components to create Incomplete Freund’s Adjuvant (IFA) and so reduce 
the inflammatory response, but this could in turn reduce the effectiveness of the vaccine and so 
other adjuvants have been investigated. 277, 278, 280 
 
Whilst there are adjuvants such as CFA which are very effective there are concerns over the safety of 
adjuvants in vaccines.  This has arisen due to incidents such as withdrawal of the rotavirus vaccine 
due to cases where patients who had received the vaccine suffered from intussusception of the 
intestines.  Another notable incident was an increase in the incidence of Guillain Barre Syndrome 
which was linked with a swine flu vaccination in 1976. 286 
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7.2  Alum 
 
Alum and other aluminium compounds are popular as adjuvants and some of these have been FDA 
approved. 275, 278, 287  Alum works by interacting directly with the cell membrane of dendritic cells, 
thus triggering an immune response terminating in activation of CD4+ T cell activation.  Alum is 
currently used in the vaccinations for many infectious diseases such as diphtheria and tetanus.  It has 
the advantage of being suitable for large scale production and being relatively safe compared with 
many of the adjuvants that have been trialled, and the mercury that it has replaced.  However, it is 
only suitable for simple immune responses and is not useful for pathogens such as HIV and malaria 
that remain in the body for a prolonged period of time.  In addition to this Alum is known to create 
granulomas at the injection site which can lead to problems when booster injections are required, as 
would be the case with cancer vaccines.  There are also concerns that because aluminium is a 
neurotoxin it could be linked with autism although these claims are as yet unfounded. 275, 278, 287 
 
7.3  Oil in Water Emulsions 
 
Oil in water emulsions are a popular choice for adjuvants, as the antigen is released slowly from the 
mixture over a period of time, and in fact some of these emulsions have been FDA approved. 275, 278  
Squalene and squalane have recently been used to replace some of the more popular mineral oils 
traditionally used in these preparations. 275, 278  These oils have been chosen as they are easy for the 
body to metabolize and so are less likely to cause side effects and granulomas.  At present these new 
studies aim to reduce the oil content in each emulsion to < 5%.  Monophosphoryl Lipid A (MF59®) is 
a TLR-4 targeted adjuvant containing squalene, that is safe for use, but has a reduced effect when 
compared to CFA.  Another drawback of this particular adjuvant is that one of the key ingredients is 
shark oil, and as one of the aims for production of a successful adjuvant is that it is inexpensive to 
produce, shark oil is not ideal.  In addition to this, shark oil is not a sustainable resource and must 
first be extracted.  For these reasons a more efficient adjuvant that can be created on a large 
sustainable scale must be produced.  
 
3-O-desacyl-4’-monophosphoryl Lipid A (MPL) is a similar adjuvant which was recently approved, 
and is present in the HPV vaccine Cervrix®. 288  This is an effective adjuvant but comes with the 
102 | P a g e  
 
added drawback that part of its manufacturing process requires a 20- year batch fermenting process.  
This is both expensive and time consuming, and has high energy requirements.  It has also been 
pointed out that in order to meet worldwide demand a batch process which occasionally leads to 
failure due to the complex components of the mixture, and which takes 20 years, would be 
insufficient. 275, 278 
 
7.4  Heat Shock Proteins 
 
The primary function of heat shock proteins (HSPs) is to maintain cell homeostasis under stress or 
heat conditions. 284  They have previously been mentioned in relation to the fevers produced as a 
result of bacterial infection, and have received much attention recently due to their use as non-
specific adjuvants. 289  These special proteins interact with surface receptors on APCs such as 
dendritic cells and through cell signalling this leads to a cascade immune responses which includes 
activating NK cells.  When used in combination with antigens, HSPs can increase the presentation of 
that antigen on the DC surface and so possibly lead to an increased immune response to that 
antigen.  Figure 46 illustrates how heat shock proteins and antigens can interact to form the complex 
used for immunisation.  Again, mycobacteria have been used in the production of heat shock 
proteins, namely mycobacterium tuberculosis HSP70 for the treatment of porcine circovirus type 2. 
282  All organisms studied to date produce a heat shock protein encoded by the HSP70 gene family 
when temperatures become elevated, and it is possible to produce these proteins in large quantities 
by isolating, for example, the murine gene, replicating it by PCR, and then using a gene transfection 
agent to splice this into bacterial cells such as Escherichia coli. which will replicate and express the 
gene. 282 
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Figure 46. Illustration of the formation of an HSP-antigen complex 
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Section 8: Research Hypothesis, Aims and Objectives 
 
The research hypothesis for this thesis was that functionalised metal and metal oxide nanoparticles 
could be synthesised via a novel route, and then used for a variety of biomedical applications. 
The aim of the research was to synthesise a variety of metal and metal oxide nanoparticles; to 
functionalise and purify the particles; and to use these particles for NMR contrast, cancer 
immunotherapy, and transdermal drug delivery. 
The individual objectives were as follows: 
 To synthesis metal and metal oxide nanoparticles via well documented methods 
o Synthesis of gold nanoparticles using a citrate capped method 
o Synthesis of iron oxide nanoparticles via co-precipitation and spinning disc methods 
o Synthesis of calcium oxide nanoparticles via spinning disc methods 
o Characterisation of particles via ICP-AES and TEM 
 To synthesise biologically active peptides using solid-phase peptide synthesis 
o P53 variants for cancer immunotherapy 
o Cell penetrating peptide for transdermal drug delivery 
 To functionalise nanoparticles via a novel solvent-free route 
o Develop a method for solvent free coating of nanoparticles with simple organic 
molecules and peptides by trialling incubation, heating and solid state methods 
o Characterisation of functionalised particles via TEM, ICP-AES, DLS and TGA 
 Develop a method functionalised particles 
o Develop a method for purification of 10-15 nm magnetic and non-magnetic 
nanoparticles  
o Trial size exclusion, dialysis, magnetic separation and centrifugation 
 To determine suitability of newly functionalised nanoparticles in biomedical applications; 
medical NMR, transdermal drug delivery, and as cancer adjuvants 
o Measure NMR relaxation of solutions containing functionalised SPIOs both with and 
without buffers to determine suitability as a CT contrast agent 
o Use mice for immunisation using particles functionalised with p53 variant as an 
adjuvant 
o Use an NMR MOUSE to track SPIOs functionalised with cell-penetrating peptide 
penetrating pig skin   
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Chapter 2:  Results and Discussion 
Section 1: Synthesis and coating of SPIOs 
 
1.1 Size, Morphology and Distribution 
 
The primary aim of the experiment was to synthesise metal and metal oxide nanoparticles via well 
documented methods.  These particles, synthesised as detailed in Ch.2. 2.1, were analysed by 
transmission electron microscopy (Figure 47) at a magnification of 100 K and were found to be 
spherical, indicative of the desired SPIOs, and fairly uniform in diameter with a size range of 8-12 
nm.  This shows that for these particular metal oxide nanoparticles the primary aim has been 
successfully met.   
The secondary aim of the research was to functionalise nanoparticles with the desired coating 
material.  The images show that there is a clear area surrounding each particle, indicative of the 
coating agent.  EDX confirmed that the particles contained iron and had coatings containing carbon, 
oxygen and nitrogen which confirms that the dark spherical areas relates to SPIOs and the 
aforementioned clear area is the organic coating material (Figure 48).  This data combined with the 
fact that the particles had become soluble following the coating method, indicates that the 
secondary aim has also been met. 
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Figure 47. TEM image showing p53(108) coated SPIOs.  The red line indicates the SPIO itself which is 
around 15 nm and the green line shows the peptide coating at around 2 – 4 nm.  The scale for the 
bottom right hand image shows the amount of transmission of electrons through the sample and is 
in arbitrary units. *Poor image resolution is due to limitations of the available transmission electron 
microscope. 
 
 
Figure 48. EDX of p53(108) coated SPIOs showing Cu (the TEM grid), Fe (iron oxide nanoparticle), O 
(oxygen from peptide) N, and C (both from the peptide). 
 
Whilst the primary aim has already been met, spinning disc synthesis was trialled to determine if this 
was a better way to synthesis superparamagnetic iron oxide nanoparticles in terms of size and 
morphology.  This was also carried out with a view to scale up the reaction for commercial 
application.  The SPIOs synthesised using the SDR were found to be less uniform in size with ranges 
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of 7-40 nm for ammonia liquid and 15-42 nm for gaseous ammonia as illustrated in Figure 49 and 50.  
Literature suggests that the particles should be more uniform in size due to the micro-mixing effect.  
Additionally, there were some rod shaped structures present in the sample which on investigation 
turned out to be made of iron oxide (not excess iron chloride as had been previously assumed).  
Both of these findings lead to the question of why the SDR was not producing uniform particles.  One 
suggestion is that the fast spin speeds whilst leading to formation of smaller particles, will also mean 
that excess iron chloride solution will be spun onto the sides of the reaction vessel.  It is possible that 
in this case the smaller particles then act as a nucleation site as the remaining reactants carry on 
reaction on leaving the disc, leading to formation of larger nanoparticles, and the additional 
nanorods.  This theory was further supported by the absence of nanorods in the samples 
synthesised using gaseous ammonia. In these samples the particles also showed much less 
aggregation/agglomeration, providing further evidence that in the absence of ammonia in the liquid 
and precipitate collected, the particles could not carry on reacting and so nucleate bigger particles. 
    
Figure 4947. TEM image of SPIOs synthesised using SDR.  Blue line indicates particles measured in Fig 
61. *Poor image resolution is due to limitations of the available transmission electron microscope. 
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Figure 5048. Depth profile showing particle highlighted in Fig. 60 to be 10 nm 
 
 
Figure 51. TEM image showing rod/crystal type structures in the SDR SPIO sample. *Poor image 
resolution is due to limitations of the available transmission electron microscope. 
 
1.2 Coating Methods 
 
Going back to the secondary aim, of functionalising the nanoparticles, the following methods were 
trialled: Incubation, sonication, heating, ball mill, pestle and mortar, and coffee grinder.  These 
showed varying rates of success, with the pestle and mortar and coffee grinder being deemed the 
most successful; all 20 amino acids and various other organic substances could be attached to the 
SPIOs using these methods.   
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For each methods, the products when solubilised were analysed by DLS, TEM, ICP, and NMR 
MOUSE®.  Methods were considered successful if the solutions contained particles of 10-20 nm with 
a clear coating, contained iron and were successful in inducing shorter relaxation times for water by 
NMR.   
The incubation method brought about some difficulties as many of the amino acids were only 
sparingly soluble in distilled water; however, it was assumed that as a small amount of coating 
material bound to the SPIOs this would shift the equilibrium and so a further small amount of amino 
acid would dissolve in the water.  However, the results indicated that only one amino acid, 
threonine, successfully bound to the SPIOs to yield a pale brown solution containing particles of 10-
20 nm with a clear area around them, again corresponding to the coating material.  Bearing this in 
mind it is very likely that it is the solubility issues that have prevented this method from being 
successful.   
Sonication proved to be completely unsuccessful.  Whilst sonication aided synthesis of the particles 
themselves, every sample analysed was devoid of iron.  This could be attributed to the energy from 
sonication being directed to break the electrostatic forces of attraction, and thus removing any 
bound coating material rather than helping to attach it.  It has been concluded that regardless of any 
adjustments made sonication will not be a viable coating method. 
Amino acids tend to degrade rather than having melting points and so it was essential when 
attempting to use heat to attach them to SPIOs that this point was not exceeded.  Both Bunsen 
burners and heat guns were trialled but these proved to be too efficient at heating, often leading to 
decomposition.  Following these attempts SPIOs were heated using a hot plate with careful 
temperature control.  For every sample a dark brown solution was produced containing iron 
although none of these were able to alter NMR relaxation times.  When viewed under the electron 
microscope it was clear to see that the particles, rather than being single particles with a clear area 
surrounding them, were clumped together into large aggregates of several µm.  DLS confirmed 
aggregates of ca. 1000 nm at least.  These results indicate that the heating method is not able to 
produce coated particles that are separate from one another, but rather it partially decomposes the 
coating, causing the particles and coating to stick together in a large mass which is no longer able to 
move.  This aggregation of particles renders the particles unable to move in solution and so they 
cannot align with the magnetic field as single particles or smaller aggregates are able to.  So, it can 
be concluded that the heating method is not suitable for producing coated SPIOs that can be used as 
NMR imaging agents. 
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What is of note, as illustrated in Figure 52, is that the heating method led to the greatest amount of 
coating of iron oxide, with iron concentrations being in excess of 1000 mg.l-1 vs. incubation and 
sonication which both resulted in concentrations below 100 mg.l-1.  So although the particles were 
not MRI active, they did have a high iron content, and this could be exploited for other applications 
such as treatment of anaemia or doping of other substances with iron. 
In order to keep the particles separate during coating and avoid the negative effects associated with 
aggregation, it was decided that a ball mill would be used.  It was possible to heat the ball mill and so 
agitation and heating were combined in the next method.  The ball mill on its own was unable to 
produce coated particles, with any samples giving rise to solutions devoid of iron.  The heating 
method was successful in producing solution containing iron.  However, these were similar to the 
sample observed in the heating method, giving large aggregates which were not MRI active.  
  
 
Figure 52. ICP results for alternative methods of coating SPIOs with threonine. 
 
In keeping with the agitation theme the ball mill was replaced with a pestle and mortar.  The 
mixtures were energetically agitated for a minimum of 5 min and the resultant powders once take 
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up into solution were found to contain iron, be MRI active, and contain evenly coated particles of 10-
20 nm.  This method was successful for all compounds trialled that contained the following 
functional groups: -OH, -COOH, -NH2.  It was also important that the correct solvent was used to 
ensure maximum uptake into solution, as the solubility of the coated SPIO was less than the coating 
material itself.   
When considering taking this method and applying it on a larger industrial scale it quickly became 
clear that it would not work on a larger scale due to mixing effects.  As shown in the use of the ball 
mill, the mixtures require close contact and a higher pressure for successful binding.  The coffee 
grinder was trialled as the burrs would provide the close contact and grinding action that was found 
to be successful in the pestle and mortar method, with the material needing to be passed through 
the grinder a minimum of four times.  Further passes through the grinder resulted in a further loss of 
product, with some of the material becoming stuck inside the grinder on each pass.  
The method was found to be successful for all samples that were able to attach via pestle and 
mortar.  However, the method led to a lower yield and was not as effective as the pestle and mortar, 
in terms of the amount of iron taken up into solution following processing.  This method is limited by 
the limited positions in which the burrs can be placed, and by the large size of the grooves within the 
burrs themselves.  In order to process materials on the nanoscale the burrs needed both to have 
smaller grooves, and to be closer together.  Despite this, this method is effective and provides the 
most promising method for scaling up.  Whilst this was not one of the aims of the research project, it 
does lead well into future research. 
 
1.3 Further Coffee Grinder Experiments 
 
It has already been mentioned that the secondary aim of functionalization was met through the 
pestle and mortar method, but as with the use of the spinning disc reactor, a method needed to be 
developed that could be scaled up for commercial application.  For this reason a coffee grinder was 
used, which allowed more material to be ground together at any one time than the pestle and 
mortar method.  The results in Table 18 show that the coffee grinder is a suitable alternative to the 
pestle and mortar for attaching the coating material to the SPIOs via a solvent free grinding method.  
What is also clear from the table is that the number of times that the material passes through the 
grinder will affect how much of the iron ends up in the solution, which indicates the amount of SPIO 
successfully coated.  This could be due to the following reasons: 
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1. The powder produced from grinding several times as opposed to just one is much finer than 
if only one grind is applied.  This will mean that the finer powder will be more soluble in 
water due to its larger surface area. 
2. With each successive grind, more of the particles are successfully coated, due to more of the 
coating particles and SPIOs being forced close together and thus forming electrostatic 
interactions. 
3. The heat from the friction of the burrs could be causing some of the coating material to be 
melted onto the SPIOs.  Whilst in the heating method this led to a large degree of 
aggregation, in this method the action of the burrs would keep the particles apart and 
reduce aggregation. 
Any of these possibilities is likely but further investigation would be required to determine which of 
these is occurring, if not something else entirely. 
As mentioned, the grinding process provides energy in the form of heat from friction.  This will 
possibly help to overcome electrostatic repulsion between particles, and break intermolecular forces 
between them, thus forcing the particles closer together.  When they are close to each other they 
will have more chance to interact with each other and so form an electrostatic interaction.  In 
solution the particles and molecules are able to diffuse randomly and so there is a chance that they 
will bump into each other or come close enough for an electrostatic interaction to occur.  In solid 
state the grinding action first makes the particles and coating agent into a fine powder.  This 
increases the surface area of both agents and so increases the likelihood of the coating agent and 
particle coming into close contact with each other. 
Solubility was found to be the biggest issue during this method, which was overcome by forming the 
HCl salt of any difficult materials.  Once solubility was not an issue these materials could be coated 
onto the SPIOs via the solvent free grinding method (typically the pestle and mortar method) as 
described.  These salts coated SPIOs to form particles of 10-20 nm with a clear area surrounding 
them, as observed using TEM.  This led to exploration of salts, namely ammonium chloride, and 
sodium chloride, as coatings.  Neither of these were successful coating materials, further supporting 
the theory that –OH, -COOH or –NH2 are needed in order for sufficient electrostatic interactions to 
occur. 
 
1.4 Suggestion for mode of action of solvent free grinding method 
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Now that we know that it is possible to functionalise the particles via a novel solvent free method, it 
is important to be able to understand how this is happening.  As previously mentioned, the coating 
of nanoparticles relies on electrostatic interactions between the particle and a functional group on 
the coating agent.  It could be suggested that with the hydrated form of the SPIOs there are 
hydrogen bonds between the Fe-OH functionality and the coating materials, however the IR data for 
the SPIOs has proved that we do not have this form, so this form of bonding can be ruled out. 
The particles themselves have both Fe3+and Fe2+ ions at the surface of the particle.  This gives the 
surface a positive charge, and so it can interact with any materials with functional groups that are 
negatively charged.  In solution the particles and molecules are able to diffuse randomly and so 
there is a chance that they will bump into each other or come close enough for this type of 
electrostatic interaction to occur.  In solid state the grinding action first makes the particles and 
coating agent into a fine powder.  This increases the surface area of both agents and so increases the 
likelihood of the coating agent and particle coming into close contact with each other. 
The grinding process also provides energy in the form of kinetic energy and a small amount of heat.  
This will possibly help to overcome electrostatic repulsion between particles, and break 
intermolecular forces between them, thus forcing the particles closer together.  When they are close 
to each other they will have more chance to interact with each other and so form an electrostatic 
interaction.  
In order to test the theory that all coating materials could be attached to SPIOs via the solvent-free 
grinding method all 20 naturally occurring amino acids were attempted.  Whilst every amino acid 
could be successfully bound to the SPIOs the effectiveness of this differed between amino acids.     
 
 
1.5 Coating of SPIOs with all 20 naturally occurring amino acids 
 
For the research hypothesis to be successfully met, it was important for the nanoparticles to be 
coated with a plethora of molecules.  As we were extending to peptides later in the project, amino 
acids seemed like the perfect starting point.  They are also very varied so if successful, would prove 
that the method was viable for many different coatings. 
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As can be seen from Figure 53, the properties of amino acid side chains differ significantly, and it is 
possible that it is the properties of these side chains that gives rise to the differences in binding to 
the SPIOs.  For example, in the preliminary experiments it was noted that threonine had a very high 
binding capacity without recrystallization.  By looking at the structures depicted in Figure 53, it can 
be seen that this particular amino acid is nucleophilic.  It also contains an alcohol, amine and 
carboxylic acid group, all three of which have been shown to bind to the particles.  It is possible then 
that the ease with which threonine binds to the SPIOs is due to the nucelophilic nature of all three 
functional groups.  However, it was decided that the good solubility of this particular amino acid in 
water was the biggest factor in it being able to bind.  In contrast to this glycine contains the least 
electron donating groups, and contains only one amino, and one carboxylic acid moiety.  However, 
the results clearly show that for glycine there is not much difference so other factors must be 
involved such as interaction with the solvent or steric hindrance.   
 
 
Figure 53. Showing all 20 naturally occurring amino acids 
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Table 3. Results for coating of SPIOs with HCl salts of each of the 20 naturally occurring amino acids. 
 
This finding has potential applications when attempting to attach active pharmaceutical ingredients 
or peptides to the particles, as it may be possible to modify the coatings slightly to increase the 
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attachment, or it may simply make it easier to identify which potential coating agents are likely to 
bind, which goes some way to meeting the aim of using these particles for biomedical applications. 
 
1.6 Determination of mode of binding to SPIOs 
 
Whilst the literature states that it is the carboxylic acid groups of the coating materials that bind to 
the SPIOs, the salts of the amino acids were used which may have altered their binding.   
The initial experiments with amino acids indicated that the coating materials that will bind to the 
nanoparticles with the highest affinity would be those with charged groups.  It appears that those 
groups containing lone electron pairs are able to coordinate to the particle with the most ease.  As 
we are relying on electrostatic type interaction, the increased binding exhibited by the salts of 
various coating agents could be attributed to an increased electrostatic interaction between the 
coating and the particle.  Amino acids are amphoteric and in making them into salts the potential to 
have charge and dissociate turns into the actual dissociation of the particle to form a charged 
species.  As with any electrostatic interaction, an increase in charge leads stronger interactions and 
so the binding becomes more favourable in accordance with Coulomb’s Law. 
However, it should be noted that salts on their own do not bind to the SPIOs.  When NaCl and NH4Cl 
were trialled using the solvent free grinding method, the resultant solutions contained no iron, 
suggesting that they did not bind to the SPIOs.  So, it can be suggested that the binding relies 
primarily on the presence of the nucleophilic groups (COOH, NH2, OH, PO4 etc.) but can be enhanced 
by presenting these in the salt form. 
These finding could also help to increase binding of substances that will only sparingly bind.  It may 
be that by turning the compound into a salt it will increase the likelihood of an electrostatic 
interaction. 
 
1.7 Assessing if the salt form of the coating affects degradation of the particle 
 
If particles are to be used in biomedical applications it is essential that they are stable in biological 
and buffered solutions.  It has previously been reported that SPIOs degrade in both buffered and 
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acidic solutions, with the degradation being due to the iron oxide dissolving in the acid or buffer.  As 
the particles are charged they are effectively pulled apart in solutions containing ions which can 
hydrolyse the bonds between the iron and oxygen atoms.  
Bearing in mind that these particles would be coated with a material that could potentially degrade 
them, the HCl salt coatings were assessed to confirm whether or not they had an effect on 
degradation of the coated SPIOs.  A degradation study using the MRI MOUSE was carried out with 
both T1 and T2 being measured every minute for the duration of the experiment.  The results are 
shown in the graphs below (Figure 54 and 55), which illustrate how the relaxation times changed 
over time. 
 
Figure 54. Graphs showing how T¬1 and T2 changed over time for SPIOs coated with ascorbic acid 
(non-salt).  These graphs indicate little or no degradation only fluctuation in readings due to 
inhomogeneities in the magnetic field. 
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Figure 55. Graphs showing how T1 and T¬¬2 change over time for SPIOs coated with the HCl salt of 
ascorbic acid.  Any fluctuations are due to inhomogeneities in the magnetic field. 
 
What these graphs show is that there is little or no change in the relaxation times for these coated 
particles.  The T1 decreases slightly but the change is negligible.  So, it is unlikely that the salt form of 
a coating material would have any adverse effect on SPIOs relative to the neat coating material, 
although this should be assessed on a case by case basis for certain applications as this may not 
always be the case. 
One possibility is that as the coating material binds via the aforementioned functional groups, they 
form a protective layer around the particle, much in the same way as when Gd is chelated by EDTA.  
In this way the salt would dissociate in water but the particle would be shielded from any changes in 
pH in the surrounding solution, and so would not degrade.  Stability of particles will be further 
explored in a comparison with commercially available alternatives.   
As previously mentioned, it is possible to bind materials to SPIOs via several functional groups, but 
liquids have not been explored.  To primarily determine if –OH was able to facilitate binding to SPIOs 
hexadecanediol was used as a coating material via the solvent-free grinding method.  The resultant 
hexadecanediol-SPIO solution (in chloroform) was pale brown, indicating an attachment.  TEM 
results indicated that there were particles of 78 nm with lots of agglomeration. The agglomeration 
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can be attributed to the effect of the chloroform evaporating from the disc and causing the particles 
to clump together, or due to hydrophobic interactions forcing the coated SPIOs to form micelles.  As 
there were no other functional groups present on the hexadecanediol, and the chloroform itself was 
not able to bind to SPIOs it can be concluded that it is the –OH group that is responsible for the 
binding.  This was further supported during investigation of the suitability of liquids for solvent-free 
grinding.    
To allow grinding to occur, a viscous alcohol was chosen, in this case glycerol.  The mixture formed 
was solubilised in water, an on filtering the glycerol-SPIO solutions they were observed to be dark 
yellow/brown in colour, an initial indication that the attachment had been successful and the 
solution contains iron oxide.  In addition to this the TEM results indicated particles of ca. 15 nm with 
an organic coating; the clear area observed in previous TEM samples.  ICP results showed that there 
was an iron concentration of 103.1 mg.l-1, confirming that the particles had been coated with 
glycerol prior to filtration.  Attempts with a less viscous alcohol: ethanol, were unsuccessful, 
indicating that the viscosity of the sample is important for efficient grinding and thus attachment.  
 
1.8 Determining optimum mass ratio for solvent free grinding method 
 
If the solvent free method is to be scaled up or used for other applications, then in order to waste 
materials it is useful to know the optimum ratio that should be used for the process.  As can be seen 
from the results in Figure 56 where Histidine.HCl was used as the coating material, as the mass of 
coating relative to SPIO increases the iron content of the resultant solution decreases, with the 
concentration of iron in solution dropping from ca. 1250 mg.l-1 to ca. 450 mg.l-1 as we increase the 
mass of coating material.  This is attributed to mixing effects as at larger quantities there will be less 
complete contact between SPIO and coating.  This indicates a possible problem for scale-up, as at 
even larger quantities there will be even less complete contact and therefore lower concentrations 
of SPIOs coated (and taken up into solution).   A chemical engineer would need to be consulted in 
order to overcome this problem.   
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Figure 56. Preliminary results into how mass ratio of coating material to SPIO affects preparation. 
 
Working on the assumption that coating would be more effective at lower ratio’s the experiment 
was repeated with ratios from 4:1 to 1:2, also using histidine.HCl as the coating agent.  These 
findings were less conclusive as illustrated in Figure 57.  The results still show a general decrease in 
effectiveness of coating as the mass of coating material relative to SPIO increases.  However it does 
show a large degree of variability.  It is possible that the variation is due to large inhomogeneities in 
the mixing method.  The pestle and mortar method is difficult to reproduce exactly as it is done by 
hand, and conditions such as pressure and speed are difficult to control.   
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Figure 57. Graph showing ICP results for experiment to determine optimum ratio for coating SPIOs 
via solvent-free grinding method. 
 
The coffee grinder method was previously mentioned in relation to scaling up the process, but it 
could also be used to increase reproducibility and produce a more homogeneous sample, although 
the same machine would have to be used due to possible differences in burr size, rotation speed, 
and groove size affecting results.  When SPIOs and HCl histidine salt were processed together ten 
times each with either a mortar and pestle or a coffee grinder, it was found that the coffee grinder 
was better at producing a homogeneous sample than the pestle and mortar.  Standard Deviation for 
pestle and mortar samples was 11.28 with a mean value of 100.301 mg.l-1.  The coffee grinder 
sample had a standard deviation of 4.18 with a mean value of 55.483 mg.l-1.  These results indicate 
that although the yield using the coffee grinder is lower, confirming that with the current design 
there is a large amount of the materials wasted, the coffee grinder increases precision and produces 
a more homogeneous sample, with a range of only 13.50 mg.l-1 vs. 32.16 mg.l-1 for coffee grinder vs. 
human grinding respectively.  
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1.9 Calculation of the number of molecules of ascorbic acid coating each SPIO 
 
Further to the aim of using coating SPIOs for biomedical applications it was essential to determine 
how much material was bound to the particles.  This is particularly important for cancer 
immunotherapy where the concentration of immunogenic peptide delivered is crucial.   
Using the Oxford Crystal Database the unit cell for magnetite was found.  This was applied to the 
following calculations: 
There are 8 Fe3O4 units per unit cell of the inverse spinel structure, with each cell having a volume of 
8.3967 Å3 ( or 0.83967 nm).  Each SPIO is found by TEM, to have a mean diameter of 15 nm, giving 
each SPIO a mean volume of 1.415 x 107 Å3. 
So, if each SPIO has a volume of ~ 1.415 x 107 Å3 and each unit has a volume of 8.3967 Å3 , each 
containing 32 Fe atoms, then: 
                             (               )   
          
                                                    
                                                  
            
From the ICP results the concentration of iron per ml was found to be 149.2 mg.l-1.  A 10 ml sample 
was used, so the actual mass of iron present in the original sample was 1.492 mg.  
                      
           
Given the number of moles it is now possible to calculate the number of SPIO particles in the 
sample: 
                                               
           
 Moles of O in this sample can be calculated as follows: 
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If there are 2.664 x 10-5 moles Fe then: 
                       
           
                          
            
Now having the mass of oxygen and the mass of iron it is possible to calculate the mass of ascorbic 
acid, and thus the number of moles and molecules present in this sample, and the approximate 
number of ascorbic acid molecules binding to each SPIO. 
                
              
                   
                                     
                                                
                                                        
                                                               
          
So, according to these calculations there are 1095 million ascorbic acid molecules per SPIO particle. 
A repeat of this experiment gave a value of 930 million ascorbic acid molecules per SPIO particle, 
close to the original value. 
The total surface area of each SPIO can be estimated using the following: 
  4πr2  = 4 x 3.14 x (10)
2 = 1256.6 nm2 
Assuming that the molecules are binding at the carboxylic acid group this would mean that each 
binding site requires an area of 1.52Å to bind successfully.  The maximum number of molecules that 
could bind, not taking into account any repulsion or steric effects, is 82,671; over 11,000 times less 
than calculated.  This suggests one of the following possibilities: 
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Figure 58. Dimension of a molecule of acetic acid to show dimension on binding carboxyl group. 
 
1) The coating formed on the surface of the particle is not a monolayer and so the results are 
higher than expected, as monolayer coverage was assumed. 
2) There is free coating material present in the sample due to insufficient separation. 
3) Many of the coated particles are larger than was observed by TEM. 
4) The sample was not completely dry and so the mass measured was incorrect. 
Regardless of the reason, this measurement tool is still effective for calculating the mass of “active 
ingredient” in a SPIO preparation, assuming that the sample is completely dry.  It is also worth 
considering that even after separation steps have been carried out, there will still be a certain 
amount of free coating material in any solutions prepared as the coating agent, only joined by an 
electrostatic interaction with the particle, is able to dissociate in equilibrium with the solution.  This 
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makes a separation step less important and illustrates the importance of quantifying and controlling 
the total amount of coating material, bound or unbound, in the sample.   
Due to the equilibrium effects of the coating agent in solution it is important to determine the effect 
of this dissociation, and if it has any effect on degradation of the particle or on the T1 or T2 relaxation 
times.  pH buffers were used to investigate these effects, which could be applied to the biological 
aspects of the research. 
 
1.10 Results of pH study  
 
To determine if the functionalised particles would be stable enough in biological buffers, the effects 
of different buffers were investigated. The plot for T1 shows that changes in T1 for all amino acid 
coated SPIOs are slightly larger than that of water, represented in these graphs as buffer pH 0, 
regardless of the pH with the exception of pH 9.00 which will be discussed in further detail later on 
(Figure 59).  Other exceptions are the acidic coating, glutamic acid, at pH 4.00, and the basic coating, 
histidine, at pH 11.00.  These findings suggest that in pH solutions with pH similar to that of the 
coating material there may be more interactions between the coated SPIOs and the solutions which 
leads to either an enhancement or dampening of the superparamagnetic effect.  This has caused a 
larger increase in T1 for hisitine and a smaller increase in T1 for glutamic acid in comparison with the 
other amino acids.  However, as explained previously any inconsistencies could be explained away as 
inhomogeneities in the magnetic field.  So we turn to the results for T2 to confirm or reject these 
findings.  
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Figure 59. Graph showing T1 when different amino acids are put into buffers of different pH. 
 
Analysis of the data for T2, displayed in the graph in Figure 60, shows that changes in T2 are again 
slightly higher than for dilution with water alone.  Also of note is the absence of consistency both 
overall at pH 9.00, and with glutamic acid and histidine at low and high pH respectively.  This 
supports the theory of inhomogeneities in the magnetic field being the cause of fluctuations in T1, 
which is much more susceptable to these inhomogeneities.  This sensitivity is also the likely cause of 
the effects at pH 9.00.  It is likely that an error occurred during dilution of the buffer which has in 
turn affected the results.  It was not considered necessary to repeat the results as T2 results did not 
show the same inconsistency, and the aim of the experiment was to determine if there were any 
large adverse effects in the presence of buffers, which there were not.   
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*Buffer pH 0 is the amino acids diluted with 1 ml water rather than placed into 1 ml buffer. 
Figure 60. Graph showing T2 when different amino acids are put into buffers of different pH. 
 
From these results it can be concluded that when placed into buffers the coating material does not 
undergo a degree of dissociation significant enough to expose the SPIOs to degradation, and so 
SPIOs coated by this method appear to be stable in biological solutions. This goes some way to 
meeting the aim of using the particles for biomedical applications. 
 
1.11 Autoclaving 
 
If these particles are to be used in vivo then it is essential that they are sterile to meet FDA 
regulations.  The easiest method available to us was to autoclave the particles, but it was not clear if 
this would have any adverse effects on the particles themselves.   
On completion of autoclaving it was noticed that the SPIOs had become brown in colour.  This 
suggests that oxidation had taken place which would lead to a reduction in formation of Fe2O3 
(hematite).  In addition to this, any samples containing ascorbic acid appeared to have melted or 
decomposed slightly.  The TEM results (Figure 61) indicated that there was more agglomeration of 
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particles that had been autoclaved, although all particles still seemed to be spherical in shape and to 
be sufficiently coated.  MRI measurements gave T1 of 1103.95 ms and T2 of 12.84 ms for the non-
autoclaved sample, and T1 of 927.24 ms and T2 of 12.84 ms for the autoclaved sample, with both 
samples being dissolved 12 mg of ascorbic acid coated SPIOs in 3 ml distilled water.  These results 
indicated that the autoclaving process did not produce any deleterious effects and so can be used to 
sterilise these types of particles, adding to the case for their suitability for biomedical applications. 
 
Figure 61. TEM image showing agglomeration of ascorbic acid coated SPIOs rehydrated following 
autoclaving.  Particles appear to be ca. 20 nm and above in diameter but have not formed large 
aggregates. 
 
 
 
1.12 Separation of particles using size exclusion chromatography 
 
Particularly when aiming to use particles for applications such as cancer vaccines, or anything else in 
vivo, the particles need to be pure to meet regulations.  The first method of separation trialled was 
size exclusion, working on the principle that the coated particles would elute later than the free 
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coating materials.  G50 sephadex was used as it was deemed to have the perfect pore size, and 
distilled water was used for elution in case buffer solution caused some of the particles to fall out of 
solution.  The ICP data for each fraction collected was plotted against fraction number to give Figure 
62.   
 
 
 
Figure 62. This plot shows how the iron oxide nanoparticles are eluted from the column containing 
G50 Sephadex 
 
This graph shows that the SPIOs started to elute around fraction 5 but there were insufficient 
fractions to collect all of the SPIOs, as indicated by the line not returning back to 0 mg.l-1 of iron.  It 
was therefore decided that in future experiments a minimum of 30 fractions would be collected.  It 
was predicted that the SPIOs would elute first followed in later fractions by the free glutamic acid 
due to the size of the particles.  Larger particles, in this case the coated SPIOs, pass around the 
porous beads of the Sephadex.  The smaller coating materials will take a longer path through the 
beads and so elute later.  As an insufficient number of fractions were collected it was not possible to 
test this theory by removing the solvent in vacuo to reveal if free coating material was present in 
later fractions.  It is predicted that there will be a number of fractions between the iron containing 
fractions and the glutamic acid containing fractions so that a good separation can be guaranteed.  
This could be adjusted in further experiments by either using a longer column, different beads, or by 
using a slower flow rate. 
Results of Initial Size Exclusion Chromatography
with Glutamic Acid Coated SPIOs
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When the separation was repeated using more fractions (Figure 63), it can be seen that the 
concentration of Fe returns to 0 mg.l-1.  This confirms that the separation method can be effective 
although results are indicative of three sets of coated SPIOs, each of which will differ in size either 
due to coverage of coating material or due to variability of the particles themselves.  The presence of 
different peaks with particles showing such small variation illustrates the sensitivity of this method, 
which when developed could be exploited. 
 
Figure 63. Plot to show conc. of Fe in each fraction collected when number of fractions was increased 
 
Disappointingly this method was not successful for the larger coatings such as the immunogenic 
peptides.  What was observed in these cases, was that irrespective of the packing material, column 
length or solvent used for elution, SEC was ineffective.  In all cases the sample stuck at the top of the 
column and did not move down the column at all.  Initially it was assumed that this was due to the 
size of the particles but trialling of different sized beads soon eliminated this possibility.  So, it was 
decided that other methods should be trialled for separation of free peptide from peptide coated 
SPIOs. 
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1.13 Eppendorf and centrifuge 
 
Before moving on to the alternative separation methods, a system was devised with the possibility 
of increasing the efficiency of the size exclusion method.  For each of the conditions in which the 
Sephadex was used in a centrifuge column, the Sephadex dried out before any separation could take 
place as there was no way of keeping the top of the column wet.  Even with the lowest speed and 
shortest spin time the column was completely dry.  In addition to this the length of the column was 
too short, thus not allowing sufficient separation to take place and so any SPIO solution collected 
would also contain free coating agent.  In conclusion this is not a suitable method for separation of 
SPIOs from free coating material in solution.   
 
1.14 Separation using antisolvents 
 
Although for this research the aim was to avoid solvents as much as possible, the importance of 
obtaining a pure product for medical applications led to the investigation of antisolvents as a means 
of separation.  This type of separation produced some mixed results.  When SPIO solutions were 
mixed with solvents that were miscible with water, namely Acetone, Ethanol, ACN or THF, each 
mixture should have led to a certain amount of coated SPIO precipitating out of solution.  The results 
show that the mixture of water and solvent in some instances did not lead to the desired effect.  
Both ethanol and THF did not produce any precipitate, even when left in the freezer overnight, 
marking them as unsuitable antisolvents for this experiment.  The most effective antisolvent was 
acetone, producing a large amount of precipite on initial addition, and further precipitate when left 
in the freezer.  This was effective for all of the amino acid coated SPIOs trialled.  It should be noted 
however that due to its effectiveness as an antisolvent it was difficult to add acetone, even in 100 µl 
increments, without leading to a small amount of white precipitate (characterised as the coating 
material by NMR and IR).  It is possible that the acetone is too effective and so the next best 
antisolvent, ACN should be considered.  ACN was also effective in producing the desired brown 
precipitate but did not produce such a large quantity of unwanted free coating material.  It was thus 
much easier to tailor the ACN method to give the desired product, although again at 100 µl 
increments a small amount of white solid was observed (characterised as the coating material by 
NMR and IR).   
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Overall, despite the use of antisolvents being cited as a method for purifying nanoparticles, it was 
both unreliable and inconsistent for the particles coated via this method.  So, this method was 
abandoned and magnetic separation investigated as the alternative.   
 
1.15 Separation by Magnetic Force 
 
The literature suggests that SPIOs in solution are too small to be affected by the magnetic field of 
even a strong magnet.  However, if the mixture of free SPIO, coating material and coated SPIO could 
be separated when not in solution, then it could become a useable method.  In this instance a 
solvent in which the coated SPIOs and coating material would not be soluble was used as illustrated 
in Figure 64.  
 
 
Figure 64.  Schematic to show process of separation using magnetic force and a variety of solvents. 
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The SPIOs showed considerable magnetic properties prior to coating, so working on this principle a 
device was constructed consisting of a magnet with a piece of thin tubing wrapped tightly around it 
and a needle at one end through which a solution could be passed.  The principle was that as the 
SPIO solution was forced through the tubing the SPIOs would remain around the magnet and any 
free coating (amino acid or peptide) would pass through the tubing without attraction, leading to a 
pure sample of the coated SPIOs with no free coating. 
However, it was found that once in solution the SPIOs were not attracted to the magnet, as 
predicted in the literature, and so passed through the tubing together with the free coating.  It was 
decided that this method was ineffective for SPIOs in solution. 
Following this, a system was devised in which the SPIOs were coated with histidine HCl salt and the 
mixture suspended in acetonitrile.  The aim of this was to provide a mobile phase in which both the 
coating material and coated SPIOs were insoluble, with the aim that it would carry along any 
particles that were not attracted to the magnet.  The coated SPIOs and free SPIOs would therefore 
remain attached to the magnet until the second solvent, in which the coating material and thus the 
coated SPIOs were soluble, was passed through.  As the magnetic field is not strong enough to hold 
the SPIOs in solution onto the magnet, the coated SPIOs would dissolve in the second solvent and be 
carried through the tubing to the collecting syringe.  All that would remain on the magnet would be 
uncoated SPIOs which could be removed upon removal of the magnetic field. 
The fractions collected when water was passed through the tubing were found to have iron by ICP, 
but the fractions collected with acetonitrile did not contain any free coating material, as discovered 
when the solvent was removed in vacuo.  This could mean that either the separation step was 
ineffective, or there was no free coating material in solution.  During further experiments it was 
found that the flow of solvent was sufficient to push the larger and magnetically attracted SPIOs 
through the tubing and so it could reasonably be assumed that the coating agent would pass 
through the tubing with more ease.  As such, it was assumed that the grinding method, using the 
ratio of 1:1 led to an excess of SPIO, but not any free coating material.     
This method was found to be effective for amino acid salt coated SPIOs but was not suitable for the 
ascorbic acid coated particles, showing that it could not be applied to all coatings.  The solvent was 
altered for a less dense, less viscous solvent, as some of the SPIOs were being carried through on the 
primary solvent.  However, this was not effective for all coatings and this method was therefore 
stopped in favour of an alternative method.   
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1.16 Separation using a Magnetic Separation Rack 
 
A random variety of samples were chosen from what was most readily available.  These are detailed 
in Table 29.  For each of the samples trialled, the magnets showed some effectiveness in attracting 
the coated SPIOs in solution, which had not proved possible when using the neodymium magnet.  
However despite this promising start the force had not been effective enough to pull the particles 
completely out of solution, merely creating a “bubble” of ferrofluid.  It was also not possible to 
separate this ferrofluid, as the effects of either gravity when tipping the supernatant from the 
eppendorfs, or the suction from a pipette was enough to pull the fluid away from the magnet.  The 
limitation in this equipment was the strength of the magnet and it could be speculated that with a 
stronger magnet this method would have been effective. 
 
1.17 Separation using centrifugal force 
 
    
 
  
Figure 65. Showing the pellet formed during high speed centrifugation.  The samples that show no 
defined pellet had a very high concentration of iron and so a more dilute sample or several 
centrifugation steps may have been required for separation. 
 
A reliable method of purification is essential for the application of nanoparticles in biomedical fields.  
As the previous methods described were unsuccessful overall, this final method was investigated.  
The centrifugal force at 60 000 rpm was expected to be effective at separating the particles in 
solution, and could have been further investigated by using solvent gradients.  However, due to a 
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technical error it was not possible to analyse the samples from the high speed centrifugation 
experiment.  What was noticed though, was that on removal from the rotor (Figure 76) the tubes 
contained a pellet of dark material and a colourless solvent separated from this.  The only dark 
material present in the sample was the SPIOs and the solvent was water.  Therefore, we can assume 
that the pellet contains SPIOs that are separated from the solvent.  Due to the aforementioned 
problems it was not possible to determine if the solvent still contained the free amino acid or if the 
free coating material is inside the pellet as on defrosting the pellet became re-suspended in the 
solvent.  Due to damages to the equipment it was not possible to repeat this experiment and so no 
conclusive results could be drawn.  
As this method has been reported previously for separation of similar particles, it can be assumed 
that, had the equipment been in full working order, the particles and coating material would have 
been separated out.  However, it is likely that a gradient would increase the degree of separation 
observed.  This could utilise the antisolvents that have been previously described, or alternatively 
solvents of different viscosity which would separate different sized particles out according to their 
density and the density of solvents used. 
 
1.18 Iron (III) tin (II) oxide particles 
 
The research hypothesis states that metal and metal oxide particles will be synthesised, but the 
results so far are from iron oxide particles only.  As the other aim was for biomedical applications 
including medical imaging, the idea arose for a particle consisting of iron oxide, which would provide 
the desired NMR contrast, and tin, which with an Ar of 118.71 g.mol-1 would provide sufficient 
contrast for CT.  The results shown in Table 4 and Figure 66 combined indicate that spherical 
nanoparticles with the chemical formula Fe5Sn2O9 have been successfully formed, as was the general 
aim of the experiment, although it was assumed that the Sn would occupy the Fe(II) site leading to 
particles with the chemical formula Fe2SnO4.  The crystal structure of this compound could not be 
determined, which would confirm the suggested formula.  What has been successfully illustrated is 
that a nanocomposite containing both tin and iron can be formed, which has the potential to be 
useful for both CT and MRI.  It also shows that these mixed metal oxide particles can also be coated 
successfully using the solvent-free grinding method. 
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The MRI results indicate that the particles formed are magnetically active, or even 
superparamagnetic, which is possibly due to the presence of both Fe2+ and Fe3+ ions.  The T1 of 
236.91 ms and T2 of 5.19 ms are comparable with iron oxide nanoparticles (SPIOs). 
 
Element Weight% Atomic% 
O K 50.36 83.20 
Cl K 0.53 0.39 
Fe K 21.83 10.33 
Sn L 27.29 6.08 
   
Totals 100.00  
 
Table 4. Showing the EDX results for analysis of the iron tin oxide nanocomposite. 
 
 
 
Figure 66. Graph of EDX results showing the elemental composition of the iron tin oxide 
nanocomposite 
 
1.19 Calcium Oxide Nanoparticles 
 
As has been previously mentioned, the research hypothesis aims to investigate more than one type 
of particle.  Calcium oxide was investigated as it is possible that the calcium in the particle could be 
used as a vitamin supplement, and a further vitamin or drug molecule attached to the surface of the 
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particle making it multifunctional.  Figures 67 and 68 show TEM picture and the relative EDX results 
respectively.  TEM results indicate that spherical particles of ca. 5-10 nm have been formed from the 
spinning disc reaction, and the EDX data proves that these particles are composed of calcium and 
oxygen.  The EDX shows chlorine in the ratio of 1:2 with oxygen.  This equates to a 1:1 ratio of 
oxygen to chlorine on the histidine as illustrated in Figure 80.  This leaves 1 equivalent which is 
present in the form of oxygen in the CaO nanoparticle.  The ratio of calcium to oxygen is 1:2.5 
respectively, leaving an excess of oxygen, which could mean that the sample had not completely 
dried before analysis, leading to a small amount of residual water and thus oxygen in the sample.   
 
 
Figure 67. EDX result for CaO nanoparticles.  The grid is made of Cu accounting for the Cu peaks.  
Other peaks show Ca, O and Cl, with the large peak on the left showing the presence of organic 
matter (mostly a mixture of H, C and N present in the organic coating 
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Figure 49. TEM image of CaO nanoparticles showing spherical particles of ca. 5-10 nm.  Arrows are 
poining to individual nanoparticles.  *Poor image is due to limitations of the transmission electron 
microscope. 
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+
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Figure 69. Structural formula for Histidine indicating one protonated site at pH 4 
 
In addition to confirmation that CaO nanoparticles can be formed using an SDR method, these 
results also indicate that the solvent-free grinding method is also effective for coating of CaO 
nanoparticles.  CaO NP’s were not soluble in water themselves and aggregated, thus stopping them 
from passing through the filter.  This means that any particles present in the resultant solution must 
have been coated successfully coated prior to filtration.  This has implications for other metal oxide 
particles, suggesting that there are a plethora of nanoparticles that can be coated using this method.   
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1.20 Gold nanoparticles 
 
Finally, in order to meet the research aims the gold nanoparticles were synthesised with the aim of 
proving that coating methods would be successful for naked metal nanoparticles as well as metal 
oxide.  Using EDX and TEM at a magnification of 100K the images shown in Figure 70 indicate that 
gold nanoparticles were successfully formed via the methods described in the previous chapter.  The 
product was isolate at 30 sec, 60 seconds and 90 seconds after the reducing agent was added as 
there was a distinct colour change from pale yellow to purple and then to red as the reaction 
progressed.  It was found that the particles isolated at 30 seconds (purple) were smaller in diameter 
at around 5 nm, than the particles isolated at 60 and 90 seconds (red), which were > 10 nm in 
diameter.  It was also found that the red particles were subject to a degree of agglomeration. 
 
  
 
Figure 70.  TEM image showing gold nanoparticles of 40 nm length and 20 nm width.  Arrow 
indicated a smaller particle of ~ 5 nm suggesting that these particles are made up of smaller 
particles. 
 
When higher concentrations of HAuCl4 were used, a black precipitate formed.  This was the case 
from 0.02 – 0.10 %.  The particles would not suspend in solution, indicating that they were 
aggregated rather than agglomerated (Figure 71).  The reason for this, is that the high surface energy 
on the gold nanoparticles will lead to them clumping together in order to increase their stability.  At 
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lower concentrations the water molecules separate the molecules and keep them far enough apart 
that the high surface energy is not enough to overcome the distance.  At higher concentrations the 
distance between molecules is reduced and so they attract each other and form larger particles in a 
process similar to Ostwald ripening.  However, in order to increase the concentration of gold in the 
solution some of the solvent was removed in vacuo, leading to the particles being closer together in 
the solution, and in this case no aggregation was observed.  So, it could be suggested that the 
environment of the gold ions prior to reduction and coating is more important to dispersion than 
their environment following synthesis, and also that the coating material reduces or masks the high 
surface energy, thus protecting the particle from aggregation. 
When the peptide (p53(108))was added to the solution as the reducing agent in place of the citrate, 
it was found that at higher concentrations it led to the particles aggregating as characterised by a 
black solid precipitating out of the solution.  This shows that it is not only the concentration of gold 
but that of the coating material itself that can lead to aggregation.  
  
Figure 71. Images to show appearance of peptide (p53(108)) coated GNPs when peptide added at 
high concentration (left) and at low concentration (right) 
 
Whilst the particles have been successfully synthesised and coated, it was not possible to isolate the 
gold nanoparticles in sufficient quantities to trial the solvent free grinding method.  Reagents were 
expensive and no more than 2 mg of particles were made during each experiment; these quantities 
cannot be manipulated with the pestle and mortar.  
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Section 2: Medical Imaging 
 
2.1 Preliminary test with gold nanoparticles 
 
This project aims to prove that nanoparticles synthesised and functionalised using these methods 
can be used for biomedical applications.  This includes CT scanning, which was kept in mind during 
the design of the iron tin oxide nanoparticle.  However, as the literature leans towards the potential 
for gold nanoparticles as CT contrast, the focus was on these. 
To determine a starting point for the synthesis of gold nanoparticles (GNPs) for X-ray contrast, glass 
vials containing solutions of dodecylamine capped GNPs dissolved by weight in methyl methacrylate 
(MMA), were placed into plastic tubes so that they fit into a CT Phantom.  However, on attempting 
to measure the CT number of these solutions it was found that they could not be measured if there 
were any air bubbles inside the tube.  So, it was suggested that a block of polymer that would not 
interact strongly with the X-Rays, should be cut into tubes that would fit into the phantom, and vials 
milled into each end of the tube, to hold 1 ml of solution each.  When imaging was attempted it was 
found that CT measurements were inaccurate for this low volume of solution due to pixilation where 
each pixel of the image is so large that they overlap and it is not possible to distinguish the area with 
the solution in it apart from the rest of the vial.  It was suggested that a larger volume be used.  For 
this reason the containers were drilled to a volume of 2 ml and the experiments repeated.  These 
vessels were found to be suitable for measuring CT number of various solutions and can also be 
cleaned with ease using dilute nitric acid. 
 
2.2 CT testing with citrate capped gold nanoparticles 
 
If these particles are to be used as contrast agents then the optimum concentration for that 
application must be found.  The first experiments to determine the concentration of gold that would 
be required for in vivo use of GNPs as a contrast agent were carried out using the dodecylamine 
capped GNPs dissolved in methylmethacrylate (MMA).  Figure 72 shows that the CT number, which 
increases linearly with increasing concentration of gold, for these preparations was very low but the 
experiments were successfully used to devise a vessel for use in the phantom.  
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Figure 72. Plot of CT number vs % w/v of dodecylamine capped GNPs dissolved in 
methylmethacrylate when measured using tailored vesself for phantom. 
 
The GNPs were synthesised via the sodium citrate reduction method and samples of different 
concentrations placed into the phantom vessels and sealed.  These were then analysed and given a 
CT number (Figure 73) 
 
Figure 73. Plot to show CT number for citrate capped GNPs at various concentrations in water. 
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A CT number of 500 is needed for in vivo contrast which would mean a gold concentration of 3700 
mg.l-1, indicating the GNPs at the concentrations currently being synthesised, are not suitable.  It is 
possible to remove solvent in vacuo to increase the gold concentration but this will prove to be both 
time consuming and expensive so other options may need to be pursued.   
 
2.3 Determining optimum concentration of SPIO solutions for MRI experiments 
 
As with the CT studies, in order to use the SPIOs for MRI imaging, the optimum concentration of 
SPIOs functionalised via the solvent free method must be found.  To do this we first created a 
calibration graph for concentration vs. NMR relaxation times.  Calibration standards were analysed 
using the 0.25 T MRI MOUSE to determine the T1 and T2 relaxation times for each standard.  The 
results are shown in Figure 74 below.  T2 time decreases in a linear manner as concentration of iron 
increases.  Due to limitations of the machine it is very difficult to measure relaxation times that fall 
below 5 ms.  For this reason the optimum concentration was chosen to be between 50 and 250 mg.l-
1.  Another factor to take into consideration is the quantification of any sedimentation that may 
occur as the SPIOs fall out of solution, either due to aggregation or pH effects.  For this reason, the 
highest workable concentration was determined to be 250 mg.l-1.  
 
Figure 74. Showing calibration for T2 with SPIOs from which optimum concentration can be found. 
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2.4 Lysosome simulation experiment 
 
On entry into the body it is very likely that the particles will be taken up by macrophages as the site 
of entry, and will be put into lysosomes which have an acidic environment typically used to kill 
microbes.  As has been previously mentioned these kinds of acidic environments can potentially 
decompose SPIOs, and so it was important to test if the coated SPIOs could withstand these harsh 
conditions.  To simulate the environment that encapsulation in a lysosome would present to a SPIO a 
buffer solution of pH 4 was used, as this most closely matches the pH inside the lysosome.  Within 
the scope of the project it was not possible to exactly recreate the complete lysosomal environment 
(enzymes and other chemicals).   
Over a period of 6 hours the Histidine coated SPIOs were kept at room temperature in the buffered 
solution.  The degradation of signal is shown in Figure 75.  The loss of signal shown is 6 x 10-3 seconds 
for T2.  As has been previously discussed, SPIOs are used mainly for T2 weighted images and so for 
the purposes of this experiment the T1 results can be ignored although they also show a minimal 
change.  The small change in signal would not results in any change in image resolution and so it can 
be concluded that as far as the pH is concerned, SPIOs coated in this way can withstand the 
conditions and still produce a good signal.   
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Figure 75. T1 and T2 relaxation time lapse study for histidine HCl coated SPIOs in pH4 buffer over a 
period of 6 hours. 
 
It is generally considered that SPIOs are not suitable for oral administration as an MRI imaging agent 
due to the degradation they would undergo in the acidic conditions in the stomach.  In a similar 
study at pH 2 it was shown that, again, the SPIOs coated in this manner were not degraded and 
instead showed good stability over the 6 hours they were studied. (Figure 76). 
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Figure 76. T1 and T2 relaxation time lapse study for Histidine HCl coated SPIOs in pH2 buffer over a 
period of 6 hours. 
 
2.5 Comparision of prepared particles with Endorem ® 
 
If the SPIOs are to become a commercially viable alternative to current technologies it is essential for 
them to be able to compete and in some way outperform what is already available.  When 
compared with Endorem®, both at a concentration of 250 mg.l-1, it was found that the SPIOs had a 
comparable relaxation effect to Endorem® (Table 35), with both T1 and T2 relaxation times being 
very similar.  What is of more significance is the observed stability of the particles.   Whilst the 
particles prepared via the solvent free grinding method have been shown to be stable as both a 
powder or solution for a matter of weeks with some handling and exposure to air, it was found that 
once the vial to the Endorem® was opened the solution was very unstable and even in a sealed vial 
the solid particles dropped out of solution and soon could not be used. 
 
These findings suggest that the coated SPIOs prepared using these methods could be an 
improvement on the Endorem® as it is much more stable and so could have a longer shelf-life 
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leading to less waste and easier preparation.  The particles can also be dehydrated and then 
rehydrated when required, providing ease of storage and a possible longer shelf-life. 
What should be noted is that the dehydrated particles did not completely re-dissolve in water, and 
that in PBS there were further solubility issues.  In PBS the same quantity of SPIO gave a T2 of 1113.4 
ms, which is over 10 times longer than the rehydrated histidine coated SPIOs.  This could present 
problems in a clinical setting, where water cannot be used due to osmotic effects.  However, these 
experiments were carried out using very low concentrations of SPIO and at larger concentrations it is 
likely that the diluting effects of PBS would be lessened. 
 
2.6 Blood Studies 
 
Before thinking about using these particles in vivo it is essential to know how they behave in blood 
as well as the other physiological solutions that have been previously discussed. When SPIOs were 
added to blood samples, the results were surprising, with the blood coagulating.  It is likely that the 
ethylenetriaminetetraacetic acid (EDTA) which is present as an anticoagulant preferentially binds to 
the SPIOs instead of the blood.  Without the anticoagulant being active in the blood, the blood is 
free to coagulate and so the NMR relaxation time is increased due to restricted movement of 
molecules in the blood.  Despite this, the SPIO solution and dehydrated SPIOs led to a significant 
decrease in T1 from 1000.2 ms for blood alone, to 62.7 ms with blood and SPIO.  There was also a 
small decrease in T2 from 11.9 ms to 5.6 ms.  This means that SPIOs synthesised via the solvent free 
grinding method would be suitable for T1 weighted MRI imaging, but do not produce a large enough 
decrease in T2 for a T2 weighted image.  However, it is possible that if the blood had not coagulated 
then the difference in T2 may have been significant enough to produce a T2 weighted image.   
As different organs in the body have different proton density and so different relaxation times, it is 
possible that the SPIOs will have a greater relaxation effect on other tissues as it passes through the 
circulatory system.  This would need to be further investigated in vivo or using an MRI phantom. 
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Section 3: Transdermal drug delivery 
 
3.1 Analysis of CPP 
 
MALDI-TOF gave a molecular ion peak with m/z 1661.96.  This corresponds to the CPP described in 
the experimental section, and show below (Figure 77).  It would have been beneficial to carry out 
amino acid sequencing for the peptide but due to the large quantity of Arginine present there were 
large interference peaks and fragments that could be isolated for sequencing were near impossible 
to produce.  For this reason the only confirmation that the correct peptide was synthesized is the 
molecular ion peak.  
 
 
Figure 77. Structural formula of the cell-penetrating peptide 
 
HPLC of the peptide showed a peak accounting for 89.95 % of the sample at 13.22 minutes.  As 
previously mentioned this could not be confirmed by MALDI-TOF due to poor fragmentation but was 
taken to be the true value as there was a correlation between the main peak HPLC and the 
molecular ion peak from MS. 
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3.2 Characterisation of SPIOs coated with CPP 
 
The SPIO-CPP complex was analysed using ICP, TEM and DLS and particles were found to be on 
average around 50 nm in diameter by TEM and 10 nm in diameter by DLS containing an average of 
9.4 mg.l-1 of Fe.  Distribution of particles on the grid was sparse and so it was not possible to 
determine if there was a clear coating area around the particles.  However, if the particles had not 
been coated then they would not have been taken up into solution and so could not be analysed by 
either ICP, DLS or TEM following microfiltration.  This suggests that on drying the particles clump 
together on the TEM disc to give larger agglomerates of 50 nm.  Regardless of the size of these 
particles, these images and measurements indicate that the particles are within the desired range of 
40-60 nm for cell uptake and thus transdermal delivery.  These results again confirm the 
effectiveness of the coating method with peptides. 
 
 
Figure 78. TEM image of CPP coated SPIOs showing diameters of ca. 50 nm. 
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Figure 79.  DLS graph indicating CPP coated SPIOs to be ca. 10 nm in diameter. 
 
 
3.3 Optimisation of conditions for pig skin incubation 
 
After application of the gel preparations it was unclear which methods might be suitable for optimal 
uptake of gel and preservation of pig skin so several conditions were trialled; on a glass slide at room 
temperature, glass slide in an incubator at 37°C, glass slide in 50 ml centrifuge tube at 37°C, glass 
slide in 50 ml centrifuge tube with 10 ml PBS underneath slide at 37°C.   
In all but the final condition the pig skin began to curl up at the edge which made performing a 
depth profile on the MOUSE difficult, and the results unreliable.  In some conditions the pig skin also 
dried out during the incubation period meaning that it would not simulate the real conditions of the 
skin and thus would not show reliably if uptake would occur.  For all experiments henceforth the pig 
skin was placed on a glass slide which was inserted into a 50 ml centrifuge tube, with the glass slide 
suspended above 10 ml of PBS (Figure 80), and kept in an incubator at 37°C for the desired 
incubation time.  These skin samples were still warm and moist after incubation, more closely 
representing a true skin sample. 
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Figure 80. Schematic of optimised pig skin incubation set up. 
 
 
3.3 MRI Imaging to determine SPIO-CPP uptake 
 
The 2.45 T BIOSPEC imaging system was used to determine if the SPIO-CPP had been taken up by the 
skin.  Following incubation the pieces of skin had been washed in PBS to remove any remaining gel 
preparations on the surface of the skin.  Figure 81 shows the control piece of skin.  The large spot 
shows the position in which the gel was positioned on the skin.  This indicates that the gel itself has 
been soaked into the skin, thus altering its relaxivity.  It can be seen that the area of skin without gel 
has been unaffected during incubation. 
Figure 82 shows the same dark red/blue spot at the bottom of the skin where gel alone has been 
applied in the spot.  It also shows a smaller light blue/yellow spot.  This is from an area where the 
same volume of gel was applied but this one containing the SPIO-CPP mixture.  This is promising as it 
shows that the SPIOs, as expected, have reduced the signal intensity of the gel as they have 
penetrated along with the gel.  As the skin has been washed thoroughly prior to imaging it can be 
concluded that the SPIOs have been able to penetrate the skin along with the gel, indicating that the 
experiment was a success. 
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Figure 8150. BIOSPEC Image indicating the position of the gel control on the skin.  The large red/blue 
spot indicates a difference in relaxivity between the skin itself and the area into which the gel has 
soaked, showing that the gel itself is able to penetrate. 
 
 
Figure 82. BIOSPEC Image indicating the position of the gel control (blue/red) and further up, the 
diminished signal from the penetrating gel which contains SPIOs.  This image shows that the SPIOs 
are reducing the image produced by the gel and so must have soaked 
 
To further clarify the success of these preparations in penetrating the skin, further experiments were 
carried out on the same skin samples, under the same conditions but in this case using the 0.25 T 
MRI MOUSE.  Here the T1 and T2 relaxation at different cross sections through the skin, referred to as 
a depth profile, were measured and these plotted on a graph.  The difference in the graphs 
produced are due to optimisation of the instrument and do not reflect different conditions being 
used before and after the application of the gel.  Figure 83 shows the profile through the skin prior 
to incubation with the SPIO-CPP gel.  Figure 84 shows a profile through the same piece of skin which 
was treated with gel only.  As can be seen, there has been no significant change in signal through the 
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depth profile and so we can conclude that the gel itself does not cause any difference that can be 
observed using this type of instrumentation. 
However, what we can see from the depth profile for the skin incubated with CPP-SPIO gel 
preparation (Figure 85), is that there is a marked decrease in signal at 800-1400 µm.  This indicates 
that the SPIO-CPP has penetrated to between 400 – 1000 µm into the skin.  This corresponds to a 
penetration all the way through the porcine stratum corneum (20 µm). 
 
 Figure 83. Depth profile showing relaxivity at 100 µm slices through a section of pig skin prior to 
treatment with any type of gel preparation. 
 
 
Figure 84. Depth profile showing relaxivity at 100 µm slices through a section of pig skin after 
incubation with gel only. 
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 Figure 85. Depth profile showing relaxivity at 50 µm slices through a section of pig skin after 
incubation with SPIO-CPP 
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Section 4: Immunotherapy 
 
4.1 Synthesis of peptides 
 
4.1.1 Optimisation 
 
Through repeated synthesis of p53(108) it had been found that purity was variable and often lower 
than expected.  Peptides whose synthesis was interrupted by storage in the freezer between 
couplings were found to have much lower purity than those synthesised without stopping.  This 
could be due to the beads shrinking during storage and not successfully swelling before continuing 
synthesis.  This means that many of the peptides would not be sufficiently exposed to the reagents 
and so reaction would be stopped, leading to some deletion sequences.  It could be assumed that a 
second swelling step prior to continuing synthesis would overcome this problem.  However, despite 
trialling a second swelling step the purity continued to remain low (ca. 40 %) so it was concluded 
that peptides should be synthesised from start to finish without stopping.   
Certain amino acids are known to be problematic in terms of coupling.  A suggested solution to this 
is longer coupling times for these amino acids, such as 10 minutes at 50 °C rather than 5 minutes at 
75 °C for histidine and cysteine, and two couplings for arginine (30 mins room temperature followed 
by 5 minutes at 75 °C).  Using this approach it was decided that longer coupling times could be of 
benefit for increasing purity of peptides known to give low purity such as p53(108).  So, for all amino 
acids the coupling times were doubled, with the exception of the 30 minutes at room temperature 
for the first addition of arginine. 
The peptides were analysed by HPLC (Figure 86 and 87) and those synthesised using regular coupling 
times were found to have lower yield and purity than those synthesised using longer coupling times.   
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Figure 86. Showing a section of the HPLC graph for p53(108) synthesised using standard 5 minute 
coupling times,  indicating purity of ca. 45 % (MS results were in agreement) 
 
 
Figure 87. Showing part of the HPLC graph for p53(108) synthesised using longer coupling times and 
without long gaps between couplings, indicating purity of ca. 75 % by HPLC (MS results were in 
agreement). 
 
4.1.2 p53(108) 
 
For the desired application of SPIOs for cancer immunotherapy adjuvants, it was important to 
choose a peptide that was being used in current research.  The John van Geest cancer research 
group were using this peptide and were in the process of developing a tumor model for it during the 
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course of this research.  For this reason P53(108) (Figure 88) was synthesised several times during 
the course of the project with a view to attaching it to SPIOs and using those in immunotherapy.  
Typically yields of 150 mg per synthesis were obtained.  The purity of these preparations varied and 
was typically much lower if the peptide was stored in the freezer in between couplings.  To 
investigate the optimal method to synthesise peptides of the highest purity different conditions 
were trialled. 
However, for the traditional synthesis requiring 5 minute couplings at 75 °C it was found that the 
peptide was successfully synthesised, as illustrated by the MS-MS results in Figure 89.  MS-MS 
isolates the main peak, in this case the peak at m/z 1576.85 corresponding to the desired p53(108) 
peptide, and directs the molecular ions back through the MS procedure to give fractions 
corresponding to the main units making up that molecular ion in order.  It was then possible to 
manually pick out the peaks corresponding to the expected fractions and so determine that the 
correct peptide sequence had been synthesised. 
 
 
 
Figure 88. Structural formula of p53(108) (Mass: 1576.85 g.mol-1) 
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Figure 89. MS-MS results showing the molecular ion at 1576.880, and the fragments formed from 
this peak proving that the correct peptide had been formed. 
 
 
4.1.3 p53(105) 
 
p53(105) (Figure 90) was synthesised via SPPS and analysed by HPLC.   
 
Figure 90. Structural formula of p53(105) (Mass: 1547.81 g.mol-1). 
 
HPLC on the sample was carried out as in general experimental.  There was a peak at 30.206 minutes 
corresponds to p53(105), with this peak accounting for 71.23 % of the total product injected onto 
the column.  Unfortunately the zip tip preparation could not be carried out for MS and so there are 
both Na and K adducts of the peptide present in the spectra making it difficult to determine purity of 
the peptide alone.  However, by combining the Na and K adducts along with the peak for the peptide 
alone the total comes to 53 % supporting identification of the HPLC peak at 30.206 minutes 
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corresponds to p53(105).  For the purpose of the rest of the experiments using p53(105) the purity 
was taken as 70 % by HPLC.    
 
4.2 Checking immunogenicity following recrystallisation 
 
In order to determine if the p53(108) was still immunogenically active following recrystallisation with 
hydrochloric acid and also in part to check whether or not the peptide had been successfully 
synthesised, it was tested against the commercially purchased peptide via ELISPOT using 
spleenocytes from DR1 mice (kept in sterile conditions – barrier, conventional conditions – 
conventional, and taken from the barrier into the conventional – “barrier-conventional”) previously 
immunised with the commercially bought peptide.  The results are shown in Figures 91 and 92. 
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Figure 91. Complete ELISPOT results for all conditions of mice for checking immunogenicity of 
recrystallized peptides.  The left hand bars are for T cells without any stimulating agent or DCs.  The 
second set of bars shows the number of spots when the T cells are re-stimulated with the DCs that 
have taken up the commercial p53(108).  The third set of bars shows the number of spots when the T 
cells are re-stimulated with DCs that have taken up the recrystallized p53(108).  The fourth set of bars 
shows the number of spots when the T cells are re-stimulated with DCs that have taken up a non-
specific peptide to which they should not show an immune response.  The final set of bars shows the 
number of spots when the T cells are re-stimulated with DCs that have not taken any peptide up.  
Each differently coloured bar represents a different mouse immunised.  X-axis shows number of 
spots.   
 
 
Figure 92. ELISPOT results for mice kept in the conventional conditions showing a higher response for 
the processed peptide (p53 108 (Vicky)) than for the commercially bought peptide (p53 108 (AB))  
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These results show that the recrystallized p53(108) produces an immune response when used to 
stimulate spleenocytes from mice immunised with commercially bought p53(108), and this reponse 
is significantly larger than that for the irrelevant peptide.  This is promising as it shows that the 
recrystallization process does not affect the immunogenicity of the peptide and so for sparingly 
soluble peptides it could be a suitable option to use this method to increase attachment to SPIOs or 
even solubility in general. 
 
4.3 Formation and analysis of SPIO-Peptide Complexes 
 
Peptides contain a number of side chains and groups that could potentially bind to SPIOs.  The 
p53(105) used in the immunology studies contains many amine and hydroxyl side chains along with 
its terminal carboxylic acid and amine; groups like this have been shown to bind well to the surface 
of the positively charged SPIOs.  On recrystallization the binding of the peptide to SPIO improves as 
has been previously discussed, so that the particles coated with peptide can easily be taken up into 
both water and DMSO (used to solubilise difficult materials prior to injection).  The iron content of 
the particles by ICP was found to be 15.03 mg.l-1 for 3 mg of the powder dissolved in 6 ml of water.  
This means that the iron content of the particles can be calculated as follows: 
                                        
                                
                               
                                     
                        (       ) 
This means that the remainder of the 3 mg of sample is made up of peptide which gives 2.97 mg 
p53(108).  As it is difficult to control the content of iron, the experiment was controlled by mass of 
peptide, and so the SPIO-peptide was dissolved to give 10 mg/ml of peptide.  This technique was 
also used to successfully quantify the mass of peptide in the SPIO-peptide complex used for 
p53(105) immunisations. 
This technique is beneficial as it allows control of peptide concentration.  However, as there is the 
possibility of free peptide in the mixture it is difficult to fully assess the effectiveness of the SPIOs in 
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any application as ideally all peptide present would be bound to SPIO.  Due to equilibrium effects 
some peptide will always be free in solution due to dissociation, but this could be greatly reduced by 
further development of a suitable separation step.  The centrifugation process looks like the most 
promising option but further experimentation would be required to develop this fully.  
 
 
4.4  U937 Uptake Study 
 
In order for the coated SPIOs to be used successfully in cancer immunotherapy it must be possible 
for them to be engulfed by phagocytes.  To this end the cell line U937 was selected and used for 
some preliminary studies.  The cells were incubated with the SPIOs coated with histidine.HCl, as 
described in the experimental section before analysis to determine if they were indeed taking up the 
SPIOs.   
T1 and T2 relaxation times of the cells following incubation was measured and results indicated an 
anomaly with the cells incubated for 1.5 hrs and also that the concentration of SPIOs in the cells is 
too low to be detectable using this low field MRI (Figure 93).   
 
As the uptake of SPIO could not be determined by MRI the cells were digested in nitric acid and 
diluted for ICP analysis as displayed in Figure 94. 
The results show a general trend, with the amount of iron in the cells following incubation being 
higher than in the control cells; however, there are large fluctuations so results are inconclusive.  
The result was much more exaggerated in the repeat experiment when experimentation had been 
optimised, however in this case only two samples were successful and so again results are 
inconclusive.  Combining the sets of results together, there is a general increase in the concentration 
of iron with increased incubation times although the difference between the times is very small.  
This would need further investigation in order for any conclusive results to be drawn.  Saying this, it 
was decided on the limited evidence that the optimum incubation time for further experiments 
should be 2 hrs.   
To increase the reliability of this study an NMR with a larger magnetic field could have improved the 
sensitivity to SPIOs inside the cells and so produced valid results.  The MRI and ICP-AES results in 
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combination would have been preferential.  Alternatively using a Prussian blue would have allowed 
quantitative results by colorimetry, for how much SPIO had been taken up into the cells.  
Unfortunately at this point in the experiment the cells had been destroyed through digestion in nitric 
acid and so this was not possible. 
 
 
Figure 93. Plot to show iron concentration in U937 cells incubated with SPIOs  *Cells with media only 
have an average Fe conc. of 0.818 mg.l-1 
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 Figure 94. Graph to show NMR relaxation times for U937 incubated for varying times with SPIOs 
 
4.5  Investigation into uptake of coated SPIOs by bone marrow dendritic cells (BMDCs)  
 
4.5.1 Culturing of BMDCs 
 
Moving the studies on from simple uptake studies in vitro we moved on to test the SPIOs using 
dendritic cells from mice with humanised immune systems.  For the first stage of this BMDCs were 
harvested from mouse bone marrow and cultured as described in the General Experimental section.   
Figure 95 shows a light microscope image of BMDCs grown as described.  These were adhered to the 
well plate, as confirmed by their elongated shape.  The fact that these cells are adhered means they 
are alive and healthy; unhealthy or dead D’s do not adhere to the plate and so are not elongated.  
This is essential for the uptake study as the membranes of these cells change as they become 
unhealthy and cell death occurs.  These cells were grown from cells isolated from mouse hind legs, 
and so were part of an impure population as illustrated in Figure 96 which shows the BMDCs to be 
only ca. 45 % of the total population.  In order to obtain a pure population the cells were passed 
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through a CD11c+ MACS column in subsequent experiments.  By ensuring a pure population the 
accuracy of the results is increased, ensuring any results are specific to BMDCs.  
 
Figure 95. Light microscope image of adhered BMDCs 
 
 
Figure 96. FACS data showing population of BMDCs prior to purification using CD11c+ column. 
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4.5.2 Culture of BMDC’s on different types of plate 
 
Before it was viable to take the immunology section to the next stage it was essential to get some 
reliable results on a slightly larger scale.  However, whenever any attempt was made to culture 
BMDCs a very small impure population was found.  This hampered results as repeats and statistical 
analysis was not possible on a such a small number of cells.  The suggestions for overcoming this 
problem were i) to grown the cells on different plates and ii) to grow the cells in T25 flasks which 
could be vacuated using a cell scraper rather than a pipette tip, thus reducing the chance of killing 
cells during the scraping process. 
 
Three different plates were trialled:  Normal coating, amine coating and carboxyl coating.  At first 
glance the results seem to indicate that the carboxyl coated plates are much better for growing 
BMDCs (Figure 97).  However this may not mean a larger quantity of BMDCs as the number of any 
type of cell grown on the carboxyl plates is larger than for the normal or amine plates.  It is logical to 
assume there will be more BMDCs overall, as the total number of cells is much larger and so if the % 
population of BMDCs remains the same regardless of plate then the number of BMDCs should 
increase with increasing cell number.  This is confirmed when the data is normalised (i.e. the number 
of BMDCs is divided by the total number of cells for each plate).  The graph in Figure 98 shows that 
the relative number of BMDCs overall is not higher on the carboxyl plates than for any of the other 
plates and in fact for plate 1 the normal plate has more BMDC’s present on it than the carboxyl 
plate. 
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Figure 97. Graph to show difference in total number of cells grown on different types of plate. 
 
 
Figure 98. Graph to show total number of BMDC’s grown on different types of plate. 
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Figure 99. Graph showing normalisation of number of BMDC’s grown on different plates relative to 
total number of cells grown on plates. 
 
 
T Test  
Normal vs Carboxyl 0.173 
Normal vs Amine 0.225 
Amine vs Carboxyl 0.094 
 
Table 5. T Test results showing no significant difference between the number of BMDC’s on different 
plates following normalisation. 
 
Statistical tests carried out on the number of BMDCs following CD11c+ isolation (Table 5) indicates 
that there is no significant difference between the results obtained from the different plates, 
however there were significantly more cells overall on the carboxyl plates relative to the normal 
plates and amine plates (p = 0.005 and p = 0.004 respectively).  A possible explanation for the overall 
increase in the number of cells may be that they adhere better on the carboxyl plates and so fewer 
cells are lost during the washing steps.  This would require further investigation but in the meantime 
carboxyl plates can be used to generate more cells overall. 
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4.5.3 Uptake results 
 
Whilst the preliminary results into uptake of coated SPIOs by U937 cells were reasonably successful, 
it was not repeated enough times to make it reliable.  It was also not possible to determine if the 
SPIOs had actually entered the cell and so further investigations relying on coating of SPIOs with a 
peptide containing fluorescein, were carried out.  Here we incubated the SPIOs with BMDCs and 
observed them under the microscope following the 6 hour incubation process.   
BMDCs were isolated, cultured and incubated with SPIO-peptide complex, and uptake of the 
complexes determined by fluorescence microscopy with DAPI stain being used to highlight the 
nucleus of the cell and the presence of FITC (green stain) inside the cell being used as the positive 
result. 
These images (Figure 100) clearly show the nuclei of the cells, with the blue nuclear stain (DAPI) 
highlighting them in the image.  What can also be seen is the green colour of the fluorescein, which 
is attached to the peptide, in some of the cells.  This colour spreads out to the edges of each cell that 
it is present in, picking out the shape of the cells.  It could be assumed that this confirms that the 
peptide has been delivered into the cell, however fluorescein has a tendency to stick to the outside 
of the cell membrane.   
      
Figure 100. Fluoresence microscope images of cells incubated with SPIO-peptide where peptide has 
been synthesised with fluorescein at the end.  Blue colour is nuclear stain DAPI and green colour is 
FITC attached to peptide. 
 
170 | P a g e  
 
One of the conditions in this experiment was the p53(108) peptide-fluorescein without SPIO 
attached to it.  If binding was occurring on the outside of the membrane only, then this would 
happen irrespective of whether SPIO was bound to the peptide or not.  What was observed was that 
in this condition there was not a single cell observed that exhibited the green fluorophore. 
The green colour was only observed when both p53(108) peptide-fluorescein and SPIO were 
present.  This suggests that the p53(108) peptide alone cannot enter the cell, but with the SPIO 
acting as a vector entry is possible.  This is promising for applications such as vaccinations, as uptake 
of antigens (in this case the peptide is the antigen) is essential for a full immune response.   
The uptake of these complexes is most likely occurring due to the optimal size of the SPIO-peptide.  
As seen in TEM images, the longer peptides such as p53(108) form small clusters of particles that 
have a diameter in the range of 40-60 nm.  As has been previously mentioned, the literature 
suggests that 50 nm is the optimum size for a particles to be engulfed by endocytosis as it is neither 
too small to be energetically favourable, nor too large to be too sterically restricted.   
 
4.6 Maturation of BMDC’s using SPIOs 
 
Whilst it was not the primary aim of the experiment, it was decided that the SPIOs would be tested 
for their ability to induce maturation of the immune cells.  Following incubation with SPIO-p53(108) 
peptide complexes, maturation of DCs with and without lipopolysaccharide (LPS) was monitored 
using fluorescence microscopy with the red stain phycoerythrin (PE) being used as a positive result. 
During the majority of studies using BMDC’s Poly-IC and LPS are used to mature BMDC’s.  This is 
necessary to activate the BMDC’s to produce the required signalling molecules to illicit an immune 
response, and must be carried artificially in vitro as it would usually occur in the lymph nodes.  Using 
the cell marker CD86 the possibility that SPIO-peptide preparations, or more SPIOs themselves, 
might be able to induce cell maturation was explored.   
What was observed was a very small number of cells that had been fluorescently labelled by the red 
fluorophore (PE) but many with the blue nuclear stain (DAPI) was still visible, showing the location of 
cells on the slide (Figure 101).  This indicates that there were very few cells that had matured to 
express the CD86 molecule, and so it is not possible to confirm whether or not the SPIOs caused 
maturation.  Given the small numbers it is possible that another factor such as maturation prior to 
isolation, or maturation due to an impurity in any of the media or reagents was responsible.  Bearing 
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this in mind, this experiment should be repeated with larger numbers of cells and higher 
concentrations of SPIO.   
 
Figure 101. Cells incubated without LPS but with p53(108)- SPIO complex at 50 μg / ml.  Blue colour 
indicates the nuclear stain DAPI, and red colour indicates CD86 linked to the red stain PE. 
 
4.7 Cytotoxicity Assay 
 
If the particles are to be successfully applied to biomedical applications then it is of the utmost 
importance that they are not toxic to cells in the doses in which they will be administered.  Simple 
cytotoxicity assays looking at the viability of cells after incubation with the coated SPIOs was carried 
out in the hope of proving that the particles were benign.  The results of the cell count showed all 
conditions to contain similar numbers of cells after incubation from the same original cell count of 
250 000 cells (Table 49) with the mean cell count being 1.24 x 105 cells with a standard deviation of 
3.97 x 104.  So, it can be deduced that the complexes have little or no toxicity to cells.  However, this 
study was carried out using an impure population of dendritic cells and so all cells present will be 
taken into account.  Also, this method only takes into account complete cell death, ignoring cells 
undergoing apoptosis, and so could be painting an incomplete picture of how harmful the 
preparations are.  In future studies markers for cells that are undergoing apoptosis but have not yet 
died should be used, such as those in the Annexin V kit.  This will give a more complete picture of the 
cytotoxicity of these compounds. 
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4.8 QuantumTM FITC kit 
 
QuantumTM FITC MESF (Molecules of Equivalent Soluble Fluorochrome) beads are microspheres that 
contain a known quantity of fluorescent molecules, in this case fluorescein isothiocyanate (FITC).  As 
there is a known quantity it is possible to use the intensity of their fluorescence along with the 
known concentrations to create a calibration graph from which it is possible to determine the 
concentration and so quantity of fluorescent molecules within cells.  The beads for the QuantumTM 
FITC MESF kit were diluted as directed, and the graphs below created from these standards using a 
fluorescence assisted cell sorting system.  This was going to be carried out on a culture of BMDCs 
that had been incubated with either fluorescent peptide and alone or fluorescent peptide attached 
to SPIO, as a measure of how effective the SPIOs are as vectors.  As the peptides, namely p53(105) 
and p53(108) have been synthesised with a 1:1 ratio of peptide to fluorescein it would be possible 
from the concentration of fluorescein to determine the concentration, and so number of peptide 
molecules within a cell.  This would be a useful tool for studying immunology, as the number of 
molecules taken into a macrophage may have an effect on the type of immune response and 
whether or not long-lived T-Cells are formed.   
Unfortunately due to problems during cell culture it was not possible to carry out any measurements 
on the cells themselves.  Due to time constraints there was not an opportunity to repeat the cell 
culture and conclude how effective a vector the SPIOs are.  However, Figure 102 shows the initial 
calibration graph created that could have potentially been used to determine the average number of 
peptide molecules in each cell.  
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Figure 102. Quantum FITC MESF 5 Kit preliminary calibration results 
 
4.9  Mouse immunisations with p53(105) SPIOs 
 
Mice were immunised with either p53(105) in the adjuvant IFA or with p53(105)-SPIO complex.  As 
has been discussed it is very difficult to find adjuvants that enhance the immune response to weak 
antigens without creating side effects.  SPIOs are FDA approved and degrade in the body to produce 
iron ions which can be used to make haemoglobin, and so if they could be used as adjuvants these 
properties would be beneficial.  The aim of the immunisations was to determine if SPIOs could be 
used as an adjuvant and if so, could they produce a stronger immune response that the current 
alternative, in this case IFA. 
Following immunisations the spleenocytes were harvested and analysed by ELISpot, with the spots 
being counted using a C.T.L. Immunospot counter.  The counter was calibrated to only take into 
account spots of a certain darkness, so as to avoid false positive results.  Figure 103 and 104 shows 
the key findings from this experiment, and the T Test results shown in Table 6 which show whether 
or not the results are significantly different. 
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Figure 103. Photograph of ELISPOT plate showing spots for each positive result 
 
From this image it appears that there has been a much larger immune response in the second 
mouse, specifically to the p53(105) complex at 0.1, 1 and 10 µg of peptide, as shown by the much 
darker colour of the wells in question due to a larger number of spots.  Each spot indicates one 
antibody that has been produced that is specific to p53(105) showing that immunisation has been 
effective.  There are inconsistencies elsewhere in the plate but here each well shows a large 
increase.  This is the first piece of evidence to suggest that the SPIOs are a suitable vector for 
delivery of immunogenic peptides. 
 
This graph (Figure 104) also supports those results, with the peaks for Mouse 2 immunised with 
peptide-SPIO showing a much larger immune response than all of the other mice.  However, it 
should be noted that this same large immune response has not been exhibited by either Mouse 1 or 
Mouse 3 with respect to the peptide-SPIO immunisations, and so it may be that the results for 
Mouse 2 are due to chance. 
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Figure 104. Graph showing the results for comparison between IFA and SPIO as vectors for 
immunisation with p53(105) 
 
T Test Mouse 
1 
Mouse 
2 
Mouse 
3 
Naïve 
10 0.33158 0.009071 0.103424 0.935651 
1 0.176351 0.021035 0.459788 0.200283 
0.1 0.812606 0.020873 0.199917 0.716 
0.01 0.247561 0.00656 0.00073 0.157834 
 
Table 6. T Test results for immunisation showing difference between IFA and SPIO as vector. 
 
The T Test results indicate that overall there is no significant difference, in either direction, between 
the SPIOs and the IFA, although there is a significant different for M2, in favour of mice immunised 
with the SPIO complex.  This result was matched when the experiment was repeated, with there 
being no significant difference in the immune response from either type of immunisation.   
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Whilst this does not show the desired result, that the SPIOs would work better than IFA as an 
adjuvant, the results are very promising and show that the SPIOs are at least equivalent to the IFA as 
an adjuvant.  It was noticed that some of the SPIO-p53(105) had fallen out of solution on storage, 
which may have reduced the effectiveness of the SPIO as an adjuvant.  It may be possible that if all 
of the SPIO had remained in solution the results may have shown a significant difference in favour of 
the SPIO.  It is also possible that Mouse 2 received a larger dose that Mouse 1 and Mouse 3, possibly 
having the only injection to contain the desired amount of p53(105)-SPIO complex.   
To overcome this problem it is suggested that the SPIO-p53(105) or other relevant peptide, should 
not be dissolved in DMSO and diluted until immediately prior to injection, to reduce the chance of 
sedimentation.  It is also possible that solubility is an issue and so the original formulation needs to 
be adjusted to make it easier to dissolve the complex in DMSO rather than water. 
Restimulation results (Figure 105) do not show an increased immune response to DC’s pulsed with 
the peptide for mice immunised with the SPIO complex.  This is in keeping with the results from the 
ELISPOT which indicate that there is not an increase in the strength of the immune response. 
However, there is a significant decrease in non-specific response, meaning that the cells are not 
significantly responsive to peptides other than the peptide that was used for immunisation.  
Additionally there is a significant decrease in response to peptide without DC’s as indicated by 
statistical T Test analysis (Table 7).   
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Figure 105. ELISpot results for restimulation of spleenocytes from mouse immunisations. 
 
 M1 M2 M3 
T cells alone 0.496841 0.056288 0.017233 
T cells and DC Peptide 0.11348 0.500241 0.921297 
1 ug peptide 0.00393 0.003146 0.030783 
Irrelevant peptide 0.004659 0.001273 0.023178 
 
Table 7. Showing T Test results for restimulation with Peptide-IFA vs Peptide-SPIO 
 
A T Test for T cells plus peptide pulsed DC’s vs. T cells with a) irrelevant peptide and b) peptide 
alone, was carried out and the results shown in Tables 8 and 9.  These results show that the number 
of spots produced by T cells from mice immunised using IFA adjuvant when stimulated with either 
peptide only, irrelevant peptide or DC’s pulsed with peptide.  This shows that any response 
generated by these cells is non-specific and so the response to p53(105) on APC’s cannot be taken as 
a true response but rather that they are reacting to any type of antigen.   
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In contrast the T cells taken from mice immunised using SPIO as the adjuvant showed a significantly 
larger response to DC’s pulsed with peptide compared to either peptide only or the irrelevant 
peptide.  This shows that the T cells activated/produced when SPIO is used as an adjuvant respond 
specifically to the relevant antigen (peptide, p53(105)).  This is significant as it goes some way to 
proving that not only is SPIO successful as an adjuvant, but also that it is superior to IFA in the 
response that it produces.  In order for an immunisation to be effective it needs to create a response 
that is specific to that antigen, and it appears that the IFA is not helping to create this scenario, but is 
rather stimulating the T-cells to produce a non-specific immune response similar to inflammation or 
an allergic reaction.  What the SPIOs are doing is producing a specific immune response so that the 
cells will only be affected by p53(105).  As cancer cells are so specific in their nature and their 
antigens so similar to that of healthy cells, the specificity of the immune response is exceptionally 
important. 
Peptide    
 M1 M2 M3 
DC peptide vs irrelelevant peptide 0.966316 0.563394 0.152127 
DC peptide vs peptide only 0.661825 0.672573 0.511865 
 
Table 8. Showing T Test results for DC peptide stimulated T cells vs. Irrelevant peptide or peptide only 
stimulated T cells for T cells isolated from mice immunised with IFA-p53(105).  Flu-DR1 is used as the 
irrelevant peptide. 
 
SPIO    
 M1 M2 M3 
DC peptide vs. irrelevant peptide 0.006997 0.027468 0.023875 
DC peptide vs. peptide only 0.031612 0.021272 0.004625 
 
Table 9. Showing T Test results for DC peptide stimulated T cells vs. Irrelevant peptide or peptide only 
stimulated T cells for T cells isolated from mice immunised with SPIO-p53(105).  Flu-DR1 is used as 
the irrelevant peptide. 
 
In addition to the realisation that SPIOs can be used as adjuvants, these results also support the 
theory that SPIOs can be used as vectors for delivery of peptide into BMDC’s as without the vector 
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peptide would not be taken up into the cells sufficiently and so a significant immune response could 
not be mounted.  This can be tied in with previous results in which the results of the fluorescence 
microscopy were ambiguous owing to fluorescein’s ability to bind to the outer membrane.  So it is 
clear that SPIOs have the potential to be useful and versatile vectors. 
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Chapter 3:  Materials and Methodology 
 
Section 1: General Experimental 
 
All chemicals were used as received by the suppliers (Sigma Aldrich, Acros, Alfa Aesar) unless stated 
otherwise. All other solvents were used as supplied (Laboratory, Analytical or HPLC grade), without 
further purification.  
Microwave experiments were performed on CEM Discover®-SP microwave (CEM Corporation, UK), 
dynamic with temperature or pressure control, 30 sec pre-stirring, power max function 
(simultaneous air cooling). Peptides syntheses were carried out on CEM Discover®-SPS Microwave 
peptide synthesiser (CEM Corporation, UK). 
Mass spectra were obtained using a Bruker MALDI-TOF mass spectrometer using a raster mode and 
1000 averages, using 1α-cyano-4-hydroxy-cinnamic acid (CHCA) as a matrix with only molecular ions 
and major peaks reported. Molecular ion peaks were isolated and run back through the 
spectrometer to further fragment and identify amino acid sequence.  
UV-vis spectrometry was achieved on a JASCO V530 (Jasco, USA) 
TEM images were generated on a JEOL JEM-2010, accelerating voltage 200 keV, tungsten filament, 
electron beam current 10 µA; using a Gatan SC1000 ORIUS CCD camera.  
SEM were performed on JEOL JSM-A840A scanning electron microscope (SEM), (Jeol Ltd, UK). 
T1 and T2 measurements were made using a 0.25 T NMR MOUSE
®. 
Dynamic light scattering (DLS) and Zeta potential measurements were carried out using a Malvern 
Nano Zetasizer using low volume sizing cuvettes at 4 °C for DLS and zeta cuvettes at 25 °C for zeta 
potential measurements.   
 
1.1 Culture of U937 Cells 
RPMI media (500 ml containing foetal calf serum (FCS) (50 ml) and L-glutamine (2%)) was freshly 
prepared.  Frozen U937 cells were allowed to defrost at room temperature and then suspended in 
the media (10 ml).  Cells were centrifuged (3 min, 2500 rpm).  The pellet was re-suspended in media 
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(2 ml) and counted using trypan blue and haemocytometry.  Cells were then re-suspended (5 x 106 
cells, 20 ml media) and incubated at (37 °C, 5.1 % CO2).   
Cells were split down by removing half of the media containing cells and replacing this with fresh 
media every three days. 
1.2 General method for solid phase peptide synthesis (SPPS) 
All Fmoc amino acids and resins were purchased from Merck4Biosciences and used without further 
purification. 
The Fmoc amino acids used: 
Fmoc-Ala-OH.H2O 
Fmoc-Arg(Pbf)-OH 
Fmoc-Asn(Trt)-OH 
Fmoc-Asp(OtBu)-OH 
Fmoc-Cys-(Trt)-OH 
Fmoc-Gln(OtBu)-OH 
Fmoc-Gly-OH 
Fmoc-His(Trt)-OH 
Fmoc-Ile-OH 
Fmoc-Leu-OH 
Fmoc-Lys(Boc)-OH 
Fmoc-Met-OH 
Fmoc-Phe-OH 
Fmoc-Pro-OH 
Fmoc-Ser(tBu)-OH 
Fmoc-Thr(tBu)-OH 
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Fmoc-Trp(Boc)-OH 
Fmoc-Tyr(Boc)-OH 
Fmoc-Val-OH 
In a SPPS reaction vessel, Fmoc protected Wang resin (0.1 mmol) was swelled in a  dimethyl 
formamide (DMF)/ dichloromethane (DCM) mixture (2.5 ml/2.5 ml) for 30 min and was then drained 
and rinsed with DMF (5 ml).  
Resin deprotection was carried out by addition of piperazine (4.1 mmol, 0.58 M, 7 ml) and reacted 
for 30 sec at 75 °C (+/- 5 °C, 50 W), drained and piperazine added (4.1 mmol , 0.58 M, 7 ml) and 
reacted for further 3 min at 75 °C (+/- 5 °C, 50 W). The deprotected resin was then drained under 
vacuum and rinsed with DMF (3 x 5 ml).  
Fmoc protected amino acid (0.25 mmol, 2.5 equiv.) dissolved in DMF (2.5 ml) was added to the 
deprotected resin with O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU) (0.47 mmol, 1 ml, 0.474 M, 4.7 equiv.) and diisopropylethylamine (DIEA) in N-methyl 
pyrollidine (NMP) (1.3 mmol, 0.5 ml, 2.58 M, 13 equiv.). The reaction was performed under 
microwave irradiation using different temperature and coupling time depending on the amino acid 
used (details included in peptide synthesis tables). Typically all amino acids except  arginine, 
histidine and cysteine, were reacted for 5 min at 75 °C (+/- 5 °C, 25W). Arginine was reacted for 30 
min at 25 °C (+/- 5 °C, 0W) drained and more amino acid (0.25 mmol, 2.5 equiv.) was added and 
reacted for further 5 min at 25 °C (+/- 5 °C, 0W). Histidine and cysteine were reacted for 10 min at 50 
°C (+/- 5 °C, 25W). 
Final deprotection was done by addition of piperazine (4.1 mmol, 0.58 M, 7 ml) which was reacted 
for 30 sec for the first deprotection, then the same quantities added and reacted for 3 min at 75 °C 
(+/- 5 °C, 50 W), then repeated. The reaction mixture was drained and washed with DMF (3 x 5 ml) 
and rinsed with DCM (3 x 5 ml) and left to dry under air for 15 min.  
The resin was then transferred into a cleavage mix solution containing H2O (0.25 ml), 
triisopropylsilane (TIS) (4.86 mmol, 0.1ml), 3,6-dioxa-1,8-octanedithiol (DODT) (3.1 x mmol, 0.5ml) 
and trifluoroacetic acid (TFA) (0.13 mol, 9.4 ml) and stirred at room temperature for 1 – 3 hrs 
depending on the peptide.  
The peptide was filtrated into a chilled solution of diethylether (100 ml), and the resin washed with 
DCM (2 x 5 ml). The ether solution was placed in the freezer for a minimum of 1 hr, to yield a white 
precipitate. 
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The mixture was centrifuged (10 min, 3000 rpm, <10 °C), the supernatant removed and clean, chilled 
diethyl ether (30 ml) was added. This was repeated three times to ensure a clean product.  
The recovered white waxy solid was left to dry in air overnight, or freeze-dried using liquid nitrogen 
under vacuum. Peptide purity was analysed using HPLC and MALDI-TOF MS (see standard 
procedures).  
*Note: The method used has since been discovered to be incorrect.  The correct procedure for any 
future peptides requires exactly 2.5 molar equivalents of HBTU (0.25 mmol, 1 ml, 0.25 M, 2.5 equiv.). 
 
1.3 FACS staining protocol 
 
Cells were seeded at 2x105 cells per fluorescence assisted cell sorting (FACS) tube (2 ml suspension 
per tube) and washed with FACS buffer.  To the cell pellet was added 10 µl of primary antibody 
(1:100) and incubated on ice for 30 min.  Samples then washed once with FACS buffer and secondary 
antibody added to the pellet (1:1000) and incubated for a further 30 min on ice.  Isotone (500 µl) 
added and samples run through FACS as in general procedure. 
 
1.4  CD86 – with PE (Red) 
 
A solution containing phosphate-buffered saline (500 ml), bovine serum albumin (2.5 ml) and EDTA 
(2 mM) was prepared and kept cold (2 – 8 °C).  Cells were counted and resuspended at 107 cells per 
100 μl of buffer.  The CD86 antibody (10 μl) was added, mixed well and incubated for 10 min in the 
dark at 2 – 8 °C.  Cells washed with buffer (1-2 ml) and centrifuged (1500 rpm, 10 min) before 
aspiration.  Cells were re-suspended in buffer (ca. 2 ml) for further analysis by FACS or fluorescence 
microscopy. 
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1.5  DAPI Nuclear Staining  
 
Cell sample to be analysed was washed with PBS (ca. 5 ml).  DAPI stock solution was diluted to 300 
nM in PBS and added (300 μl) to the coverslip preparation, making sure all cells were covered.  
Sample was incubated (1 – 5 min) before rinsing three times with PBS (3 x 5 ml).  Excess buffer was 
drained and the coverslip mounted ready for microscopy. 
 
1.6  Cell Counting by haemocytometry using trypan blue 
 
Cells were centrifuged (5 min, 1500 rpm), and supernatant discarded.  The cell pellet was re-
suspended in RPMI media.  Cell suspension (50 μl) was added to acetic acid (450 μl) and mixed by 
pipette.  The mixture (50 μl) was added to trypan blue (450 μl) and mixed by pipette to give a 
dilution of 100.  This mixture was plated on a haemocytometer slide and number of cells per 1 mm 
corner square (see Figure 106) counted and averaged over the four squares taking into account cells 
within the 16 corner squares but not touching the top line or left hand line.  Number of cells counted 
was multiplied by 104 then multiplied by the dilution factor of 102 to give number of viable cells per 1 
ml of cell suspension.   
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Figure 106. Picture of haemocytometer indicating corner squares used for cell counting.  
 
1.7  High performance liquid chromatography (HPLC)  
 
All HPLC herein was carried out using an Agilent HPLC system  
Column: Hypersil Gold 250 x 4.6 mm, 5 µm particles size, C18 column 
Flow rate: 1.500 ml/min 
Injection: 10 µl 
UV detection: 220 nm 
HPLC Buffer: 5 % Triethanolamine (TEA), 7.5 % Trifluoroacetic acid (TFA), 25 % HPLC Grade 
Acetonitrile (ACN), 62.5 % HPLC Grade Water. 
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Solvent A:  1 % HPLC Buffer, 10 % ACN, 89 % H2O 
Solvent B:  1 % HPLC Buffer, 75 % ACN, 24 % H2O 
Gradient: 
Time (mins) % A % B 
0 100 0 
20 70 30 
30 65 35 
39 65 35 
40 100 0 
 
Table 9. Gradient for HPLC 
 
Samples were dissolved 2 mg/ml I 50:50 ACN:H2O and processed through a 0.2 µm filter. 
 
1.8  Zip-tip preparation of samples for Mass Spectrometry 
 
All samples were dissolved in an aqueous solution containing 10% acetonitrile (ACN) in 0.1 % TFA.  
80 % ACN containing 0.1 % TFA (2 x 10 µl) was used to wash the zip tip (C18 silica).  0.1 % TFA (2 x 10 
µl ) was then used to rinse the zip-tip.  The sample (10 µl) was then loaded onto the tip by 
repeatedly taking up and ejecting the solution to provide optimum binding.  The tip was then 
washed with 0.1 % TFA (10 µl  x 3) and the peptide then eluted using 80 % ACN in 0.1 % TFA (4 µl), by 
taking up and ejecting the solution twenty times. 
The sample was then mixed with recrystallised 1α-cyano-4-hydroxy-cinnamic acid (CHCA) matrix on 
a target plate and left to dry. 
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1.9  Mass Spectrometry of Samples 
 
Peptide samples were processed and then analysed by MALDI-TOF MS using an Ultraflex 3158A by 
adjusting the laser power to the lowest power producing fragments (ca. 30 % but variable).  MS-MS 
was carried out by isolating the peak of interest, filtering for this peak only and increasing laser 
power to further fragment the peak.  Amino acids sequences were identified manually. 
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Section 2: Synthesis, functionalization and purification of iron oxide 
nanoparticles (SPIOs) 
 
2.1 Co-precipitation General Route 
 
To FeCl2.4H2O (10 g, 0.05 mol) was added FeCl3.6H2O (24.3 g, 0.09 mol) both dissolved in distilled 
water (100 ml).  35 % aqueous NH3 solution (50 ml, 0.90 mol) was added dropwise with stirring (ca. 5 
min) then sonicated in a sonic bath (1 hr).  The mixture was filtered using a sintered funnel and 
washed (2 x 50 ml distilled water, 2 x 50 ml diethyl ether) and allowed to dry in air before storing in a 
sealed vial.  The solution was found to be stable in a sealed vial 2 months from the time of storage.  
See Table 10 for other methods trialled. 
Moles 
FeCl2 
Moles 
FeCl3 
Base (50 
ml) 
Conditions Result 
0.05 0.09 NH3(aq) No sonication Black solid responsive to magnetic stimuli formed, 
particles by TEM 10-60 nm.  Size not uniform. 
0.05 0.09 NH3(aq) Sonication for 
10 minutes 
Black solid responsive to magnetic stimuli formed, 
particles by TEM 10-40 nm.  Size not uniform. 
0.05 0.09 NH3(aq) Sonication for 
30 minutes 
Black solid responsive to magnetic stimuli formed, 
particles by TEM 10-40 nm. Size not uniform. 
0.05 0.09 NH3(aq) Sonication for 
60 minutes 
Black solid responsive to magnetic stimuli formed, 
particles by TEM 10-20 nm, fairly uniform in size.* 
0.05 0.09 NH3(aq) Base added in 
one addition 
rather than 
dropwise; 
sonication for 
60 minutes 
Black solid responsive to magnetic stimuli formed, 
particles by TEM indistinguishable, very clumped together.  
Particles could not be coated by solvent free route. 
0.05 0.09 NH3(aq) Base added 
dropwise; 
sonication for 
60 minutes 
Black solid responsive to magnetic stimuli formed, 
particles by TEM 10-20 nm, fairly uniform in size.  
Successfully coated via solvent free grinding route. 
0.05 0.09 NaOH(aq) 
1.0M 
Alternative base 
added dropwise 
Black solid responsive to magnetic stimuli formed, 
particles by TEM indistinguishable, very clumped together.  
Particles could not be coated by solvent free route. 
0.05 0.09 NaOH(aq) 
0.25M 
Alternative 
weaker base 
added dropwise 
Black solid responsive to magnetic stimuli formed, 
particles by TEM indistinguishable, very clumped together.  
Particles could not be coated by solvent free route. 
 
 Table 10. Conditions trialled for synthesis of SPIOs by co-precipitation 
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*For these conditions there was a yield of 10.8 g giving a % yield of 93.3 %.  Other methods yielded 
similar results although they were not repeated due to the highlighted method being better 
optimised.  The size of these particles was found to be 8-10 nm by TEM when suspended in ethanol.  
The IR results indicated that there were no hydroxyl groups present, indicating that the particles 
were not in the hydrated form. The appearance of these particles was as a black solid, responsive to 
magnetic stimuli. 
 
2.2 Spinning Disc Reactor 
2.2.1 Ammonia solution 
FeCl2.4H2O(s) (50.0 g, 0.25 mol) and FeCl3.6H2O(s) (121.3g, 0.45 mol) were dissolved in distilled water 
to make 1.0 L of stock solution.  This was fed into the spinning disc reactor with the addition of 
ammonia solution (500 ml, 35 %, 9.0 mol).  The resultant black precipitate was washed thrice with 
distilled water, twice with ethyl acetate, filtered under vacuum and air dried to yield a crystalline 
black powder.  This powder was stored at room temperature in a sealed vial for a period of 2 
months.  Samples were analysed for TEM for size and morphology.  Observations showed spherical 
particles with significant agglomeration, and that the spin rate has no effect on the size of the 
particles, with large overlaps in particles sizes over all rates.   
Spin speeds were altered as shown in Table 11. 
Voltage 
(V) 
60V 80V 100V 120V 140V 160V 180V 200V 220V 240V 
Spin-
rate 
(rpm) 
352.9 705.9 1000.0 1250.0 1578.9 1818.2 2069.0 2307.7 2449.0 2727.3 
Particle 
Size 
(nm) 
15-30 10-30 12-35 10-35 8-40 10-35 10-35 10-30 8-25 7-25 
 
Table 11. Conditions for SPIO synthesis using SDR with ammonia solution 
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2.2.2 Ammonia gas 
 
FeCl2.4H2O(s) (50.0 g, 0.25 mol) and FeCl3.6H2O(s) (121.3g, 0.45 mol) were dissolved in distilled water 
to make 1.0 L of stock solution.  This was fed into the spinning disc reactor with the addition of 
ammonia gas.  The resultant black precipitate was washed thrice with distilled water (50 ml per 50 g 
of reactants), twice with ethyl acetate (50 ml per 50 g of reactants), filtered under vacuum and air 
dried to yield a crystalline black powder.  This powder was stored at room temperature in a sealed 
vial for a period of 2 months. 
Spin speeds were altered as shown in Table 12.  Particles were analysed using TEM to determine size 
and morphology.  Observations showed spherical particles that were well separated displaying 
minimal agglomeration. 
Voltag
e (V) 
60V 80V 100V 120V 140V 160V 180V 200V 220V 240V 
Spin-
rate 
(rpm) 
352.9 705.9 1000.0 1250.0 1578.9 1818.2 2069.0 2307.7 2449.0 2727.3 
Particl
e Size 
(nm) 
19-25 18-25 19-25 16-28 18-24 16-35 20-42 15-35 17-27 15-30 
 
Table 12. Conditions for SPIO synthesis using SDR with ammonia gas. 
 
2.3 Using a ball mill to attach coatings onto SPIOs 
 
Typically coating material and SPIO were placed in a micro ball mill and processed (5 mins, 25 Hz).  
The resultant powder was taken up into water, filtered (0.2 µm microfilter) and analysed.  
Alternative methods are detailed in Table 13.  Mass was used rather than moles as the grinding 
method is subject to mixing effects which are more affected by mass of reactants.  The method also 
consistently leads to multilayer coverage. 
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Mass of SPIO (g) Mass of histidine coating 
(g) 
Other conditions Observations 
0.100 0.100 None No iron observed in resultant 
solution and no particles by 
TEM. 
0.100 0.200 None No iron observed in resultant 
solution and no particles by 
TEM. 
0.200 0.100 None No iron observed in resultant 
solution and no particles by 
TEM. 
0.200 0.200 None No iron observed in resultant 
solution and no particles by 
TEM. 
0.200 0.200 Heated with heat 
gun during milling 
The container exploded during 
this reaction as the pressure 
build up from heating a sealed 
vial could not be contained.  The 
SPIO-coating materials mixture 
expanded during the reaction. 
 
Table 13. Conditions trialled for coating of SPIOs using a ball mill 
 
2.4 Incubation of SPIOs with coating material 
 
Threonine (0.5 g, 4.2 mmol) was vortexed in 5 ml distilled water until dissolved.  To this solution was 
added SPIO powder (0.25 g, 1.1 mmol).  The mixture was stirred overnight before being processed 
through a 0.2 µm microfilter.  A clear brown solution was obtained and analysed.  Table 14 indicates 
other methods trialled.  The only successful method was using threonine.  The success is attributed 
to the high solubility of this amino acid. 
TEM indicated for threonine only there were clusters of particles of 10-20 nm in size with a clear 
area around them.  DLS confirmed particles of 18 nm in size.  ICP showed iron in the sample. 
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Amino Acids Observations Analysis 
Alanine, Cysteine, Aspartic Acid, 
Glutamic Acid, Phenylalanine, Glycine, 
Histidine, Isoleucine, Lysins, Leucine, 
Methionine, Asparagine, Proline, 
Glutamine, Arginine, Serine, Valine, 
Tryptophan, Tyrosine 
Insoluble/sparingly 
soluble.  Colourless 
solution produced. 
No particles by TEM or DLS.  ICP 
indicated no iron present in the 
solution 
Threonine Highly soluble in water. 
Pale brown solution 
produced. 
Spherical particles of 8-10 nm by DLS 
and TEM  observed.  TEM images show 
a clear area around the particles 
indicating a layer of organic coating 
material. 
 
Table 14. Conditions trialled for incubation to coat SPIOs 
 
2.5 Sonication 
 
Typically 0.5 g of coating material (Table 15) was dissolved in distilled water (20 ml) and SPIO (0.25 g, 
1.1 x mmol) added.  The mixture was then sonicated for 180 min before being filtered (0.2 µm 
microfilter).   
Coating material Observations Analysis 
Threonine Colourless solution No particles by TEM or DLS.  No 
iron present in the solution by ICP. 
Glutamic acid Not fully soluble in the water.  
Colourless solution formed 
No particles by TEM or DLS.  No 
iron present in the solution by ICP. 
Aspartic acid Not fully soluble in water. 
Colourless solution formed 
No particles by TEM or DLS.  No 
iron present in the solution by ICP. 
 
Table 15. Conditions trialled for coating SPIOs using sonication 
 
2.6 Heating method for coating particles 
 
Typically SPIOs (0.500 g, 2.2 mmol) and coating material (see Table 16) were placed into a vial and 
heated until a change from solid to liquid was observed.  The resultant black/brown solid was then 
taken up into water, filtered (0.2 µm mirofilter) and analysed by TEM, DLS, ICP and MRI MOUSE. 
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Coating 
material  
Mass (g) Moles  DLS/TEM  Iron 
present 
by ICP 
Y/N? 
T1 (ms) T2 (ms) 
Alanine 0.500 5.61 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Cysteine 0.500 4.13 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Aspartic Acid 0.500 3.76 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Glutamic Acid 0.500 3.40 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Phenylalanine 0.500 3.03 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Glycine 0.500 6.66 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Histidine 0.500 3.22 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Isoleucine 0.500 3.81 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Lysine 0.500 3.42 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Leucine 0.500 3.81 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Methionine 0.500 3.35 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Asparagine 0.500 3.78 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Proline 0.500 4.34 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
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Glutamine 0.500 3.42 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Arginine 0.500 2.87 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Serine 0.500 4.76 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Threonine 0.500 4.20 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Valine 0.500 4.27 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Tryptophan 0.500 2.45 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
Tyrosine 0.500 2.76 x 10
-03
 Large aggregates of ~ 
1000 nm, no individual 
particles observed 
Y Could not 
be 
measured 
(too long) 
Could not 
be 
measured 
(too long) 
* Samples showed significant sedimentation and measurements were not possible due to limitations 
of the MRI MOUSE®.  T1 and T2 were too long to be measured. 
Table 16. Conditions trialled for coating SPIOs using heat 
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2.7 Solvent-free grinding of aqueous soluble substances with SPIOs 
2.7.1 Pestle and Mortar 
 
Typically, SPIO (0.25 g, 1.1 mmol) and coating agent (see Table 17) were vigorously agitated using a 
mortar and pestle (ca. 5 min).  The homogeneous brown powder was vigorously agitated with 
distilled water (ca. 10 ml) before filtration (0.2 μm disposable microfilter) to yield a colourless – dark 
brown solution free of visible particles.  The equipment is illustrated in Figure 107.   
 
Figure 107. Mortar and Pestle with SPIOs and ascorbic acid pre-grinding 
 
TEM indicated  Spherical particles of 8-10 nm in diameter with clear area indicating coating agent. 
ICP and DLS showed various iron concentrations and size distributions depending on the coating 
agent and variable between experiments (see Table 17). There was no consistent pattern other than 
that spherical particles coated with an organic coating were found for all experiments.   
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Coating Agent Mass 
(g) 
Moles Observations Iron 
present 
in ICP 
Y/N? 
Size by DLS and TEM 
Alanine 0.500 5.61 x 10
-03
 Colourless solution N No particles observed 
Cysteine 0.500 4.13 x 10
-03
 Colourless solution N No particles observed 
Aspartic Acid 0.500 3.76 x 10
-03
 Pale brown 
solution 
Y Spherical particles 10-20 nm in 
diameter in small clusters 
Glutamic Acid 0.500 3.40 x 10
-03
 Pale brown 
solution 
Y Spherical particles 10-20 nm in 
diameter in small clusters 
Phenylalanine 0.500 3.03 x 10
-03
 Colourless solution N No particles observed 
Glycine 0.500 6.66 x 10
-03
 Colourless solution N No particles observed 
Histidine 0.500 3.22 x 10
-03
 Colourless solution N No particles observed 
Isoleucine 0.500 3.81 x 10
-03
 Colourless solution N No particles observed 
Lysine 0.500 3.42 x 10
-03
 Colourless solution N No particles observed 
Leucine 0.500 3.81 x 10
-03
 Colourless solution N No particles observed 
Methionine 0.500 3.35 x 10
-03
 Colourless solution N No particles observed 
Asparagine 0.500 3.78 x 10
-03
 Colourless solution N No particles observed 
Proline 0.500 4.34 x 10
-03
 Colourless solution N No particles observed 
Glutamine 0.500 3.42 x 10
-03
 Colourless solution N No particles observed 
Arginine 0.500 2.87 x 10
-03
 Colourless solution N No particles observed 
Serine 0.500 4.76 x 10
-03
 Colourless solution N No particles observed 
Threonine 0.500 4.20 x 10
-03
 Pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle, in 
small clusters. 
Valine 0.500 4.27 x 10
-03
 Colourless solution N No particles observed 
Tryptophan 0.500 2.45 x 10
-03
 Colourless 
solution, amino 
acid not soluble in 
water 
N No particles observed 
Tyrosine 0.500 2.76 x 10
-03
 Colourless solution N No particles observed 
Palmitic Acid 0.500 1.95 x 10
-03 
 
Brown solution 
when taken up 
into chloroform 
Y Particles in large clusters.  10-
20 nm in diameter where not 
clustered. 
Paracetamol 0.500 3.31 x 10
-03 
 
Colourless solution N No particles observed 
Ascorbic Acid 0.500 2.84 x 10
-03 
 
Pale brown 
solution 
Y Particles of 10-20 nm in 
diameter in small clusters with 
clear area around each particle 
Glycerol 0.500 5.43 x 10
-03 
 
Dark brown 
solution 
Y Particles equally distributed, 
10-20 nm in diameter with 
clear area around each particle 
Diclofenac 0.500 1.69 x 10
-03 
 
Pale brown 
solution when 
taken up into 
chloroform 
Y Particles clumped together 
and indistinguishable 
Aspirin 0.500 2.78 x 10
-03 
 
Colourless solution N No particles observed 
Hexadecanediol 0.500 1.93 x 10
-03 
 
Colourless solution N No particles observed 
Table 17. Conditions trialled for solvent-free grinding using pestle and mortar 
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2.7.2  Using a coffee grinder to carry out solvent free coating of SPIOs 
 
A Kitchen Aid™ Artesan Coffee Grinder was set with the metal burrs as close together as possible.  
To the top of the coffee grinder SPIO (1.00 g, 4.4 mmol) and a coating agent were added as detailed 
in Table 18.  The grinder was switched on and the mixture passed through the coffee grinder in 
accordance with Table 12.  The resultant homogeneous brown powder was dissolved in distilled 
water (10 ml), filtered (0.2 µm microfilter) and analysed for iron content by ICP.  The T1 and T2 
relaxation times of the samples were measured, to ensure that the coffee grinder process had not 
altered the activity of the SPIOs. 
Coating 
material 
Mass (g) Moles Observations Fe present 
by ICP 
Y/N? 
TEM/DLS 
Aspirin 1.00 5.55 x 10
-03
 
 
Colourless solution N No particles 
observed 
Paracetamol 1.00 6.62 x 10
-03
 
 
Colourless solution N No particles 
observed 
Diclofenac 1.00 3.38 x 10
-03
 
 
Brown solution when 
taken up into chloroform 
Y Particles in large 
clusters.  10-20 nm 
in diameter where 
not clustered. 
Ascorbic Acid 1.00 5.68 x 10
-03
 
 
Brown solution Y Spherical particles 
10 -20 nm diameter 
in small clusters 
Histidine 1.00 6.44 x 10
-03
 
 
Brown solution Y Spherical particles 
10 -20 nm diameter 
in small clusters 
 
Table 18. Conditions trialled for coating SPIOs using a coffee grinder 
 
Although this method was found to be successful certain drawbacks would need to be addressed 
before further investigations carried out.  The size of the burrs, the size of the grooves in the burrs 
(0.8 mm for the Artisan®) and the speed at which the burrs spin must all be reproducible.  There will 
also be an issue during scale-up as with larger quantities of SPIO the feed rate, burr speed, and 
groove size may need to be altered.   
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2.8 Processing of amino acids / peptides 
 
For amino acids and peptides presenting aqueous solubility problems, coating agent (2 g) was 
dissolved in HCl aq (20 ml, 4M) aided by vortex (see Table 19).  Solvent removed in vacuo to yield a 
dry white/off-white crystalline powder (5 mbar, 40/60°C peptide/amino acid respectively).  
Alternatively acetone was added to the solution and kept at – 20 °C for 24 hours to yield an off-white 
precipitate.  Mixture centrifuged (10 min, 3000 rpm), supernatant removed and solid product 
washed with diethyl ether (3 x 50 ml) then dried in air before grinding with SPIO via solvent free 
route and analysis by ICP, DLS and TEM. 
 
 
Coating Agent Mass 
(g) 
Moles Observations Iron 
present in 
ICP Y/N? 
Size by DLS and TEM 
Alanine.HCl 0.500 5.61 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Cysteine.HCl 0.500 4.13 x 
10
-03
 
Dark brown solution, 
precipitation 
occurred over 24 hrs 
Y Particles no distinguishable 
from each other  
Aspartic Acid.HCl 0.500 3.76 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Glutamic Acid.HCl 0.500 3.40 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Phenylalanine.HCl 0.500 3.03 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Glycine.HCl 0.500 6.66 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Histidine.HCl 0.500 3.22 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Isoleucine.HCl 0.500 3.81 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
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Coating Agent Mass 
(g) 
Moles Observations Iron 
present in 
ICP Y/N? 
Size by DLS and TEM 
Lysine.HCl 0.500 3.42 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Leucine.HCl 0.500 3.81 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Methionine.HCl 0.500 3.35 x 
10
-03
 
Dark brown solution, 
precipitation 
occurred over 24 hrs 
Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Asparagine.HCl 0.500 3.78 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Proline.HCl 0.500 4.34 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Glutamine.HCl 0.500 3.42 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Arginine.HCl 0.500 2.87 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Serine.HCl 0.500 4.76 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Threonine.HCl 0.500 4.20 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Valine.HCl 0.500 4.27 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Tryptophan.HCl 0.500 2.45 x 
10
-03
 
Very pale brown 
solution 
Y 10-20 nm particles in small 
clusters.  Very few particles  
Tyrosine.HCl 0.500 2.76 x 
10
-03
 
Dark brown solution Y 10-20 nm particles with clear 
area around each particle.  
Many distinguishable particles 
clustered together  
Pap-161.HCl 0.050 2.78 x 
10
-05 
 
Very pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle.  Few 
small clusters of particles  
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Coating Agent Mass 
(g) 
Moles Observations Iron 
present in 
ICP Y/N? 
Size by DLS and TEM 
p53(108).HCl 0.050 3.17 x 
10
-05 
 
Very pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle.  Few 
small clusters of particles  
p53(105).HCl 0.050 3.23 x 
10
-05 
 
Very pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle.  Few 
small clusters of particles  
Flu DR1.HCl 0.050 3.32 x 
10
-05 
 
Very pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle.  Few 
small clusters of particles  
TRP2.HCl 0.050 4.25 x 
10
-05 
 
Very pale brown 
solution 
Y 10-20 nm particles with clear 
area around each particle.  Few 
small clusters of particles  
 
 Table 19. Results for grinding of SPIOs with HCl salts of amino acids and peptides 
 
Zeta potential measurements show neat amino acid coatings give ca. + 10 mV and HCl salt amino 
acid coatings give ca. – 15 mV. 
 
2.9 Assessing inorganic salts as a coating 
 
SPIO (0.25 g, 1.1 mmol) and salts were ground in 1:1 mass ratio in a mortar (5 min) then taken up 
into distilled water (10 ml), filtered (0.2 µm microfilter), and the resultant solution analysed by ICP 
(Table 20). 
Compound Mass (g) Moles Observations Fe present by 
ICP Y/N? 
Size by 
DLS/TEM 
NaCl 0.250 4.28 x 10
-03
 Colourless 
solution formed 
N No particles 
observed 
NH4Cl 0.250 4.67 x 10
-03
 Colourless 
solution formed 
N No particles 
observed.  
Table 20. Results for trialling inorganic salts as coatings 
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2.10 Determining if using the HCl salt will lead to degradation of the particle 
 
SPIO coated with a) ascorbic acid and b) HCl salt of ascorbic acid was prepared as in 2.8, analysed for 
Fe content by ICP, diluted to 400 mg.l-1 using distilled water and the relaxation time (T1 and T2) 
measured every 10 min for a period of  350-400 min. 
 
2.11 Determining if alcohols bind to the SPIOs via the solvent free grinding method 
 
2.11.1 Solids 
 
Hexadecanediol (100 mg, 3.87 mmol) was added to SPIO (100 mg, 4.31 mmol).  The mixture was 
ground in a mortar for ca. 5 min, dissolved in chloroform and centrifuged to remove free particles.  
The supernatant was then removed and used for analysis by TEM which showed aggregates of 78 
nm. 
 
2.11.2 Liquids 
 
Glycerol (1 g, 1.09 x 10-2 mol, 0.79 ml) was added to SPIO (1 g, 4.31 mmol).  The mixture was ground 
in a mortar for five minutes and taken up into distilled water before being processed through a 0.2 
µm filter.  The resultant brown solution was analysed by TEM and ICP showing spherical particles of 
15-20 nm and Fe conc. of 103.1 mg.l-1. 
 
2.12 Determining the Optimum Mass Ratio for solvent free grinding 
 
SPIOs synthesised as described previously were ground (ca. 5 min) with aspartic acid hydrochloride 
in the mass ratios indicated in Table 21.  The resultant powder was taken up into 5 ml of distilled 
water and processed through a filter (0.2 µm) and analysed for iron content by ICP. 
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Mass SPIO (mg) Mass Coating (mg) Mass Ratio Fe Conc. mg.l-1 
50 100 1:2 1253.3 
50 200 1:4 625.6 
50 300 1:6 454.8 
 
Table 213. Showing mass ratio of coating to SPIO investigated; 1:2 – 1:6 
 
This experiment was repeated for different ratios of SPIO to histidine hydrochloride salt as described 
in Table 22 and the final solution analysed for Fe concentration by ICP-AES. 
Mass SPIO (mg) Mass Coating 
(mg) 
Ratio SPIO:Coating Fe Conc. mg.l-1 
100 25 4:1 1497.8 
100 50 2:1 717.8 
100 75 4:3 985.5 
100 100 1:1 1326.2 
100 125 4:5 828.4 
100 150 2:3 1059.7 
100 175 4:7 923.7 
100 200 1:2 729.6 
 
Table 22. Showing mass ratio of coating to SPIO; 4:1 – 1:2 
 
2.13  Determining if the mortar and pestle or coffee grinder produces a more homogeneous 
sample 
 
HCl salt of histidine (0.100 g, 0.706 m mol)) and SPIO (0.100 g, 0.431 mmol) were weighed and mixed 
either through the coffee grinder five times, or using a pestle and mortar for ca. 5 min.  Samples 
were then taken up into distilled water (10 ml) and filtered (0.2 µm microfilter).  The resultant 
solutions were analysed for Fe content by ICP and size by TEM and DLS (Table 23).  
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Sample Fe conc. mg.l-1 Sample Fe conc. mg.l-1 
P1 115.5 C1 53.1 
P2 84.24 C2 48.62 
P3 94.15 C3 54.02 
P4 116.4 C4 50.59 
P5 96.75 C5 55.58 
P6 98.12 C6 56.99 
P7 89.88 C7 62.12 
P8 91.27 C8 56.08 
P9 111.6 C9 60.96 
P10 105.1 C10 56.77 
 
Table 23. Results to test homogeneity of pestle and morter (P) vs. coffee grinder (C). 
 
2.14 Calculating the amount of coating material relative to the mass of SPIO 
 
A sample of ascorbic acid coated SPIOs (10 ml) prepared via the solvent free grinding method was 
analysed by ICP and found to contain 129 mg.l-1 of iron.  Using mole calculations and Avogadro’s 
constant the amount of coating material in both grams, moles and molecules was calculated. 
 
2.15 pH Buffer Experiments 
 
All buffers were purchased as concentrated FIXANAL® buffers from Sigma Aldrich, and were made 
up to 500 ml with deionised water and kept at room temperature. 
One of each type of amino acid; acidic, basic, hydrophobic, and hydrophilic was chosen.  Each of 
these was attached to SPIOs via the solvent free grinding method, taken up into distilled water and 
filtered.  Following determination of Fe content by ICP, all samples were diluted to 25 mg.l-1 of iron 
with distilled water and their initial T1 and T2 relaxation times measured using a 0.25 T NMR MOUSE.  
The repetition time was initially set to 500 ms with 32 Echoes and 32 Averages, although this was 
altered to obtain the most accurate results for each condition. 
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1 ml each of the solutions containing coated SPIOs as the desired concentration was placed into 
vials, with three repeats for each condition.  To each vial was added a buffer (1 ml), as indicated in 
Table 24.  After 30 min T1 and T2 were measured for each solution. 
   pH of buffer solution  
Amino Acid NMR 
Mouse 
Measurem
ent 
Neat 
(no 
buffer) 
2.00 4.00 7.00 9.00 11.00 Water 
added 
(cm3) 
Alanine.HCl T1 (ms) 42.6 217.2 250.6 58.6 123.8 166.1 51.3 
 T2 (ms) 7.9 10.6 10.2 6.9 9.6 8.7 6.3 
Glycine.HCl T1 (ms) 31.4 271.2 240.1 117.4 112.7 113.9 61.0 
 T2 (ms) 6.2 11.3 9.7 6.9 10.2 7.7 8.1 
Glutamic 
Acid.HCl 
T1 (ms) 53.7 192.5 175.2 53.2 69.8 175.4 47.8 
 T2 (ms) 9.4 10.4 9.7 7.0 7.2 8.6 5.5 
Histidine.HCl T1 (ms) 51.9 206.7 266.7 86.8 106.2 265.7 57.0 
 T2 (ms) 8.9 10.5 11.0 8.3 9.9 9.8 8.8 
 
Table 24. Showing the amino acids used and the pH of buffer used. 
 
2.16 Autoclaving of samples 
 
SPIOs were synthesised as previously described and Ascorbic Acid purchased from Sigma Aldrich.  
Samples were prepared as detailed in Table 25. One set of samples was kept at room temperature 
overnight, and the other samples autoclaved (121°C, 103 KPa).  The samples were then analysed by 
TEM to determine if the particles had undergone adverse changes during the autoclaving process, 
and any visual and microscopic observations recorded.  MRI measurements were also taken to 
determine if the magnetic activity of the particles had been affected. 
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Sample T1 (ms) T2 (ms) Observations 
Ascorbic acid  - - Free flowing white crystalline 
powder. 
Ascorbic acid autoclaved - - Clumpy off-white/pale yellow 
crystalline powder.  
SPIOs - - Black powder responsive to magnetic 
stimuli 
SPIOs autoclaved - - Brown powder responsive to 
magnetic stimuli 
Ascorbic acid coated SPIOs 1103.95 12.84 Black powder 
Ascorbic acid coated SPIOs autoclaved 927.24 12.84 Brown powder 
 
Table 25. Showing the conditions trialled for autoclaving. 
 
2.17 Size Exclusion Chromatography 
 
G50 Sephadex (10 g) was swelled in water (100 ml) at 37 °C for two hours and then packed into a 1 x 
15 cm glass size exclusion column.  The column was kept flowing with distilled deionised water.  An 
aqueous solution containing histidine coated SPIO (1 ml, 250 mg.l-1 Fe) was added to the top of the 
column and run through with distilled deionised water.  Fractions (1.5 ml) were collected with a total 
of 20 fractions collected.  Each fraction was analysed by ICP-AES to find Fe content.  This was 
repeated for other samples (Table 26). 
Coating material Observation Successful Y/N? 
Histidine.HCl Fractions collected were pale brown and indicated separation 
had occurred.  20 fraction was not sufficient. 
Y 
Glutamic Acid.HCl Fractions collected were pale brown and indicated separation 
had occurred.  20 fraction was not sufficient. 
Y 
p53 (105).HCl Sample was stuck at the top of the column and did not separate 
at all.  Experiment repeated with G25 Sephadex which was also 
unsuccessful. 
N 
 
Table 26. Samples used for size exclusion chromatography 
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2.18 Finding a suitable antisolvent for coated SPIOs 
 
A solution containing glutamic acid hydrochloride coated SPIOs (125 mg.l-1 of iron) was prepared and 
1 ml transferred to each of seven vials.  3 ml of solvent was added as detailed in Table 27. 
Vial Solvent Condition Observations 
1 Acetone Room temperature Some brown precipitate with small amount of white 
precipitate 
1a Acetone  6 hours at -2 ° C (freezer) Some brown precipitate with large amount of white 
precipitate 
2 Ethanol Room temperature No precipitate 
2a Ethanol 6 hours at -2 ° C (freezer) No precipitate 
3 Acetonitrile Room temperature Brown precipitate with very small amount of white 
precipitate 
4 THF Room temperature No precipitate 
4a THF 6 hours at -2 ° C (freezer) No precipitate 
 
Table 27. Antisolvents and conditions used to precipitate amino acid coated SPIOs 
 
2.19 Separation using a Neodymium magnet 
 
SPIO mixture was prepared as in section 2.8 containing coated SPIOs, free SPIO, free coating material 
as in Table 28 and water was forced through tubing wrapped around a neodymium magnet, as 
illustrated in Figure 108.  Fractions of the liquid exiting the tube were collected.  This was repeated 
with different solvents to remove the free coating agent, followed by water to solubilise the coated 
SPIOs to elute them from the tubing.   
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Figure 108. Syringe containing SPIO mixture is attached to tubing wrapped around neodymium 
magnet, with a collecting syringe on the other end of the tubing 
 
Fractions were analysed for Fe content using ICP.  Initial fractions had their solvent removed in 
vacuo to determine if they contained free coating agent. 
Coating on SPIOs Solvent used Observation 
Ascorbic acid Water Magnetic particles moved through the tube and were 
not separated 
Glutamic acid.HCl Water Magnetic particles moved through the tube and were 
not separated 
p53(105).HCl Water Magnetic particles moved through the tube and were 
not separated 
Ascorbic acid Acetonitrile Magnetic particles moved through the tube and were 
not separated 
Glutamic acid.HCl Acetonitrile All magnetic particles were separated and stayed on the 
magnet, colourless solvent eluted.  Following addition of 
water magnetic particles were solubilised and a brown 
solution eluted.  Colourless solvent did not contain free 
coating agent. 
p53(105).HCl Acetonitrile Magnetic particles moved through the tube and were 
not separated 
Ascorbic acid Ethyl acetate Magnetic particles moved through the tube and were 
not separated 
Glutamic acid.HCl Ethyl acetate Magnetic particles moved through the tube and were 
not separated 
p53(105).HCl Ethyl acetate Magnetic particles moved through the tube and were 
not separated 
 
Table 284. Conditions used for trialling magnetic separation method 
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2.20 Separation using a Magnetic Separation Rack 
 
A magnetic separation rack from BioLabs was used as supplied (Figure 109).  The eppendorfs were 
filled with coated SPIO solutions as in Table 29 (2 ml, 250 mg.l-1) and left for 10 min to separate.     
 
Figure 109. Magnetic separation rack 
 
Coating material Observation 
Histidine.HCl A mass of SPIO appearing as a “bubble” collected at the magnetic points.  On 
removal of supernatant the SPIOs did not remain on the side of the tube. 
Ascorbic Acid A smaller mass of SPIO appearing as a “bubble” collected at the magnetic points.  On 
removal of supernatant the SPIOs did not remain on the side of the tube. 
Glutamic Acid.HCl A mass of SPIO appearing as a “bubble” collected at the magnetic points.  On 
removal of supernatant the SPIOs did not remain on the side of the tube. 
 
Table 29. Samples used for trial of magnetic separation rack 
 
2.21 High Speed Centrifugation for separating SPIOs from free coating material in solution 
 
An Optima L-100 XP Ultracentrifuge was used, with 70 I rotor and tubes.  The samples were 
centrifuged for 15 minutes (including time taken to put the rotor under vacuum and build up speed) 
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at a maximum speed of 60, 000 RPM.  The samples were spun at the maximum speed for 
approximately 5 minutes (Table 30). 
 
Sample Observation 
Histidine coated SPIOs Brown pellet and clear supernatant 
Ascorbic acid coated SPIOs Brown pellet and clear supernatant 
p53(105) coated SPIOs Brown pellet and clear supernatant 
Concentrated Histidine coated SPIOs Dark brown/black pellet and brown supernatant 
 
Table 30. Samples used for separation by high speed centrifugation 
 
  
210 | P a g e  
 
Section 3: Synthesis and functionalization of other nanoparticles 
 
3.1 Synthesis of iron (III) tin (II) oxide nanoparticles 
 
Tin (II) chloride (5.3 mmol, 1.00g) and iron (III) chloride (9.5 mmol, 2.57 g) were dissolved separately 
in the minimum amount of distilled water.  These solutions were then combined and ammonia 
solution (30 %, 30 ml, 0.48 mol) was added slowly whilst stirring.  The mixture was then sonicated (1 
hr) and filtered.  The resultant brown solid was then washed with distilled water (3 x 50 ml) followed 
by ethyl acetate (2 x 50 ml), and left to dry in air. 
Tin (II) chloride (5.3 mmol, 1.00g) and iron (III) chloride (9.5 mmol, 2.57 g) were dissolved separately 
in the minimum amount of distilled water.  These solutions were then combined and ammonia 
solution (30 %, 30 ml, 0.48 mol) was added whilst stirring.  The mixture was then heated at 100 °C 
for 20 minutes, then filtered.  The resultant brown solid was  washed with distilled water (3 x 50 ml) 
followed by ethyl acetate (2 x 50 ml) and allow to dry in air.  Yield: 1.82 g (68 % yield).  
A portion of the brown powder (200 mg) was then ground with glutamic acid hydrochloride salt (200 
mg) using a solvent free grinding method.  This was taken up into water (5 ml) and processed 
through a filter (0.2 µm).  The resultant pale brown solution was analysed by TEM, EDX and ICP 
showing spherical particles of 4-10 nm containing Sn and Fe in the molar ratio of approximately 2:3. 
EDX: Atomic concentration 10 % Fe and 6 % Sn.   
ICP:  Fe = 118.32 mg.l-1,  Sn = 168.50 mg.l-1 
Moles Fe = 2.12 x 10-3 
Moles Sn = 1.42 x 10-3 
 
3.2 Synthesis of calcium oxide nanoparticles via Spinning Disc Reactor (SDR) 
 
Calcium nitrate tetrahydrate (47.24 g, 0.20 mol), was dissolved in ethylene glycol (1000 ml).  In a 
separate container sodium hydroxide (16.8 g, 0.42 mol) was dissolved in distilled water (100 ml).  
The two solutions were fed into a spinning disc reactor with a feed rate of 10:1 calcium nitrate to 
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sodium hydroxide at a speed of 1818.2 rpm.  The white paste formed was left overnight and then 
washed with distilled water (500 ml).  A sample of the mixture (250 ml) was sonicated for 60 min and  
analysed by TEM showing spherical particles of 5-10 nm diameter. 
 
3.3 Synthesis of aqueous soluble gold nanoparticles (GNPs) 
 
Typically HAuCl4 hydrate (10 mg, 25 μmol) was dissolved in distilled water (100 ml).  Sodium citrate 
(1 g, 4.67 mmol) was dissolved in distilled water (100 ml).  The gold solution (50 ml, 0.01%) was 
heated to boiling under N2.  Sodium citrate solution (1 ml, 1%) was then added and the mixture 
boiled until a colour change from yellow to purple was observed (ca. 1 min.). 
This was repeated at higher concentrations as in Table 31. 
% HAuCl4 in solution Observation 
0.01 Purple solution, particles 4-10 nm by TEM with very little 
agglomeration. 
0.02 Black precipitate formed, aggregated and would not go back into 
solution. 
0.05 Black precipitate formed, aggregated and would not go back into 
solution. 
0.075 Black precipitate formed, aggregated and would not go back into 
solution. 
0.10 Black precipitate formed, aggregated and would not go back into 
solution. 
 
Table 31. Conditions for synthesis of citrate capped gold nanoparticles 
 
3.4 Coating of gold nanoparticles with peptide. 
 
Peptide was dissolved in water (10 mg in 10 ml of distilled water).  Peptide solution was heated to 
boiling point and HAuCl4(aq.) (1 ml, 0.01%) was added.  The solution was kept at boiling temperature 
for 1 minute then left to cool.   
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The resultant purple solution was found to contain particles of 4-10 nm by TEM and DLS. 
To increase the concentration of the gold nanoparticles solvent was removed in vacuo. 
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Section 4: Medical Imaging 
 
4.1 CT analysis of gold nanoparticles 
 
Citrate capped gold nanoparticles were synthesised as previously described and concentrated down 
in vacuo.  Au concentration was determined using ICP and the solution diluted as shown in Table 32.  
The solutions were then scanned in a CT phantom (5mm slice, 120kV, 300 mA 1sec std recon 
algorithm rmi electron density phantom) to determine their CT number and the results compared 
against required CT number, using a specially designed PTFE holder. 
Conc. mg.l-1 CT Number 
1.42 21.77 
0.856 13.75 
0.571 8.37 
 
Table 32. Dilutions for CT phantom scanning for citrate capped HAuCl4(aq.) 
 
4.2  Calibration study for SPIOs 
 
SPIOs coated with histidine were prepared via the standard route and diluted to different 
concentrations with distilled water (see Table 33).  The T1 and T2 relaxation times were then 
measured using the MRI MOUSE.   
Concentration 
Fe (mg.l-1) 
Maximum Repetition 
Time (ms) 
NEchoes Number of 
averages 
T1 (ms) T2 (ms) 
500.00 50 64 284 15.92 4.82 
250.00 100 64 192 35.98 7.24 
125.00 150 64 192 71.85 9.09 
62.50 200 64 96 148.31 10.37 
31.25 400 64 48 280.00 11.11 
15.63 1500 64 12 655.50 11.28 
 
Table 33. Table for calibration study for SPIOs using NMR MOUSE® 
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4.3   Lysosome simulation 
 
A solution of HCl histidine coated SPIOs (2 ml, 250 mg.l-1) was added to buffer at pH 4.00, which is 
similar to the pH inside a lysosome.  The T1 and T2 relaxations times were measured every minute for 
a period of 6 hours at room temperature. 
 
4.4 Comparison with commercially available  
 
SPIOs coated with a) Histidine and b) p53(108), prepared via the standard method were analysed by 
ICP and diluted to give a total iron concentration of 250 mg.l-1.  The relaxation rates of these 
solutions were then measured using the 0.25 T NMR MOUSE (Table 34).   
Endorem (dextran coated SPIOs) purchased from Guerbet, Sulzbach was also diluted to give a total 
iron concentration of 250 mg.l-1 and the relaxation rates determined in the same way. 
SPIO Coating T1 (ms) T2 (ms) 
Dextran (Endorem ®) 14.2662 3.0424 
Histidine 3.3637 1.3399 
Histidine (+43 days) 9.4887 2.6079 
Histidine following dehydration 
and rehydration 
75.4144 8.5825 
Histidine diluted with PBS 1113.3641 14.0335 
Flu DR1 5.7752 1.4897 
Flu DR1 (+43 days) 4.8246 1.5813 
Water ~2500 ~100 
 
Table 34. NMR measurements for SPIO preparations vs. commercially available 
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4.5 Blood Studies 
 
Fresh human whole blood (5 ml) with EDTA (as per collection tube) to prevent coagulation was 
mixed with preparations as described in Table 35.  Observations were made and the relaxation times 
of the different preparations were recorded. 
Condition T1 (ms) T2 (ms) 
Neat SPIO (300 mg.l
-1
) 12.4071 4.0744 
SPIO + EDTA 43.8523 10.5295 
Blood only 1000.2365 11.9032 
Blood + SPIO Solution (1 ml) 62.6773 5.6386 
Blood + 0.2 g dehydrated SPIO complex 58.9634 6.9221 
 
Table 35.  NMR measurements of SPIOs in blood  
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Section 5: Transdermal drug delivery 
 
5.1 Synthesis of CPP 
 
Peptide sequence: RRRQRRKKRGYC 
Peptide was synthesised via the standard method using the optimised peptide synthesis protocol.  
Reagents and coupling times are outlined in Table 36.  The peptide was analysed for purity via HPLC 
(see General Experimental section for HPLC conditions and gradient) and MALDI-TOF MS.   
0.1639 g of Cysteine resin was swelled for 30 min in 50: 50: DCM: DMF then drained and the 
following added: 
Amino 
Acid 
Mass (g) DMF (ml) Coupling conditions 
Arginine 3.900 30 2.5 ml amino acid, 1.0 ml HBTU, 0.5 ml DIEA 
a) As above, 30 minutes at room temperature 
b)  As above, 10 minutes at 75° C 
Glutamine 0.305 2.5 2.5 ml amino acid, 1.0 ml HBTU, 0.5 ml DIEA 
Glycine 0.150 2.5 2.5 ml amino acid, 1.0 ml HBTU, 0.5 ml DIEA 
Lysine 0.470 5.0 2.5 ml amino acid, 1.0 ml HBTU, 0.5 ml DIEA 
Tyrosine 0.230 2.5 2.5 ml amino acid, 1.0 ml HBTU, 0.5 ml DIEA 
 
Table 36. Conditions for synthesis of CPP 
 
HPLC retention time: 13.127 minutes.  Purity was ca. 60 % by HPLC, but due to the high number of 
arginine residues in the peptide it was not possible to characterise by MALDI-TOF.  Due to time 
constraints and limitations of available equipment it was not possible to purify the peptide. 
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5.2 Coating onto SPIO 
 
Peptide was coated onto freshly prepared SPIOs via the standard method.  The resultant solution 
was analysed for iron concentration via ICP then diluted and used as required.  TEM and DLS 
confirmed spherical particles of 15-20 nm diameter with a clear area of coating material around each 
particle. 
 
5.3 Distribution in gel 
 
SPIO or SPIO solution (see Table 37) was added to glucosamine gel (10 ml), and was mixed 
thoroughly using a pipette and pipette filler (1000 µl) to give a homogeneous mixture.  This was 
repeated for each desired preparation and applied to skin as required. 
 
Table 37. Preparations used for CPP transdermal drug delivery trials 
 
 
 
 
 
SPIO preparation to add to 
gel 
Mass 
(mg) 
Volume 
(ml) 
Mass 
of Fe 
(mg) 
Additional 
preparations 
Final Fe 
concentration of 
gel preparation 
SPIOs Neat 10 - 7.2 Diluted 10 µl in 100 
µl gel to give 72 
mg.l
-1
 Fe  
72 mg.l
-1
 
SPIOs coated with CPP in 
solution 100 mg.l
-1 
Fe 
- 10 0.72 - 72 mg.l
-1
 
Histidine coated SPIOs inside 
liposomes 100 mg.l
-1 
Fe 
- 10 0.72 - 72 mg.l
-1
 
Histidine coated SPIOs inside 
liposomes with CPP 
functionalization 100 mg.l
-1 
- 10 0.72 - 72 mg.l
-1 
Fe 
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5.4 Preparation of pig skin 
 
The skin of a porcine ear, taken within 24 hrs of butchering, was stripped of any fat and cut into 
sections of 1.0 cm by 3.0 cm from the same area of the ear.  These were placed onto a microscope 
slide under various conditions and the quality of the resultant skin sample assessed (Table 38).   
Conditions Observation 
Placed on slide at room temperature. Skin dried out and curled up at the edges making it 
very difficult to image. 
Placed on a microscope slide in a 50 ml centrifuge 
tube at room temperature. 
Skin dried out and curled up at the edges slightly 
making it unreliable for imaging. 
Placed on a microscope slide in a 50 ml centrifuge 
tube above 10 ml PBS at room temperature. 
Skin slightly dried out and curled at the edges so less 
reliable for imaging. 
Placed on microscope slide in incubator at 37°C Skin dried up and curled slightly making it less reliable 
for imaging. 
Placed on a microscope slide in a 50 ml centrifuge 
tube at 37°C. 
Skin was very slightly curled at the edges and slightly 
drier than prior to incubation. 
Placed on a microscope slide in a 50 ml centrifuge 
tube above 10 ml of PBS at 37°C. 
Skin moist, uncurled and in optimal condition for 
imaging. 
 
Table 38. Conditions trialled for pig skin 
 
5.5 Trialling different SPIO preparations on pig skin 
 
When required, the skin was removed and 100 µl of the preparation to be tested administered to 
the centre of the skin on the stratum corneum side (see Table 39 and Figure 110).   
Pig skin was then incubated (37°C) on a microscope slide in a 50 ml centrifuge tube above PBS (10 
ml) at for a period of 2.5 hrs to allow the test preparation time to be absorbed. 
Following the incubation period pig skin was removed from the incubator and placed immediately 
onto the NMR MOUSE to obtain accurate readings.  Where the skin began to curl, a second slide was 
administered on top of the skin to keep a flat profile. 
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Sample Number Gel used Extra additive Observations 
1 Yes None No change in NMR MOUSE profile.  Contrast seen 
on Biospec with lightening of image. 
2 Yes SPIO-CPP Decrease in NMR MOUSE profile at 400 µm.  
BIOSPEC also showed a decrease in signal. 
3 No No No change in NMR MOUSE profile OR Biospec. 
 
Table 39. Showing the different samples incubated with pig skin samples to test transdermal 
penetration. 
 
 
Figure 110. Image of slides with prepared pig skin prior to MRI measurements.  From left to right: 
Slide 1: SPIO-gel only; Slide 2: Skin only; Slide 3: SPIO-gel on skin; Slide 4: skin with gel only; Slide 5: 
Two pieces of skin with SPIO-gel in between. 
 
5.6 Skin penetration profile with NMR MOUSE 0.25 T 
 
Preliminary measurements (T1 and T2) were taken at intervals of 100 µm through the skin to 
determine where the top and bottom of the skin lay with respect to the magnetic field.  The 
measurements were then repeated, starting at the top of the skin and moving down at 20 µm 
intervals. 
These measurements were carried out on both the nude skin and on the same piece of skin 
following incubation with sample.  The skin was also imaged in 2D using the Biospec 2.45 T MRI.   
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Section 6: Immunotherapy 
 
6.1 Optimisation of peptide synthesis to obtain higher purity peptides 
 
The following adjustments were made to the peptide synthesis protocol: 
The peptide p53(108) was synthesised without storage in freezer between couplings. 
Regular amino acid couplings were carried out for 10 minutes at 75 °C.  Histidine and cysteine 
couplings were carried out for 20 minutes at 50 °C.  Arginine couplings were carried out at room 
temperature for 30 minutes followed by the second coupling for 10 minutes at 75 °C. 
A comparison of p53(108) synthesised via the standard method and the optimised method showed 
the revised method to be superior (Table 40). 
Coupling Conditions Yield  
(mg) 
Purity by HPLC 
% 
Purity by MALDI-TOF 
% 
5 minute couplings 
recommended by 
manufacturer 
130 50 45-50 
10 minute extended 
couplings 
150 75 70 
 
Table 405. Conditions for optimisation of peptide synthesis 
 
6.2 Synthesis of Immunogenic Peptide(s) 
 
All peptides were synthesised via the standard solid phase peptide synthesis protocol using CEM 
Discover microwave.  For peptide sequences and reagents see tables below. 
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6.2.1 Pap 161 
 
Sequence:  CPRFQELESETLKSE 
Resin: 0.3448 g Glutamic acid resin swelled. 
 
Amino Acid Mass (g) Volume 
DMF 
(ml) 
Coupling Conditions per amino acid 
Arginine 0.650 5.0 Double coupling, each with 0.5 ml DIEA, 1.0 ml HBTU and 2.5 ml 
of amino acid : 
a)30 min at room temperature 
b)5 min 75°C 
Cysteine 0.295 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 10 min 75 °C 
Glutamine 0.305 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Glutamic 
Acid 
0.645 7.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Leucine 0.350 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Lysine 0.235 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Phenyalanine 0.195 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Proline 0.170 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Serine 0.380 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Threonine 0.200 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 min 75 °C 
Yield: 63 mg.  Purity by HPLC: ca. 55 % 
Table 41. Reagents and conditions for synthesis of Pap 161 
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6.2.2 Flu DR1  
 
Sequence: PKYVKQNTLKLAT 
0.1639 g Threonine resin swelled, 30 min, 5 ml DMF/DCM (50:50) 
 
Amino Acid Mass (g) Volume DMF 
(ml) 
Coupling Conditions per amino acid 
Alanine 0.155 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Asparagine 0.300 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Glutamine 0.305 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Leucine 0.350 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Lysine 0.705 7.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Proline 0.170 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Threonine 0.200 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Tyrosine 0.230 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Valine 0.170 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Yield: 63 mg 
Table 42. Reagents and conditions for synthesis of Flu-DR1 
 
Unfortunately the Flu-DR1 synthesised was of very low purity (> 20 % by HPLC) and so commercially 
available peptide at a purity of 80 % was used (purchased from Pepceuticals).  This was analysed for 
purity via both HPLC and MALDI-TOF prior to use and was confirmed to be 80 % pure. 
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6.2.3 P53(108) 
 
Sequence: GFRLGFLHSGTAKSV 
0.1639 g of Valine resin swelled, 30 min, 5 ml DMF/DCM (50:50) 
 
Amino Acid Mass (g) Volume DMF 
(ml) 
Conditions for coupling per amino acid 
Serine 0.380 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Lysine 0.235 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Alanine 0.155 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Threonine 0.200 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Glycine 0.450 7.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Histidine 0.310 2.5 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 
10 min 75 °C 
Leucine 0.350 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Phenylalanine 0.390 5.0 2.5 ml of amino acid, 0.5 ml DIEA, 1 ml HBTU, 5 
min 75 °C 
Arginine 0.650 5.0 Double coupling, each with 0.5 ml DIEA, 1.0 ml 
HBTU and 2.5 ml of amino acid : 
a)30 min RTP 
b)5 min 75°C 
*In order to synthesise this peptide with fluorescein on the terminal amine, following arginine 
coupling, 0.100 g of fluorescine was dissolved in 2.5 ml of DMF and coupled using 0.5 ml DIEA, 1 ml 
HBTU, for 5 minutes at 75 °C. 
Yield: 45 mg.  Purity: 75 % by HPLC and MALDI-TOF 
Table 43. Reagents and conditions for synthesis of p53(108) 
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6.2.4 Synthesis of p53(105)  
 
Sequence:  GFHLGFLQSGTAKSV 
0.1639 g of Valine resin swelled, 30 min, 5 ml DMF/DCM (50:50) 
Amino Acid Mass (g) DMF (ml) Coupling conditions 
Serine 0.380 5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Lysine 0.235 2.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Alanine 0.155 2.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Threonine 0.200 2.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Glycine 0.450 7.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Glutamine 0.305 2.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Leucine 0.350 5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Phenylalanine 0.390 5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA 
Histidine 0.310 2.5 2.5 ml amino acid, 1.0 ml 
HBTU, 0.5 ml DIEA.  20 
minute coupling at 50 °C 
Yield: 49 mg.  Purity: ca. 80 % by HPLC and MALDI-TOF 
Table 44. Reagents and conditions for synthesis of p53(105) 
 
*Note:  The immunogenic peptides were all synthesised as the peptide acids as these were the 
available reagents.  In future studies the peptide amides should be synthesised for comparison. 
 
6.3 Determining if HCl peptides were still immunogenic 
 
HCl salt of p53(108) was dissolved in DMSO to give a stock solution of 10 mg/ml.  This was used to 
restimulate spleenocytes from mice previously immunised with commercially bought p53(108) 
(Pepceuticals).  An ELISpot assay was performed and the spots counted using a C.T.L. Immunospot 
counter. 
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6.4  Synthesis of peptide-SPIO complex 
 
SPIOs were synthesised via the standard method and coated with p53 peptide using the pestle and 
mortar solvent free grinding method.  No further purification was carried out.  Solvent was removed 
from the solution in vacuo (60 °C, ca. 5 mbar).  Typically SPIO peptide (2 mg) was dissolved in 
distilled water (5 ml) and analysed for Fe content using ICP with the result being used to calculate 
mass of peptide to SPIO using the method previously described.  SPIO-peptide was then dissolved in 
sterile DMSO to give a stock solution of 10 mg/ml which could be further diluted with cell culture 
media for immunisations. (Note: peptides are measured in mg rather than moles due to the large 
molar excess used in immunological studies). 
 
6.5  Preliminary cell uptake study with U937  
 
U937 cells grown in RPMI with L-glutamine (10 %) and Foetal Calf Serum (1 %) were counted by 
haemocytometry as detailed in the general experimental section.  The cells were then plated in a 
sterile 24-well plate at a concentration of 1 x 106 cells per ml of media per well.  SPIOs at Fe 
concentration of 500 mg.l-1 were added at a volume of 1 ml per well at different times (see Figure 
111 and the corresponding Table 45) and incubated (37°C).  A sample of the SPIO solution was 
incubated (37°C) for the duration of the experiment as a control. 
 
Figure 111. Schematic of 24-well plate for preliminary studies for SPIO uptake by U937.  Wells 
marked “X” were empty. 
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X 
X 
X 
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B B 
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At 0 hours the cells were removed from the wells and centrifuged (1500 rpm, 4°C for 3 minutes), and 
washed with PBS (3 x 5 ml).  The cells were then placed into glass vials (cells from condition A 
combined, B combined, C combined, D combined and E combined) and their T1 and T2 relaxation 
times measured.  The cells were then digested in nitric acid (1 ml) and diluted with distilled water (to 
5 ml), and analysed for Fe concentration by ICP. 
Well 
Identities 
Number of 
cells per ml 
Volume of 500 mg.l-1 
SPIO solution added 
Time at 
which SPIO 
solution 
added (h) 
Fe 
conc. 
mg.l-1 
T1 (ms) T2 (ms) 
A 1000000 0 (Control, 1 ml of 
media added instead 
of SPIOs) 
-2 0.975 2675.29 11.1588 
B 1000000 1 ml -2 1.65 2928.8632 11.7707 
C 1000000 1 ml -1.5 1.120 181.0506 10.4381 
D 1000000 1 ml -1.0 1.140 2608.4202 11.4964 
E 1000000 1 ml -0.5 1.115 2790.6152 12.4531 
*Incubated SPIOs T1: 51.4773 ms; T2: 8.0734 ms 
Table 45. Shows conditions present in each well depicted in Figure 111. 
 
6.6 Uptake study with bone marrow dendritic cells (BMDCs) 
 
6.6.1 Culturing BMDCs 
6.6.1.1  Culturing on standard plates 
 
Sarstedt non-pyrogenic, non-cytotoxic standard 24-well plates were used for culture of BMDC’s.  
BMDC media containing (RPMI (500 ml), glutamine (1 %, 5 ml), FCS (5 %, 25 ml), HEPES buffer (10 
mM, 10 ml), 2-mercaptoethanol (50 μm, 500 μl), PEN-STREP (25 μg / ml, 5 ml) and Fungizone (0.25 
μg / ml, 500 μl)) was freshly prepared and stored in fridge.  On day one hind legs of DR1 mice were 
cut at the joint and muscle and fat removed.  Bone marrow was flushed into a Petri dish using a 
syringe of BMDC media (10 ml) and a needle.  Media containing cells was filtered and resultant 
media centrifuged (1500 rpm, 10 min, 4 °C) to give a cell pellet.  Cells counted using trypan blue and 
plated at 1 million cells per ml per well in 24-well plate with GMCSF (1 ng per million cells).  These 
were incubated (37 °C, 5.1 % CO2) and washed with fresh BMDC media (750 μl) on day 3 and 6 and 
harvested using a pipette tip, before being counted, purified using CD11c+ column or number of 
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BMDCs present determined by CD11c FACS.  On day 8 these were recounted and cells could then be 
re-plated as desired. 
 
6.6.1.2 Culturing in T 25 flasks 
 
Standard T 25 flasks were purchased from Sarstedt and used as received.  BMDCs were re-
suspended in media with GMCSF and transferred to a T25 flask, washed as described in the general 
experimental section, and harvested using a cell scraper.   
   
6.6.2 Trialling of different plates for optimal BMDC culturing 
 
Sarstedt standard 24-well plates were used along with BD Purecoat amine and carboxyl coated 24-
well plates. 
24-well plates with either normal, carboxyl or amine coating were seeded with BMDC’s and these 
were cultured as in section 6.6.1.1.  Following culture a total cell count and a BMDC specific cell 
count following MACS CD11c+ sorting was carried out (Table 46). 
 Plate Number Number of cells after 
harvesting (x 105) 
Number of cells following 
CD11c column (x 105) 
Number of BMDC's 
normalised (x105) 
Normal 1 4 0.75 0.19 
2 5 0.75 0.15 
3 5 0.5 0.1 
Carboxyl 1 12 1 0.08 
2 14 2.25 0.16 
3 12 3.25 0.27 
Amine 1 3 0.25 0.08 
2 4 0.5 0.13 
3 4 0.5 0.13 
 
Table 46. Results for culturing BMDCs on different plates 
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Cells were harvested from mice hind legs as in section 6.6.1.1 and seeded at a concentration of 1 x 
106 cells per ml of media per well into 3 x non-coated 24-well plate, 3 x carboxyl coated 24-well 
plate, and 3 x amine coated 24-well plate.  The cells were incubated (37 °C, 5.1% CO2) and washed 
with fresh media on day 3 and 5, and harvested and counted by haemocytometry on day 7.  The cells 
from each plate were then passed through a CD11c+ column to isolated BMDC’s and these also 
counted by haemocytometry.   
 
6.7 Incubation of BMDCs with SPIOs 
 
Peptide-SPIO solutions were prepared as previously described.  This stock solution was diluted to 
varying concentrations (see Figure 112 and Table 47) and these each added to preparations of cells 
in a 24-well plate at a volume of 500 µl per well.  Each well contained 500,000 cells in BMDC media 
(1 ml) and GMCSF (1 ng/ml), and were left to incubate (37°C, 4 hours).  After 4 hours LPS was added 
(ca. 1 ml) and the cells left to incubate (37 °C) over night.  The following day poly-IC (0.5 ml) was 
added and the cells left to incubate (37°C, 2 hours) and then harvested by scraping from the 24-well 
plate using a pipette tip. 
Cells were then counted by haemocytometry as in experimental and imaged by fluorescence 
microscopy. 
 
Figure 111. Schematic of 24-well plate used for BMDC uptake of SPIO experiments 
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Well 
Number(s) 
Conditions Number of 
cells (x 105) 
Observations with fluorescence microscope 
1, 2, 3 50 µg/ml SPIO – 
Peptide - Fluorescein 
1.80 Green colour inside cells and blue stain on 
nuclei.  Some cells with only blue nuclear stain. 
4, 5, 6 25 µg/ml SPIO – 
Peptide - Fluorescein 
1.10 Green colour inside cells and blue stain on 
nuclei.  Some cells with only blue nuclear stain. 
7, 8, 9 10 µg/ml SPIO – 
Peptide - Fluorescein 
0.90 Green colour inside cells and blue stain on 
nuclei.  Some cells with only blue nuclear stain. 
10, 11, 12 50 µg/ml SPIO – 
Peptide  
1.50 Blue colour of nuclei observed.  Absence of 
green as no fluorescein present. 
13, 14, 15 25 µg/ml SPIO – 
Peptide 
1.00 Blue colour of nuclei observed.  Absence of 
green as no fluorescein present. 
16, 17, 18 10 µg/ml SPIO – 
Peptide 
1.20 Blue colour of nuclei observed.  Absence of 
green as no fluorescein present. 
19, 20 Control Cells, RPMI 
media only 
1.00 Blue colour of nuclei observed.  Absence of 
green as no fluorescein present. 
21, 22 Peptide – Fluorescein, 
10 µg/ml 
0.80 Blue colour of nuclei observed.  No green 
fluorescent stain. 
23, 24 Peptide only, 10 
µg/ml 
1.90 Blue colour of nuclei observed.  Absence of 
green as no fluorescein present. 
 
Table 47. Showing conditions for each cell indicated in Fig. 9 with each cell holding 500, 000 BMDC 
cells in 1 ml BMDC media with 1 ng of GMCSF 
 
6.8 Determining maturation of cells with SPIO-peptide 
 
BMDCs were cultured and incubated (37°C, 24 hrs) with various concentrations of peptide-SPIO 
complexes with and without adding LPS and poly-IC to mature cells (see Figure 113 and Table 48).  
Following this, cells were incubated with CD86 (a biomarker for BMDC maturation) linked to 
fluorophore PE as described in experimental section, with uptake of the fluorophore being the 
marker for cell maturity.  The cells were then imaged via fluorescence microscopy to determine if 
cells had matured. 
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Figure 113. Plan of 24-well plate for BMDC maturation studies 
 
Well 
Identities 
Number of 
cells per ml 
Conditions in Wells LPS and Poly-IC 
added (Y/N)? 
1 – 3 150 000 50 μg / ml Peptide only N 
7 – 9 150 000 50 μg / ml SPIO - peptide N 
13 – 15 150 000 10 μg / ml Peptide-SPIO  N 
19 – 21 150 000 Control Cells N 
4 - 6 150 000 50 μg / ml Peptide only Y 
10 – 12 150 000 50 μg / ml SPIO - peptide Y 
16 – 18 150 000 10 μg / ml Peptide-SPIO  Y 
22 - 24 150 000 Control Cells Y 
 
Table 48. Showing conditions present in each well depicted in Fig. 56 for maturation of BMDCs using 
SPIOs. 
 
6.9 Cytotoxicity Assay 
 
Cytotoxicity of SPIO-peptide solutions to the cells was determined by incubating BMDCs (2.5 x 105 
cells per ml per well) in BMDC media containing GMCSF (1 ng per ml) for 24 hrs with various 
concentrations of SPIO-peptide and peptide only (p53(108)) in triplicate as described in Figure 115 
and Table 49 and carrying out a cell count by haemocytometry using trypan blue.   
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Figure 51. Diagram of 24-well plate for cytotoxicity study 
 
Condition Cell Count 
50 µg/ml p53(108)-Fluorescein 1.80E+05 
25 µg/ml p53(108)-Fluorescein 1.10E+05 
10 µg/ml SPIO - p53(108)-Fluorescein 9.00E+04 
50 µg/ml SPIO - p53(108)-Fluorescein 1.50E+05 
25 µg/ml SPIO - p53(108)-Fluorescein 1.00E+05 
10 µg/ml p53(108)-Fluorescein 1.20E+05 
10 µg/ml p53(108) 1.00E+05 
10 µg/ml SPIO - p53(108) 8.00E+04 
Control cells with 1 ml BMDC media 1.90E+05 
Mean 1.24E+05 
Standard Deviation 3.97E+04 
 
Table 49. Showing contents of each well on 24-well plate for assessing cytotoxicity of peptide and 
peptide-SPIO complex on BMDC’s. 
 
6.10  Mouse immunisations 
 
For these experiments female C57BL/6 mice aged 7-9 weeks were used following purchase from 
Charles River Laboratories, Margate, Kent, UK.  Animals were kept at 19 – 23 °C at a humidity of 40 – 
70 % and had artificial light for 12 hours out of every 24 hour period, and with air changes a 
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minimum of fifteen times per hour.  Animals were housed in accordance with the Code of Practice 
for the Housing and Care of Animals Used in Scientific Procedures and in alignment with the United 
Kingdom Home Office recommendations and requirements.  Animals were fed Rodent 2018C 
Tekland Global Certified Diet (Harlan Laboratories U.K. Ltd., Oxon, UK) and tap or pouched water ad 
libitium.  Animals were acclimatised for one week prior to experimentation. 
 
6.10.1 Immunisation schedule for mice 
 
For each mouse for immunisation with peptide only, stock peptide solution (30 µl) containing of 
p53(105) (10 mg/ml) was diluted with PBS (170 µl) and mixed with IFA (200 µl).  For each 
immunisation with peptide-SPIO stock peptide-SPIO solution (30 µl) containing peptide (10 mg/ml) 
was diluted with PBS (370 µl).  The preparation (100 µl) was used to give a total of 75 µg of peptide 
per mouse per injection. 
Mice were immunised by subcutaneous injection at the tail base on day 0, boosted using the same 
preparations on day 14, and killed and spleens and hind legs harvested on day 21.  
The experiment was repeated once staggered by one week. 
For each experiment three mice were immunised with p53(105) in IFA, three mice with p53(105)-
SPIO and a control naïve mouse was kept under the same conditions. 
 
6.10.2 Harvesting of spleens 
 
Spleens of immunised mice were isolated and all fat removed.  These were then flushed with 10 ml 
of CTL media to remove spleenocytes.  The spleen was crushed to remove any remaining 
spleenocytes.  Larger particles from the spleen were allowed to settle (120 sec) then the supernatant 
removed and spun (10 mins, 1500 RPM).  The cell pellet was resuspended in T cell media (2 ml) 
(RPMI 500 ml, 10% FCS, 2 mM L-glutamine, 20 mM HEPES buffer, 50 µM 2-mercaptoethanol, 25 mg 
streptomycin, 12.5 mg Fungizone) and counted using haemocytometry.  Cells were then be diluted 
and/or seeded as required. 
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6.10.3 Culturing of spleenocytes 
 
Spleenocytes harvested as in section 3.11.7.2 were seeded at 30 x 106 cells per 8 ml T cell media into 
T25 flasks.  These were incubated (37 °C, 5.1 % CO2) for 1 week. 
 
6.10.4 ELISpot Assay 
 
ELISpot assays were carried out using Mabtech ELISpot kit for mouse IFN-γ on 96-well plates.  
On day zero the plate was first wet with ethanol (50 µl, 70 %) per well for 2 minutes, before washing 
(5 x 200 µl sterile water per well).  The capture antibody (monoclonal antibody AN18) was diluted to 
15 µg/ml with sterile PBS, then 100 µl added per well and incubated at 4-8 °C overnight. 
On day 1 the antibody was tipped off the plate and each well washed with sterile water (5 x 200 µl), 
before adding CTL media (200 µl per well) and leaving (30 min, 37 °C).  The media was then removed 
and cells (1 x 106 per well) and stimulatory agents added as in Figure 115, before incubation (37 °C, 
5.1 % CO2, 24 hrs).   
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Figure 115. Plate plan for ELISpot following mouse immunisation with p53(105)-SPIO.  Shaded cells 
contain cells and stimulants as indicated.  For peptides at different concentrations experiments were 
run in triplicate for each mouse and all conditions were repeate 
 
To develop the plate cells were removed and each well washed with PBS (5 x 200 µl )before adding 
monoclonal biotinylated detection antibody (100 µl per well) (1 µg/ml in PBS with 0.5 % FCS) and 
leaving for 2 hrs at room temperature in the absence of light.  Wells were then washed with PBS (5 x 
200 µl) and Streptavidin-Alkaline Phosphatase (100 µl) (1:1000 in PBS with 0.5 % FCS) added and left 
at room temperature for 1 hr in the absence of light.  Finally the wells were washed with PBS (5 x 
200 µl) before the substrate solution was added (100 µl per well).  Plates were allowed to develop 
until distinct spots emerged before being washed thoroughly with tap water to prevent over-
development. 
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Once the plates were dry they were read using an C.T.L Immunospot counter (Table 50). 
 Peptide IFA Peptide-SPIO  
 Mouse 1 Mouse 2 Mouse 3 Naïve Mouse 1 Mouse 2 Mouse 3 Naïve 
10 ug peptide 67 80 21.7 26.3 58.3 193.3 42.3 27 
1 ug peptide 79 95.3 53.3 91.3 89 239.3 68.3 50 
0.1 ug 
peptide 
60.7 43 40.3 84.5 66 204.3 75.3 51 
0.01 ug 
peptide 
26.3 27 19 71.7 35 107.7 43.7 57.3 
Irrelevant 12.33 4.67 8.67  8.33 7.67 7.67  
Cells Alone 2.67 4.33 6.67  4.67 3.33 10  
 
Table 50. ELISPOT results following mouse immunisation with p53(105)-SPIO 
 
6.10.5 Restimulation and proliferation assay 
 
For restimulation ELISpot the protocol was followed as described.  Spleenocytes were seeded at 30 x 
106 cells per 8 ml T cell media in T25 flasks.  To this was added 1 µl/ ml of the 10 mg/ml stock 
peptide solution (total 10 µg) along with 1 µl/ml of vitamin E and kept in the dark for 1 week. 
On Day 1 naïve BMDC’s were pulsed with the peptide (1 µl, 10 µg per ml per well) and incubated (37 
°C, 5.1 % CO2) for 4 hours before adding LPS for cell maturation (100 µl per well or stock diluted 
1:100 with BMDC media) and incubating overnight. 
BMDC’s were then harvested and counted before resuspension in BMDC media (1 ml).  PolyIC (12.5 
µl) was then added to further mature the cells, and incubated (2 hrs, 37 °C).   
BMDCs and Spleenocytes previously stimulated with peptide were counted and seeded at 1 x 104 
BMDC’s per well and 1 x 105 T cells per well on the ELISpot plate at the point in the protocol 
requiring cells and stimulating agents (see Figure 116 and Table 51). 
Spots were counted using a C.T.L. Immunospot counter. 
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Figure 116. 96- well plate plan for restimulation ELISpot following mouse immunisations.  Wells not 
shown were left empty, shaded wells were filled as shown. 
 
 
  T cells 
alone 
T cell and DC 
peptide 
1 ug 
peptide 
Irrelevant 
Peptide 
Peptide M1 295.25 533.5 520.25 537.25 
M2 306 540 512.5 545.5 
M2 182.5 356.75 420 437 
SPIO M1 274.5 425 233.25 203 
M2 407.5 598.75 298.25 167.5 
M3 408 367.75 265.5 143 
 Naïve 244.5 50.75 323 336.75 
 
Table 51. Results for ELISPOT following restimulation of spleenocytes from mine immunised with 
p53(105)-SPIO 
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Chapter 4: Conclusion 
Section 1: Synthesis of Particles 
SPIO’s were successfully synthesised via both co-precipitation and SDR methods with co-
precipitation forming the most uniform particles of 10-15 nm.  The SDR produced particles that had 
a wide size range from 8-42 nm and due to excess reagents some rod shaped particles were formed.   
However, the SDR appeared to be the most suitable method for scaling up the reaction and so the 
method should be improved.  As the size of the particles is determined by nucleation, spin speed, 
feed rate and concentration of reagents, all of these things could be further explored.  The size of 
the grooves on the disc could also affect particle size as these affect micro-mixing effects.  In keeping 
with the effects of micro-mixing, the feed rate plays an important factor.  The results showed that 
excess reagents led to nucleation and the formation of rods, and so the effects of lower volumes of 
reagents, possibly by flow rate, should be investigated.   
The results from using the SDR also show that using gaseous ammonia rather than liquid ammonia 
can improve the quality of SPIOs, leading to less aggregation.  Again, this can be affected by the 
concentration of the reagents and the feed flow rate so these factors need to be explored in more 
detail.   
Calcium oxide nanoparticles were also formed using the SDR, yielding spherical particles of 5-10 nm 
in diameter that appeared uniform by TEM.  These particles had a much narrower size distribution 
showing that under the right conditions the SDR is suitable for forming uniform particles.  
An iron tin oxide complex was also synthesised using a co-precipitation, yielding spherical particles 
of 4-10 nm in diameter with a suggested chemical formula of Fe5Sn2O9, taken from a combination of 
ICP and EDX results.  In order to clarify if this is the correct formula, x-ray powder diffraction should 
be carried out.  
Gold nanoparticles (citrate capped) were also synthesised, in this case via a reduction method with 
sodium citrate as the reducing agent.  This was also successful, yielding spherical particles of 4-10 
nm in diameter with the colour of the solution being dependent on the size of the majority of the 
particles.  The smaller particles (4 nm) gave a purple solution, with the larger particles (10 nm) giving 
a red solution.  What was also noticed was that at higher concentrations the particles quickly 
aggregated to give black particles that would not go back into solution.    
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Section 2: Coating of particles 
The solvent-free grinding method was found to be hugely successful, with the method being 
successful for SPIOs, CaO, and FeSnO particles.  In each case particles were coated, solubilised and 
when imaged by TEM showed that there were spherical particles with a coating, shown as a clear 
area around particles.   
For this method, the pestle and mortar is currently the best method, giving rise to higher yields.  
However, the coffee grinder method produced more homogeneous particle and so would be more 
suitable for scale-up.  To optimise the method, a machine similar to the coffee grinder could be 
designed, with the burrs having smaller grooves and being closer together.   
Investigations into the effect of mass ratio of the SPIOs to coating material were inconclusive, but 
there seemed to be a very weak negative correlation between mass ratio of coating material and the 
concentration of iron in the resultant preparations.  This was attributed to mixing effects, with larger 
quantities of coating leading to less interaction between coating and particle.  This has implications 
for future synthesis, with a recommendation that the coating material be kept to a minimum. 
A heating method was trialled and this produced SPIO-coating complexes with very large 
concentrations of iron, although the particles were heavily aggregated with sizes of ~1000 nm.  As 
the method proved so successful for binding SPIO and coating together it stands to reason that once 
optimised this would be the best method.  To do this, the particles should be kept as separate as 
possible during coating so as to avoid aggregation.  Further investigation will be needed in this area. 
A combination of investigation and literature showed that –COOH, -NH2, and –OH were responsible 
for binding to the SPIOs.  This is through electrostatic interactions which, it was found, are enhanced 
by using salts of the coating materials.  This was proven for all 20 naturally occurring amino acids, 
although it was not clear if this was due to increased solubility or enhancement of the electrostatic 
interactions themselves.  Further investigation is required in this area. 
The actual coverage of the particle with coating was assessed and by calculations into the maximum 
number of coating molecules for monolayer coverage vs. the number of molecules present on a 
particle as analysed by ICP, it was clear to see that several layers of coating material have been 
bound to the particle.  In order for the results of this to be conclusive modelling software could be 
used.  This would show what kind of coverage would be expected on such a particle, and would 
either confirm or reject the idea that there are ~1000 more coating molecules present than are 
necessary for a monolayer to form.  The actual number of coating materials has implications for 
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future use, as the number /concentration of particle molecules is important for accuracy and 
consistency in biological applications. 
When autoclaving was carried out, with a view to using the particles for biological applications such 
as immunisations, results showed that although the particles has visibly changed colour from black 
to brown.  The amino acid coating showed a very small amount of degradation, but NMR 
measurements showed that there had been no adverse effects and the SPIOs were still potentially 
suitable for use in MRI imaging.  To further clarify these findings the x-ray diffraction of all particles 
could be carried out, as this is a more accurate method of looking at the microstructure. 
Additionally, buffer experiments showed the coated SPIOs to be very stable in buffered solution.  
Previously the literature had suggested that SPIOs underwent rapid degradation on exposure to 
buffers, but these particles remained stable in buffered solution for a period of 1 week.  However, 
this experiment was only carried once with some conditions repeated.  For this reason it should be 
repeated to show that results were accurate and the SPIOs prepared via the solvent free grinding 
route, were very stable in both aqueous and buffered solutions. 
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Section 3: Separation and purification of particles 
 
Size exclusion was the first method trialled and this proved to be effective for smaller sized coatings 
such as single amino acids, but was unsuitable for larger coating such as immunogenic peptides (12-
15 amino acids long).  The longer coatings caused the SPIOs to become stuck on the column, possibly 
because they were too large to pass around the beads, or because they were too small to avoid the 
pores, but too large to pass through.   
As size exclusion was effective for the smaller coatings, it is possible that with tailoring it could be 
effective for larger ones.  Further studies could include using different packing materials with larger 
or smaller bead sizes and different pore sizes.  The flow rate could also be investigated as it may be 
the case that with a slower flow rate the materials would pass through the column successfully. 
The investigation into antisolvents had mixed success with acetonitrile being identified as the most 
effective for the majority of organic coatings.  This solvent was able to cause precipitation of coated 
SPIOs whilst avoiding the majority of the coating falling out of solution.  Acetone caused 
precipitation of too much of the free coating material to be considered successful although it could 
be further investigated.   
When taking this method into consideration as a whole, the use of large volumes of solvents leads to 
high volumes of waste solvents.  It seems pointless to have developed a solvent-free approach to 
coating the particles if large volumes of solvents are then going to be used in the 
separation/purification step, so this method does not seem very viable. 
Further work could include looking at using antisolvents but in a way that allows recycling following 
use.  By reclaiming the solvents there is not real waste and so the process remains essentially 
“green”. 
The magnetic separation method was largely unsuccessful, and the SPIOs, due to their small size 
were able to overcome the magnetic forces of attraction.  In these cases the forces of Brownian 
motion were larger than that of the magnetic field, thus allowing particles to remain suspended in 
solution. 
When using the magnetic separation with tubing and a neodymium magnet there was limited 
success with HCl histidine coated particles.  These were able to separate into free coating material, 
coated SPIOs and uncoated SPIOs.  However, all other samples trialled failed even with different 
solvents.  It would be beneficial to repeat this experiment but with a wide variety of different 
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coatings in order to determine which of the coatings make particles suitable for the magnetic 
separation method.  Additionally stronger magnets could be used, thereby determining the 
minimum magnetic field strength required for successful magnetic separation. 
The final method trialled, centrifugal force, had the most potential for both a small and large scale 
separation.  When spun at a speed of 60 000 rpm, the SPIO solution separated into a brown pellet 
and a colourless supernatant.  Whilst results are not conclusive due to machinery being damaged 
during the experiment, when combined with the literature it can be assumed that this method is the 
most reliable and effective.  Further investigations should be carried out into the use of density 
gradients, and when repeated the supernatant should be tested for free coating material by 
removing the solvent in vacuo. 
Overall this part of the project was the most inconclusive and would require the most additional 
investigation. 
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Section 4: Medical Imaging 
For CT imaging gold nanoparticles were synthesised and concentrated in vacuo to give 
concentrations that could be detected by CT.  These were placed into a CT phantom for comparison 
with body tissues, and the resultant CT values showed that if these particles were to be used for CT a 
concentration of 3700 mg.l-1 would be required.  For this reason the use of gold for CT was 
abandoned.  During the course of this research it was also reported in the literature that gold 
accumulates in the liver and cannot be removed by the body, thus making it unsuitable for medical 
imaging.  What it could be used for however, is OCT imaging, where the particles could be delivered 
under the skin for imaging of subcutaneous disorders. 
Another route that could be taken is to use iodinated peptides, or possibly the iron tin oxide 
particles, as tin has a high atomic number and so would be suitable for x-ray imaging.  It may also be 
possible to attach a drug molecule such as iodipamide to SPIOs or to the peptides, thus creating a 
complex containing atoms with a high atomic number. 
Studies into incubation of cells with SPIO complexes indicated that for studies into cells in vitro the 
concentration of iron in SPIO solutions needed to be higher, or alternatively the magnetic field 
strength needed to be higher.  These studies were carried out using a 0.25 T NMR MOUSE but higher 
field strengths such as 2.45 T exhibited by the BIOSPEC would be more suitable.   
What was shown however, was that SPIOs attached to cell-penetrating peptides were able to 
penetrate porcine skin to layers below the stratum corneum, with a reduction in the relaxation time 
of the skin in that area being shown to have decreased.  This shows that SPIOs can successfully cross 
the skin, which has applications for use in hyperthermia for treating skin melanoma. 
One key problem with the skin studies was the use of non-comparable skin samples.  As they were 
taken from a pig butchered for meat rather than research the skin was uneven and results are not 
likely to be reproducible.  For future studies either a skin model or animals for research should be 
used to ensure uniformity of samples. 
In order for these preparations to be used in medical applications, they must be stable in buffered 
solutions, and studies into stability in buffers led to the conclusion that in contrast with findings 
reported in the literature these particles are very stable in both water and buffered solutions.  It can 
be assumed then that these particles would be retained in the body long enough for imaging to be 
carried out although further in vivo studies would need to be carried out.  What is promising for 
these preparations is that the cytotoxicity assay indicated that the coated SPIO’s were not toxic up 
to and including a peptide concentration of 50 µg/ml. 
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Promisingly the blood studies also showed that SPIOs coated via the solvent free grinding method 
would also be stable in blood, although in the presence of EDTA the blood clotted and firm 
conclusions could not be drawn.  It is suggested that further studies on blood plasma rather than 
whole blood should be carried out to produce more reliable results with respect to stability in blood. 
When compared to commercially available alternatives, the SPIOs gave comparable NMR relaxation 
times, but were considered to be superior as they were more stable when in solution.  Endorem® 
quickly came out of solution to form brown crystals that could not be taken back up into solution, 
when removed from the protective atmosphere of the vial despite being transferred to another 
closed vial.  In stark contrast the coated SPIOs remained stable both in powder form and in solution 
at room temperature for 1 month +.  As there are currently issues with the safety of SPIO 
preparations for MRI, coated particles formed by solvent free grinding methods may be able to 
overcome any issues, and this should be further researched. 
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Section 5: Cell Studies for uptake of coated SPIOs 
U937 cells were used for preliminary investigations into the uptake of SPIOs by monocytes.  The 
results were inconclusive due to low concentrations of SPIOs and low field strength of the NMR 
MOUSE used for imaging.  Unfortunately due to time limitations and technical problems it was not 
possible to repeat this experiment using a higher magnetic field but this could be done in further 
work.   
When studies progressed to BMDC’s a different approach was taken, using SPIOs with a 
fluorescently labelled coating to track uptake.  The images obtained showed that fluorescently 
labelled material had passed into the cytoplasm of the cells, but only when SPIO was present.  So it 
can be concluded that the SPIOs act as a successful vector for delivery of materials into dendritic 
cells.  This could be further quantified using a Quantum MESF FITC kit, which would show how many 
molecules of the coating material were entering the cell. 
For the biological applications of SPIOs cell culture was an integral part, and the successful culture of 
sufficient numbers of BMDC’s was essential.  Due to problems with culturing the type of plate was 
investigated, with the variations being standard plates, carboxyl coated and amine coated.  It was 
found that although carboxyl coated plates led to a general increase in the number of all cells it did 
not increase the number of BMDC’s specifically.  It was suggested that the washing steps were 
responsible for loss of BMDC’s as this would remove any cells that were not completely adhered.  
T25 flasks were trialled for this but did not show any increase in the number of BMDC’s.  However, 
there is less likelihood of killing cells during the scraping process so T25 flasks would be better to 
use.  As an increased number of BMDC’s would be beneficial to this type of research, time should be 
taken to investigate other coatings in this way, as there are currently no suggestions by any of the 
suppliers. 
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Section 6: Mouse Immunisations 
Before peptides can be used for immunisations they need to meet certain purity expectations, with 
the minimum being 75 % purity.  The standard peptide synthesis route was producing peptides with 
variable purity averaging at ~ 50 %.  An optimised method was devised using double coupling times 
and continuous synthesis, and this was found by both MALDI-TOF MS and HPLC to give peptides a 
purity of ~ 75 %.  To further increase purity (some protocols require 80 % plus purity) a purification 
step could be added.  This could not be carried out during the scope of this project as with the 
equipment available a minimum of three weeks would have been required to collect a 10 mg 
sample.  A much larger column would be required for this purification step to be viable. 
As has been mentioned, in order to increase solubility the peptides had to be recrystallized from 
HCl(aq) and it was not clear if this would affect immunogenicity.  An ELISPOT assay was carried out 
using spleenocytes from mice immunised with commercially available p53(108), and it was found 
that the recrystallized p53(108) created the desired immune response, thus indicating that the 
recrystallization process had not affected the immunogenicity of the peptide.  This needs to be 
checked for any peptides that are to be used, as this would not necessarily be the case with all 
peptides. 
SPIOs were tested against IFA as a vector for delivery of peptides for immunisation.  The results 
indicate that the SPIOs were equivalent to IFA in terms of the immune response produced, but 
produced a significantly more specific immune response than IFA.  The IFA- peptide immunised mice 
showed no difference in its response to the irrelevant peptide vs. the p53(105) whereas the SPIO-
peptide immunised mice showed a significantly higher response to the p53(105) compared with the 
irrelevant peptide.  This confirms that not only is SPIO suitable as a vector for peptide delivery, but 
that it also creates a much more specific immune response in the case of p53(105).  Further studies 
on other peptides should be carried out, as this may be a phenomenon specific to just one peptide, 
although the preliminary studies with BMDC’s do indicate that SPIOs can act as vectors. 
The major improvement that is required for this method is improvement of the solubility of peptide-
SPIOs in DMSO, which has already been brought up in the SPIO coating section.  
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